State: Pennsylvania Filing Company: Blue Cross of Northeastern Pennsylvania

TOI/Sub-TOI: LTC03G Group Long Term Care/LTC03G.001 Qualified

Product Name: Long-Term Care

Project Name/Number: MedAmerica Nationwide 2018 Rate Increase/145MAI01-30.06

Filing at a Glance

Company: Blue Cross of Northeastern Pennsylvania

Product Name: Long-Term Care State: Pennsylvania

TOI: LTC03G Group Long Term Care

Sub-TOI: LTC03G.001 Qualified

Filing Type: Rate - Other (Not M.U. or G.I. Product)

Date Submitted: 08/21/2018

SERFF Tr Num: MILL-131614386

SERFF Status: Assigned

State Tr Num: MILL-131614386

State Status: Received Review in Progress
Co Tr Num: SERIES 11 GROUP (BCNEPA)

Implementation On Approval

Date Requested:

Author(s): Missy Gordon, Courtney Williamson, Travis Reisch, Shawn Stender, Michael Emmert, Bryan

Rask, Alex Moore, Brandon Johnson, Jack Bridges, Dexter Mosley, Cassi Noel, Megan Anderson, Peder Swenson, Derek Lesniak, Yi Shao, Matt Mickolichek, Rylee Sevigny

Reviewer(s): Jim Laverty (primary)

Disposition Date:
Disposition Status:
Implementation Date:

State Filing Description:

Proposed 40.9% increase on 10 PA policyholders of group LTC form GRP11-342-PA-1100.

SERFF Tracking #: MILL-131614386 State Tracking #: MILL-131614386

State: Pennsylvania Filing Company: Blue Cross of Northeastern Pennsylvania

TOI/Sub-TOI: LTC03G Group Long Term Care/LTC03G.001 Qualified

Product Name: Long-Term Care

Project Name/Number: MedAmerica Nationwide 2018 Rate Increase/145MAI01-30.06

General Information

Project Name: MedAmerica Nationwide 2018 Rate Increase Status of Filing in Domicile: Pending

Project Number: 145MAI01-30.06 Date Approved in Domicile:

Domicile Status Comments: Pennsylvania is the state of Requested Filing Mode: Review & Approval

domicile.

Explanation for Combination/Other: Market Type: Group

Submission Type: New Submission Group Market Size: Small and Large

Overall Rate Impact: 40.9% Group Market Type: Employer

Filing Status Changed: 08/22/2018

State Status Changed: 08/22/2018 Deemer Date:

Created By: Derek Lesniak Submitted By: Michael Emmert

Corresponding Filing Tracking Number:

State TOI: LTC03G Group Long Term Care State Sub-TOI: LTC03G.001 Qualified

Filing Description:

On behalf of the company, we are submitting the referenced rate filing for your review. These are existing products that provide long-term care coverage on a group basis. The company issued these products in Pennsylvania from August 1, 2002 to November 1, 2002 and is no longer marketing them in any jurisdiction. The company is making a similar request on the Series 11 Individual policy form(s) in a concurrent filing (SERFF Tracking # MILL-131567828).

The company is requesting a premium rate increase on these form(s), including all associated riders. The need for a premium rate increase is due to emerging and projected experience running more adverse than previously expected.

These products were designed and priced by MedAmerica Insurance Company (MedAmerica), which is an affinity partner. The products were issued on Blue Cross of Northeastern Pennsylvania (BCNEPA) paper, while MedAmerica administers and manages the block, including underwriting and claims handling. MedAmerica has 100% of the risk on these products via a reinsurance arrangement with BCNEPA.

Additionally, MedAmerica is making a similar request in concurrent filings. These filings use identical pooled nationwide experience of MedAmerica and its affinity partners individual and group business as described in the enclosed actuarial memorandum.

The company is requesting a premium rate increase that varies by benefit period to achieve the cumulative rate increases shown in the enclosed cover letter. The rate increase varies by benefit period to better align the rate increase with the adverse experience. The enclosed cover letter provides the average prior, requested, and cumulative rate increases by benefit period for these form(s).

There have been two prior increase(s) that were filed for use in May 2010 and September 2017 on the forms. The company is seeking this rate increase request to help alleviate the adverse performance on this block of business.

Similar to the prior increase(s), the company will offer insureds affected by the premium increase the option of reducing their policy benefits to provide flexibility of choice for those insureds who wish to maintain a premium level reasonably similar to what they were paying prior to the rate increase. The company will offer a contingent benefit upon lapse to insureds that trigger a substantial rate increase. Additionally, the company will voluntarily offer a contingent benefit upon lapse to insureds affected by the rate increase, even if the increase is not considered substantial.

State ID Number:

SERFF Tracking #: MILL-131614386

State Tracking #: MILL-131614386

State: Pennsylvania Filing Company: Blue Cross of Northeastern Pennsylvania

TOI/Sub-TOI: LTC03G Group Long Term Care/LTC03G.001 Qualified

Product Name: Long-Term Care

Project Name/Number: MedAmerica Nationwide 2018 Rate Increase/145MAI01-30.06

Company and Contact

Filing Contact Information

Michael Emmert, Associate Actuary michael.emmert@milliman.com

8500 Normandale Lake Blvd. 952-820-3116 [Phone]

Suite 1850

Minneapolis, MN 55437

Filing Company Information

(This filing was made by a third party - millimaninc)

Blue Cross of Northeastern CoCode: 54747 State of Domicile:
Pennsylvania Group Code: 1270 Pennsylvania

19 North Main Street Group Name: Hosp Serv Assn of Company Type: HMDI

Wilkes-Barre, PA 18711 NEPA Gp

(570) 200-4456 ext. [Phone] FEIN Number: 24-0615177

Filing Fees

Fee Required? No Retaliatory? No

Fee Explanation:

State: Pennsylvania Filing Company: Blue Cross of Northeastern Pennsylvania

TOI/Sub-TOI: LTC03G Group Long Term Care/LTC03G.001 Qualified

Product Name: Long-Term Care

Project Name/Number: MedAmerica Nationwide 2018 Rate Increase/145MAI01-30.06

Rate Information

Rate data applies to filing.

Filing Method: Review and Approval

Rate Change Type: Increase

Overall Percentage of Last Rate Revision: 20.000%

Effective Date of Last Rate Revision: 09/22/2017

Filing Method of Last Filing: Review and Approval SERFF Tracking Number of Last Filing: MILL-130951718

Company Rate Information

Company	Overall % Indicated	Overall %	Written Premium Change for	Number of Policy Holders Affected	Written Premium for	Maximum % Change	Minimum % Change
Name: Blue Cross of Northeastern Pennsylvania	Change: 40.900%	Impact: 40.900%	\$3,618	for this Program:	\$8,847	(where req'd): 139.200%	(where req'd): 40.900%

State: Pennsylvania Filing Company: Blue Cross of Northeastern Pennsylvania

TOI/Sub-TOI: LTC03G Group Long Term Care/LTC03G.001 Qualified

Product Name: Long-Term Care

Project Name/Number: MedAmerica Nationwide 2018 Rate Increase/145MAI01-30.06

Rate/Rule Schedule

Item No.	Schedule Item Status	Document Name	Affected Form Numbers (Separated with commas)	Rate Action	Rate Action Information	Attachments
1		Series 11 Group Rate Tables	GRP11-342-PA-1100	Revised	Previous State Filing Number: MILL-130951718 Percent Rate Change Request: 40.9	PA_BCNEPA_Current Premium Rates_Series 11 Group_20180815.pdf, PA_BCNEPA_Propose d Premium Rates_Series 11 Group_20180815.pdf,

Comprehensive Tax Qualified Certificate

Group Rates for Lifetime Premium Payment Option 0 Day Elimination Period Annual Premium Rates with 20% Rate Increase Rates per \$10 Daily Benefit

Certificate: GRP11-342-PA-1100
Base Certificate with No Inflation Protection

Rider: GRP11-SIP-PA-998 Simple Inflation Protection Rider

Issue		E	Benefit Period	ı				Benefit Period	1				В	enefit Period		
Age	2 Years	3 Years	4 Years	5 Years	Lifetime	2 Years	3 Years	4 Years	5 Years	Lifetime	2 Yea	ars 3 Ye		4 Years	5 Years	Lifetime
<22	7	8	10	10	13	3	5	5	7	8		25	32	38	45	57
22	8	8	10	12	15	3	5	5	7	8		25	33	40	45	58
23	8	8	10	12	15	3	5	7	7	10		25	35	42	48	60
24	8	10	12	12	17	3	5	7	8	10		27	35	42	50	62
25	8	10	12	13	17	5	5	7	8	12		28	37	43	50	65
26	8	10	12	13	18	5	7	7	8	12		30	38	47	53	67
27	10	12	13	15	18	5	7	7	8	13		30	38	47	55	70
28	10	12	13	15	20	5	7	8	10	13		30	40	48	57	72
29	10	12	13	17	22	5	7	10	10	13		32	42	52	58	73
30	10	13	15	17	22	7	7	10	12	15		33	43	53	62	78
31	12	13	15	18	23	7	8	10	12	17		33	45	55	63	80
32	12	15	17	18	25	7	8	10	13	17		35	45	57	67	83
33	12	15	18	20	27	8	10	12	13	18		38	48	58	68	85
34	13	17	18	22	28	8	10	13	13	20		38	48	62	70	88
35	13	17	20	23	30	8	12	13	15	22		40	52	63	72	92
36	15	18	22	23	32	8	12	13	17	23		40	53	65	77	95
37	15	18	22	25	33	10	13	17	18	25		43	55	68	78	98
38	17	20	23	27	37	10	13	17	20	25		43	57	70	82	100
39	17	22	25	30	38	12	13	18	20	28		47	58	73	83	105
40	18	23	27	32	42	12	15	20	22	28		47	60	75	87	107
41	20	25	28	33	43	12	17	22	23	32		48	63	78	90	112
42	22	27	32	35	47	13	17	22	27	33		50	65	80	93	115
43	22	28	33	38	50	15	18	23	27	37		53	67	83	97	118
44	23	30	35	42	53	17	20	27	28	38		55	70	87	98	123
45	25	32	38	43	57	17	22	27	32	42		57	73	88	103	127
46	27	33	40	47	62	18	25	30	35	43		58	75	93	107	130
47	28	37	43	50	65	20	25	32	37	48		60	77	95	110	135
48	32	38	47	53	70	20	28	35	40	52		62	82	98	115	140
49	33	42	50	58	75	23	30	37	43	55		63	83	102	117	145
50	35	45	55	63	82	25	32	38	45	58		67	87	105	122	148
51	38	48	58	68	87	27	35	43	48	63		68	88	108	125	153
52	42	52	63	73	93	28	38	47	53	68		70	92	112	130	158
53	45	57	68	78	102	30	40	50	58	72		72	95	117	135	162
54	48	62	73	85	108	33	43	53	62	78		75	97	120	138	168
55	52	67	80	93	118	37	47	58	67	82			100	123	142	173
56	57	72	87	100	127	38	50	62	72	90			105	128	148	178
57	62	78	95	108	137	40	53	65	78	97		82	107	132	153	185
58	67	85	103	118	148	43	57	70	83	102		85	110	135	157	190
59	72	92	112	128	162	48	62	77	88	108		87	115	140	162	195
60	78	100	122	140	175	52	67	82	97	117		90	118	145	168	202
61	85	108	132	153	190	55	72	88	102	125		93	122	150	172	207
62	92	118	143	167	207	58	77	93	108	132		97	125	153	177	212
63	100	128	157	182	224	62	82	100	115	140		98	128	158	182	218
64	108	140	170	197	242	67	87	107	123	148		102	132	162	188	225
65	118	153	187	215	264	70	92	112	132	158		105	137	167	193	232
66	128	167	202	234	287	75	97	120	140	167		107	140	172	200	237
67	140	180	220	255	310	78	103	127	147	177		108	143	175	203	242
68	152	197	240	277	337	82	108	132	155	185		112	147	178	208	247
69	163	213	260	302	365	87	113	140	162	193			148	183	212	252
70	178	232	284	329	395	90	118	147	170	203			153	187	217	259
71	193	252	307	357	429	95	123	153	177	213			155	192	220	262
72	208	272	334	387	465	98	130	160	185	220			158	193	224	264
73	225	295	362	419	504	102	133	165	192	227		122	158	195	227	265
74	244	319	390	454	542	105	138	170	197	235		122	160	197	227	269
75	267	349	427	495	592	108	143	177	205	242		123	162	198	230	269
76	290	380	465	540	644	112	147	182	210	249			162	200	230	270
77	315	412	507	589	699	113	152	185	215	255			162	200	230	270
78	342	449	550	640	759	117	153	190	220	260			162	200	230	270
79	370	487	599	696	824	117	153	190	220	260			162	200	230	270
80	404	530	655	762	901	117	153	190	220	260			162	200	230	270
81	437	575	711	827	976	117	153	190	220	260			162	200	230	270
82	472	624	769	897	1,056	117	153	190	220	260			162	200	230	270
83	510	672	832	969	1,139	117	153	190	220	260			162	200	230	270
84	550	726	899	1,047	1,229	117	153	190	220	260			162	200	230	270
85	594	782	969	1,131	1,324	117	153	190	220	260		123	162	200	230	270

Comprehensive Tax Qualified Certificate

Group Rates for 20-Year Premium Payment Option 0 Day Elimination Period Annual Premium Rates with 20% Rate Increase Rates per \$10 Daily Benefit

Certificate: GRP11-342-PA-1100
Base Certificate with No Inflation Protection

Rider: GRP11-SIP-PA-998 Simple Inflation Protection Rider

Issue		E	Benefit Period	ı				Benefit Period	ı				Benefit Period		
Age	2 Years	3 Years	4 Years	5 Years	Lifetime	2 Years	3 Years	4 Years	5 Years	Lifetime	2 Years	3 Years	4 Years	5 Years	Lifetime
<22	12	13	17	18	23	7	8	10	13	18	7	0 92	112	130	160
22	12	13	17	18	25	7	10	12	15	18	7	2 93	113	133	163
23	12	15	17	20	27	8	10	13	15	18	7	3 95	117	135	165
24	13	15	18	20	27	8	12	13	17	22	7	3 97	118	138	170
25	13	17	20	22	28	8	12	13	17	22	7			140	173
26	13	17	20	23	30	10	12	15	17	23	7			142	175
27	15	18	22	25	32	10	12	15	17	25	. 7			143	178
28	15	18	22	25	33	10	13	17	20	27	. 8			148	182
29	17	20	23	27	35	10	13	18	20	28	8			150	185
30	17	20	25	28	37	12	17	18	22	30	8			152	188
31	18	22	27	30	38	12	17	20	23	32	8			155	192
32	18	23	27	32	42	13	17	22	25	32	8			158	193
33	20	25	28	33	43	13	17	23	27	35	8			160	198
34	20	25	30	35	47	15	20	25	28	35	8			163	200
35	22	27	32	37	48	15	20	27	30	38	9			167	203
36	23	28	35	40	52	17	22	27	30	40	9			168	207
37	23	30	37	42	55	18	23	28	33	42	9			172	210
38	25	32	38	43	57	20	25	30	35	47	9			175	215
39	27	33	40	47	60	20	27	32	37	48	9			177	217
40	28	35	43	50	65	22	28	33	38	50	9			178	218
41	30	38	45	52	68	22	28	37	43	53	9			183	224
42	32	40	48	55	72	23	32	38	45	57	10			185	227
43	33	40	52	58	77	25 25	33	30 40	48	60	10			188	229
43	35	42	53	62	80	25	35	43	52	65	10			192	234
45	37	45	53 57	67	85	30		43		68					237
45 46	40	50	60	70	90	30	38 40	50	53 57	72	10 10			193 197	239
47		53	65	70 75	95	32	40	52	60	77	10				242
	42													198	
48	45	57	68	78	102	33	45	55	65	80	10			202	245
49	47	60	73	83	108	37	47	57	68	83	11			205	247
50	50	63	77	90	115	38	50	62	72	88	11			207	250
51	53	68	82	95	122	40	53	67	77	95	11			210	254
52	57	72	88	102	128	43	57	68	80	102	11			213	259
53	60	77	93	108	137	47	60	73	85	107	11			215	260
54	63	82	100	115	147	50	63	78	92	112	11			218	262
55	68	88	107	123	157	52	67	83	97	117	12			222	265
56	73	93	115	132	167	55	72	87	102	123	12			224	269
57	78	100	122	142	177	57	75	93	107	132	12			225	272
58	83	108	132	152	190	62	78	97	113	138	12			229	274
59	90	115	140	163	202	63	83	103	118	147	12			230	277
60	97	123	152	175	217	67	88	108	125	153	12			234	280
61	103	133	162	187	232	70	92	115	133	162	12			237	284
62	110	142	173	202	249	75	98	120	138	168	12			239	285
63	118	153	187	215	265	78	102	125	147	177	13			242	289
64	127	163	200	232	285	82	108	132	153	185	13			244	289
65	137	177	215	250	305	85	113	138	160	193	13			245	294
66	147	190	232	269	327	90	117	145	168	203	13			249	295
67	157	203	250	289	352	93	123	150	175	210	13			250	297
68	168	220	269	312	377	98	127	157	182	218	13			252	300
69	182	237	289	335	405	100	132	163	190	227	13			254	302
70	195	255	312	362	437	105	137	168	197	234	13			255	302
71	210	274	337	390	470	108	143	173	203	240	13			257	302
72	225	295	362	420	505	112	147	180	208	249	13			257	304
73	242	317	390	452	542	115	150	185	215	257	13			259	304
74	260	340	419	487	582	117	155	190	220	262	13			259	304
75	284	370	454	527	629	118	157	195	227	267	13			259	304
76	305	400	492	572	681	123	162	198	230	274	13			259	304
77	330	434	534	620	737	125	163	202	235	277	13			259	304
78	357	469	577	672	797	127	167	207	239	282	13			259	304
79	385	507	625	727	861	127	167	207	239	282	13			259	304
80	417	550	679	791	934	127	167	207	239	282	13			259	304
81	450	594	734	854	1,009	127	167	207	239	282	13			259	304
82	485	640	792	924	1,087	127	167	207	239	282	13			259	304
83	522	691	854	996	1,171	127	167	207	239	282	13			259	304
84	562	742	919	1,074	1,259	127	167	207	239	282	13			259	304
85	604	799	989	1,154	1,353	127	167	207	239	282	13	8 182	224	259	304

Comprehensive Tax Qualified Certificate

Group Rates for Lifetime Premium Payment Option 0 Day Elimination Period Annual Premium Rates with the Requested Rate Increase Rates per \$10 Daily Benefit

Certificate: GRP11-342-PA-1100
Base Certificate with No Inflation Protection

Rider: GRP11-SIP-PA-998 Simple Inflation Protection Rider

Issue		Е	Benefit Period					Benefit Period	I					Benefit Period		
Age	2 Years	3 Years	4 Years	5 Years	Lifetime	2 Years	3 Years	4 Years	5 Years	Lifetime	2	Years	3 Years	4 Years	5 Years	Lifetime
						· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·						· ·	·	
<22	9	12	14	14	32	5	7	7	9	20		35	45	54	63	136
22	12	12	14	16	36	5	7	7	9	20		35	47	56	63	140
23	12	12	14	16	36	5	7	9	9	24		35	49	59	68	144
24	12	14	16	16	40	5	7	9	12	24		38	49	59	71	148
25	12	14	16	19	40	7	7	9	12	28		40	52	61	71	156
26	12	14	16	19	44	7	9	9	12	28		42	54	66	75	160
27	14	16	19	21	44	7	9	9	12	32		42	54	66	78	168
28	14	16	19	21	48	7	9	12	14	32		42	56	68	80	172
29	14	16	19	24	52	7	9	14	14	32		45	59	73	82	176
30	14	19	21	24	52	9	9	14	16	36		47	61	75	87	188
31	16	19	21	26	56	9	12	14	16	40		47	63	78	89	192
32	16	21	24	26	60	9	12	14	19	40		49	63	80	94	200
33	16	21	26	28	64	12	14	16	19	44		54	68	82	96	203
34	19	24	26	31	68	12	14	19	19	48		54	68	87	99	211
35	19	24	28	33	72	12	16	19	21	52		56	73	89	101	219
36 37	21	26	31	33 35	76 80	12	16	19	24	56		56	75 78	92	108	227
	21	26	31			14	19	24	26	60		61		96	110	235
38 39	24 24	28 31	33 35	38 42	88 92	14 16	19 19	24 26	28 28	60 68		61 66	80 82	99 103	115 118	239 251
40	24	33	38	42	100	16	21	28	31	68		66	85	103	122	255
41	28	35	40	45	104	16	21	31	33	76		68	89	110	127	267
42	31	38	45	49	112	19	24	31	38	80		71	92	113	132	275
43	31	40	47	54	120	21	26	33	38	88		75	94	118	136	283
44	33	42	49	59	128	24	28	38	40	92		78	99	122	139	295
45	35	45	54	61	136	24	31	38	45	100		80	103	125	146	303
46	38	47	56	66	148	26	35	42	49	104		82	106	132	150	311
47	40	52	61	71	156	28	35	45	52	116		85	108	134	155	323
48	45	54	66	75	168	28	40	49	56	124		87	115	139	162	335
49	47	59	71	82	180	33	42	52	61	132		89	118	143	165	347
50	49	63	78	89	196	35	45	54	63	140		94	122	148	172	355
51	54	68	82	96	207	38	49	61	68	152		96	125	153	176	367
52	59	73	89	103	223	40	54	66	75	164		99	129	157	183	379
53	63	80	96	110	243	42	56	71	82	172		101	134	165	190	387
54	68	87	103	120	259	47	61	75	87	188		106	136	169	195	403
55	73	94	113	132	283	52	66	82	94	196		110	141	174	200	415
56	80	101	122	141	303	54	71	87	101	215		113	148	181	209	427
57	87	110	134	153	327	56	75	92	110	231		115	150	186	216	443
58	94	120	146	167	355	61	80	99	118	243		120	155	190	221	455
59	101	129	157	181	387	68	87	108	125	259		122	162	197	228	467
60	110	141	172	197	419	73	94	115	136	279		127	167	204	237	483
61	120	153	186	216	455	78	101	125	143	299		132	172	212	242	495
62	129	167	202	235	495	82	108	132	153	315		136	176	216	249	507
63	141	181	221	256	535	87	115	141	162	335		139	181	223	256	523
64	153	197	240	277	579	94	122	150	174	355		143	186	228	266	539
65	167	216	263	303	630	99	129	157	186	379		148	193	235	273	555
66	181	235	284	329	686	106	136	169	197	399		150	197	242	282	567
67	197	254	310	360	742	110	146	179	207	423		153	202	247	287	579
68	214	277	338	390	806	115	153	186	219	443		157	207	251	294	591
69	230	301	367	425	874	122	160	197	228	463		162	209	259	298	602
70	251	327	400	463	946	127	167	207	240	487		165	216	263	306	618
71	273	355	432	503	1,025	134	174	216	249	511		167	219	270	310	626
72	294	383	470	545	1,113	139	183	226	261	527		169	223	273	315	630
73	317	416	510	590	1,205	143	188	233	270	543		172	223	275	320	634
74	343	449	550	639	1,297	148	195	240	277	563		172	226	277	320	642
75	376	491	602	698	1,416	153	202	249	289	579		174	228	280	324	642
76	409	536	656	761	1,540	157	207	256	296	595		174	228	282	324	646
77	444	580	714	830	1,672	160	214	261	303	610		174	228	282	324	646
78	482	632	776	902	1,815	165	216	268	310	622		174	228	282	324	646
79	522	686	844	980	1,971	165	216	268	310	622		174	228	282	324	646
80	569	747	924	1,074	2,155	165	216	268	310	622		174	228	282	324	646
81	616	811	1,001	1,166	2,334	165	216	268	310	622		174	228	282	324	646
82	665	879	1,083	1,264	2,526	165	216	268	310	622		174	228	282	324	646
83	719	947	1,173	1,365	2,725	165	216	268	310	622		174	228	282	324	646
84	776	1,022	1,267	1,476	2,941	165	216	268	310	622		174	228	282	324	646
85	837	1,102	1,365	1,593	3,168	165	216	268	310	622		174	228	282	324	646

Comprehensive Tax Qualified Certificate

Group Rates for 20-Year Premium Payment Option 0 Day Elimination Period Annual Premium Rates with the Requested Rate Increase Rates per \$10 Daily Benefit

Certificate: GRP11-342-PA-1100
Base Certificate with No Inflation Protection

Rider: GRP11-SIP-PA-998 Simple Inflation Protection Rider

Issue			Benefit Period					Benefit Period					Benefit Period		
Age	2 Years	3 Years	4 Years	5 Years	Lifetime	2 Years	3 Years	4 Years	5 Years	Lifetime	2 Years	3 Years	4 Years	5 Years	<u>Lifetime</u>
<22	16	19	24	26	56	9	12	14	19	44	99	129	157	183	383
22	16	19	24	26	60	9	14	16	21	44	101	132	160	188	391
23	16	21	24	28	64	12	14	19	21	44	103	134	165	190	395
24	19	21	26	28	64	12	16	19	24	52	103	136	167	195	407
25 26	19 19	24 24	28 28	31 33	68 72	12 14	16 16	19 21	24 24	52 56	106 110	139 141	169 174	197 200	415 419
27	21	26	31	35	76	14	16	21	24	60	110	143	176	202	427
28	21	26	31	35	80	14	19	24	28	64	113	148	181	209	435
29	24	28	33	38	84	14	19	26	28	68	113	148	183	212	443
30 31	24 26	28 31	35 38	40 42	88 92	16 16	24 24	26 28	31 33	72 76	118 118	153 155	186 188	214 219	451 459
32	26	33	38	45	100	19	24	31	35	76	122	157	193	223	463
33	28	35	40	47	104	19	24	33	38	84	122	160	197	226	475
34	28	35	42	49	112	21	28	35	40	84	125	165	200	230	479
35 36	31 33	38 40	45 49	52 56	116 124	21	28 31	38 38	42 42	92 96	127	167	202 204	235 237	487 495
37	33	40 42	49 52	56 59	124	24 26	33	38 40	42 47	100	129 132	169 172	204	242	503
38	35	45	54	61	136	28	35	42	49	112	134	174	212	247	515
39	38	47	56	66	144	28	38	45	52	116	136	176	216	249	519
40	40	49	61	71	156	31	40	47	54	120	136	181	219	251	523
41 42	42 45	54 56	63 68	73 78	164 172	31 33	40 45	52 54	61 63	128 136	139 141	181 183	223 226	259 261	535 543
43	47	59	73	82	184	35	47	56	68	144	143	188	228	266	547
44	49	63	75	87	192	38	49	61	73	156	146	190	233	270	559
45	52	66	80	94	203	42	54	66	75	164	148	193	237	273	567
46 47	56 59	71 75	85 92	99 106	215	42 45	56 59	71 73	80 85	172 184	150 153	195 197	240 242	277 280	571 579
47	63	75 80	92 96	110	227 243	45 47	63	73 78	92	184	153	200	242 247	280 284	579 587
49	66	85	103	118	259	52	66	80	96	200	157	204	249	289	591
50	71	89	108	127	275	54	71	87	101	211	157	207	254	291	599
51	75	96	115	134	291	56	75	94	108	227	160	209	256	296	606
52	80 85	101 108	125	143	307	61 66	80	96	113	243	162	214	259	301	618
53 54	85 89	115	132 141	153 162	327 351	71	85 89	103 110	120 129	255 267	165 167	216 219	263 266	303 308	622 626
55	96	125	150	174	375	73	94	118	136	279	169	219	270	313	634
56	103	132	162	186	399	78	101	122	143	295	169	223	270	315	642
57	110	141	172	200	423	80	106	132	150	315	172	226	275	317	650
58 59	118 127	153 162	186 197	214 230	455 483	87 89	110 118	136 146	160 167	331 351	174 174	226 230	277 282	322 324	654 662
60	136	174	214	247	519	94	125	153	176	367	176	233	284	329	670
61	146	188	228	263	555	99	129	162	188	387	179	235	289	334	678
62	155	200	244	284	595	106	139	169	195	403	181	237	291	336	682
63	167 179	216 230	263	303	634	110	143	176	207	423 443	183	240	294 296	341	690
64 65	179	249	282 303	327 353	682 730	115 120	153 160	186 195	216 226	443 463	186 186	242 244	296 301	343 345	690 702
66	207	268	327	378	782	127	165	204	237	487	188	247	303	350	706
67	221	287	353	407	842	132	174	212	247	503	190	249	303	353	710
68	237	310	378	439	902	139	179	221	256	523	193	249	308	355	718
69 70	256 275	334 360	407 439	472 510	970 1,045	141 148	186 193	230 237	268 277	543 559	193 195	251 254	310 310	357 360	722 722
71	275	385	439 475	550	1,125	153	202	244	287	575	195	254	313	362	722
72	317	416	510	592	1,209	157	207	254	294	595	195	256	315	362	726
73	341	447	550	637	1,297	162	212	261	303	614	195	256	315	364	726
74	367	479	590	686	1,393	165	219	268	310	626	195	256	315	364	726
75 76	400 430	522 564	639 693	743 806	1,504 1,628	167 174	221 228	275 280	320 324	638 654	195 195	256 256	315 315	364 364	726 726
77	465	611	752	874	1,764	174	230	284	331	662	195	256	315	364	726
78	503	660	813	947	1,907	179	235	291	336	674	195	256	315	364	726
79	543	714	881	1,025	2,059	179	235	291	336	674	195	256	315	364	726
80	588	776	956	1,114	2,234	179	235	291	336	674	195	256	315	364	726
81 82	635 684	837 902	1,034 1,116	1,203 1,302	2,414 2,601	179 179	235 235	291 291	336 336	674 674	195 195	256 256	315 315	364 364	726 726
83	736	973	1,203	1,403	2,801	179	235	291	336	674	195	256	315	364	726
84	792	1,046	1,295	1,513	3,012	179	235	291	336	674	195	256	315	364	726
85	851	1,126	1,394	1,626	3,236	179	235	291	336	674	195	256	315	364	726

State: Pennsylvania Filing Company: Blue Cross of Northeastern Pennsylvania

TOI/Sub-TOI: LTC03G Group Long Term Care/LTC03G.001 Qualified

Product Name: Long-Term Care

Project Name/Number: MedAmerica Nationwide 2018 Rate Increase/145MAI01-30.06

Supporting Document Schedules

Satisfied - Item:	Transmittal Letter (A&H)
Comments:	
Attachment(s):	PA_Cover Letter_BCNEPA_Group_LRRS_20180815.pdf
Item Status:	
Status Date:	
Bypassed - Item:	Actuarial Certification (A&H)
Bypass Reason:	Not applicable as this is not a form filing.
Attachment(s):	
Item Status:	
Status Date:	
Satisfied - Item:	Actuarial Memorandum and Explanatory Information (A&H)
Comments:	
Attachment(s):	PA_ActMemo_BCNEPA_Group_LRRS_20180815.pdf PA_Supplement_BCNEPA_Group_LRRS_20180815.pdf
Item Status:	
Status Date:	
Bypassed - Item:	Advertisements (A&H)
Bypass Reason:	Not applicable as this is not a form filing.
Attachment(s):	
Item Status:	
Status Date:	
Satisfied - Item:	Authorization to File (A&H)
Comments:	
Attachment(s):	2016 Highmark Letter of Authorization_20160407.pdf
Item Status:	
Status Date:	
Bypassed - Item:	Insert Page Explanation (A&H)
Bypass Reason:	Not applicable as this is not a form filing.
Attachment(s):	- · · ·
Item Status:	

SERFF Tracking #:	MILL-131014380	State Tracking #:	MILL-131614386		Company Tracking #:	SERIES 11 GROUP (BUNEPA)	
State:	Pennsylvania	Long Torm Core/LTC02C 00		Filing Company:	Blue Cross of North	eastern Pennsylvania	
Ol/Sub-TOI: Product Name:	Li Co3G Group Long-Term Car	Long Term Care/LTC03G.00	71 Qualified				
Project Name/Number:	=	e ationwide 2018 Rate Increase	2/145M∆I01-30 06				
rojeot name/namber.	wed interior ve	anonwae 2010 Nate mercae	, 140W 110 1 00.00				
Status Date:							
Satisfied - Item:		Rate Table (A&H)					
Comments:	F	Rate tables are attached	d on the Rate/Rule	e Schedule tab.			
Attachment(s):							
Item Status:							
Status Date:							
Bypassed - Item:	F	Replacement Form with	Highlighted Chan	nges (A&H)			
Bypass Reason:		Not applicable as this is		<u> </u>			
Attachment(s):							
Item Status:							
Status Date:							
Bypassed - Item:	F	Reserve Calculation (A&	ßН)				
Bypass Reason:	1	Not applicable as this is	not a form filing.				
Attachment(s):							
Item Status:							
Status Date:							
Bypassed - Item:	\	Variability Explanation (A&H)				
Bypass Reason:	1	Not applicable as this is	not a form filing.				
Attachment(s):							
Item Status:							
Status Date:							
Satisfied - Item:	1	Numerical Data in Exce	l				
Comments:							
Attachment(s):	F	PA_Supplement Attachi	ments_LRRS_201	80815.xlsb			
Item Status:							
Status Date:							
Satisfied - Item:	9	Sample Policyholder No	otification Letter				
Comments:							
Attachment(s):	F	Premier BC of NEPA Premier BC of NEPA CI	H Letter 7.16.18.pdf	df			
Item Status:			- 1 -				
Status Date:							

State: Pennsylvania Filing Company: Blue Cross of Northeastern Pennsylvania

TOI/Sub-TOI: LTC03G Group Long Term Care/LTC03G.001 Qualified

Product Name: Long-Term Care

Project Name/Number: MedAmerica Nationwide 2018 Rate Increase/145MAI01-30.06

State: Pennsylvania Filing Company: Blue Cross of Northeastern Pennsylvania

TOI/Sub-TOI: LTC03G Group Long Term Care/LTC03G.001 Qualified

Product Name: Long-Term Care

Project Name/Number: MedAmerica Nationwide 2018 Rate Increase/145MAI01-30.06

Attachment PA_Supplement Attachments_LRRS_20180815.xlsb is not a PDF document and cannot be reproduced here.



8500 Normandale Lake Blvd. Suite 1850 Minneapolis, MN 55437-3830 USA

Tel +1 952 897 5300 Fax +1 952 897 5301

milliman.com

August 15, 2018

Honorable Jessica K. Altman Insurance Commissioner Pennsylvania Department of Insurance (Department)

Via SERFF

Re: Blue Cross of Northeastern Pennsylvania (BCNEPA)
Company NAIC # 54747
SERFF Tracking # MILL-131614386
Series 11 Group
Comprehensive Form

Comprehensive Certificate

GRP11-341-PA-200 GRP11-342-PA-1100

Dear Commissioner Altman:

On behalf of the company, we are submitting the referenced rate filing for your review. These are existing products that provide long-term care coverage on a group basis. The company issued these products in Pennsylvania from August 1, 2002 to November 1, 2002 and is no longer marketing them in any jurisdiction. The company is making a similar request on the Series 11 Individual policy form(s) in a concurrent filing (SERFF Tracking # MILL-131567828).

The company is requesting a premium rate increase on the above-listed form(s), including all associated riders. The need for a premium rate increase is due to emerging and projected experience running more adverse than previously expected.

These products were designed and priced by MedAmerica Insurance Company (MedAmerica), which is an affinity partner. The products were issued on BCNEPA paper, while MedAmerica administers and manages the block, including underwriting and claims handling. MedAmerica has 100% of the risk on these products via a reinsurance arrangement with BCNEPA.

Additionally, MedAmerica is making a similar request in concurrent filings. These filings use identical pooled nationwide experience of MedAmerica and its affinity partners individual and group business as described in the enclosed actuarial memorandum.

The company is requesting a premium rate increase that varies by benefit period to achieve the cumulative rate increases shown in the following table. The rate increase varies by benefit period to better align the rate increase with the adverse experience. The following table provides the average prior, requested, and cumulative rate increases by benefit period for the above-listed form(s).

Offices in Principal Cities Worldwide

This work product was prepared solely to provide assistance to MedAmerica. Milliman does not intend to benefit and assumes no duty or liability to other parties who receive this work. Milliman recommends recipient be aided by its own actuary or other qualified professional when reviewing the Milliman work product.



Pennsylvania – BCNEPA Rate Increase Request

Policy Form Cohort	Benefit Period	Prior Increase	Requested Increase	Cumulative Increase
Series 11 Group	Non-Lifetime	66.8%	40.9%	135%
Series 11 Group	Lifetime	66.8	139.2	299
Average ^[1]		66.8	40.9	135

[1] As of December 31, 2017 and excludes policies assumed to be paid up prior to implementation of the requested rate increase.

The prior increase reflects the cumulative increase of two prior increase(s) that were filed for use in May 2010 and September 2017 on the forms. The company is seeking this rate increase request to help alleviate the adverse performance on this block of business.

Similar to the prior increase(s), the company will offer insureds affected by the premium increase the option of reducing their policy benefits to provide flexibility of choice for those insureds who wish to maintain a premium level reasonably similar to what they were paying prior to the rate increase. The company will offer a contingent benefit upon lapse to insureds that trigger a substantial rate increase. Additionally, the company will voluntarily offer a contingent benefit upon lapse to insureds affected by the rate increase, even if the increase is not considered substantial.

The following electronic items are included with this submission:

- cover letter
- letter from the company authorizing submission of this filing on its behalf
- actuarial memorandum
- supplement to the actuarial memorandum
- current and proposed premium rate schedules
- sample policyholder notification letter*

No filing fee is required for this submission.

^{*}Please note that in the future slight variations in language may occur that do not materially change the information being provided to the policyholder. It is our understanding that such variations do not need to be filed with the Department.



The contact person for this filing is:

Michael Emmert, ASA, MAAA Associate Actuary Milliman, Inc. 8500 Normandale Lake Blvd., Suite 1850 Minneapolis, MN 55437 (952) 820-3116 michael.emmert@milliman.com

Thank you for your assistance in reviewing this filing.

Respectfully,

Missy Gordon, FSA, MAAA Principal and Consulting Actuary

MAG/dpl

Enclosures

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

Series 11 and Prior Actuarial Memorandum

August 15, 2018

<u>Product</u> <u>Number</u>

Series 11 Group

Comprehensive Form GRP11-341-PA-200 Comprehensive Certificate GRP11-342-PA-1100

Blue Cross of Northeastern Pennsylvania (BCNEPA) is requesting a rate increase on the above-listed policy form(s). The company issued this policy form(s) in Pennsylvania from August 2002 through November 2002 and is no longer marketing it in any jurisdiction. As described in the enclosed cover letter, the affinity partner MedAmerica Insurance Company (MedAmerica) designed, priced, administers, and manages the above-listed policy form(s).

Nationwide, MedAmerica and its affinity partners are requesting a premium rate increase that varies by benefit period to achieve the same cumulative rate increase, except where limited by regulatory restrictions. This actuarial memorandum captures the pooled nationwide experience of the above-listed policy form(s) and similar individual and group policy forms of the same product series issued nationwide by MedAmerica and its affinity partners.

1. Purpose of Filing

This actuarial memorandum has been prepared for the purpose of demonstrating that the nationwide cumulative rate increase discussed in Section 2 meets the minimum requirements of the applicable sections of the 2014 National Association of Insurance Commissioners (NAIC) Long-Term Care Insurance Model Regulation (Model Regulation). The enclosed supplement to the actuarial memorandum demonstrates compliance with the applicable regulatory requirements of this jurisdiction to the extent they differ from the Model Regulation, and includes other commonly requested information of this jurisdiction. It may not be suitable for other purposes.

2. Requested Rate Increase

The company is requesting a rate increase that varies by benefit period to achieve the cumulative rate increases shown below. The company is seeking this current rate increase request to help alleviate the adverse performance on this block of business.

The cumulative rate increase levels were determined to vary by benefit period to better align the rate increase with the adverse experience. MedAmerica's goal is equity across all jurisdictions, to the extent practical. The rate increase was determined in such a way that minimizes subsidization across jurisdictions due to differences in the previously filed rate increases.

The table below provides the average prior, requested, and cumulative increases by benefit period based on the nationwide distribution business. The enclosed cover letter provides similar information based on the jurisdiction-specific distribution.

Nationwide Average^[1] Rate Increase Request

Policy Form	Benefit	Prior	Requested	Cumulative
Cohort	Period	Increase	Increase	Increase
Prior to Series 11	Non-Lifetime	62.0%	45.1%	135%
Filor to Selles 11	Lifetime	73.5	130.0	299
Series 11 Individual	Non-Lifetime	51.5	55.2	135
Series i i iliulviduai	Lifetime	67.0	138.9	299
Series 11 Group	Non-Lifetime	77.0	32.8	135
Selles 11 Gloup	Lifetime	69.6	135.2	299
Average		63.8	67.1	174

[1] As of December 31, 2017 and excludes policies assumed to be paid up prior to implementation of the requested rate increase. The enclosed cover letter provides the jurisdiction-specific distribution.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

Series 11 and Prior Actuarial Memorandum

August 15, 2018

A larger cumulative rate increase is needed to certify that rates will remain stable under moderately adverse conditions. The company will continue to monitor the business and reserves the right to request additional rate increases in the future.

Corresponding rate tables reflecting the proposed rate increases for the policy form(s) affected by this rate increase are enclosed with this filing. Please note that the actual rates implemented may vary from those in the enclosed rate tables slightly due to implementation rounding algorithms.

As the company is not currently marketing new business, the required statement that the renewal premium rate schedules are not greater than the new business premium rate schedules is not applicable.

3. Description of Benefits

These products provide long-term care coverage. The Series 11 products are tax-qualified, and were issued on an individual or group basis. The Prior to Series 11 product includes tax-qualified and non-tax qualified policy forms, and was issued on an individual basis. Each product has benefit eligibility requirements that involve activities of daily living (ADL) deficiencies or cognitive impairment. Waiver of premium is provided when certain benefits are being paid. A daily benefit, benefit period, and elimination period were selected at issue.

At issue, the insured may have had the option to choose one of the following inflation options, the availability of which varied by policy form: simple inflation for life, simple inflation for 20 years, or compound inflation. The two simple inflation options provide for benefit levels that increase on each anniversary date by 5% of the daily benefit amount chosen at issue for either the life of the insured or 20 years depending on the option chosen. The compound inflation option provides for benefit levels that increase on each anniversary date by 5% compounded annually for the life of the insured. These automatic increasing benefits apply even when the insured is in claim status. For Series 11 Group forms, the insured may have also had the option of a guaranteed purchase option. Under this option, the insured can purchase additional coverage amounts of 5% per year without additional underwriting.

The available choices for benefit period, elimination period, and inflation option are shown in Section 21.

At issue the insured may have had the option of selecting riders that provide the following types of coverage: nonforfeiture, restoration of benefits, return of premium, shortened benefit period, spousal benefit transfer, survivorship benefit, or monthly home health care benefit. The insured may have had the option to select a lifetime, ten-year, or twenty-year premium payment option.

A contingent benefit upon lapse (CBUL) will be available to all insureds at the time of the rate increase.

4. Renewability

These policies are guaranteed renewable for life.

5. Applicability

This rate increase applies to all policies issued on the above-listed form(s) in this jurisdiction. The rate changes will apply to the premium of the base form and all applicable options and riders associated with the base form.

6. Actuarial Assumptions

The following assumptions are used to project the experience shown in this filing.

a. Morbidity reflects claim costs developed using the 2014 Milliman Long-Term Care Guidelines (Guidelines) with adjustments for underwriting selection, an all-lives exposure basis, and three years of retrospective improvement to bring the Guidelines forward to 2017. The claim costs were further adjusted based on historical claim experience by policy form cohort, attained age, duration,

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

Series 11 and Prior Actuarial Memorandum

August 15, 2018

individual vs. group, payment type, and coverage type, to the extent credible. These adjustment factors can be found in Exhibit A-4a of Appendix A to this memorandum.

b. Mortality Rates reflect the 1994 Group Annuitant Mortality (GAM) Static gender-distinct table with retrospective improvement applied to bring this table forward to 2017. These mortality rates are further adjusted based on historical mortality experience by individual/group, issue age band, and duration as shown in the following tables.

		Mort	ality Dur	ational A	Adjustme	nt Facto	rs for In	dividual	Busines	S		
			•			Issue	Age					
Duration*	<25	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
1	25%	25%	25%	25%	25%	25%	25%	25%	25%	25%	25%	20%
2	35	35	35	35	35	35	35	35	35	35	35	30
3	40	40	40	40	40	40	40	40	40	40	40	45
4	43	43	43	43	43	43	43	43	44	45	45	50
5	46	46	46	46	46	46	46	46	48	50	50	55
6	49	49	49	49	49	49	49	49	52	55	55	60
7	52	52	52	52	52	52	52	52	56	60	60	65
8	55	55	55	55	55	55	55	55	60	65	65	70
9	56	56	56	56	56	56	56	56	61	68	69	76
10	57	57	57	57	57	57	57	57	62	71	73	82
11	58	58	58	58	58	58	58	58	63	74	77	88
12	59	59	59	59	59	59	59	59	64	77	81	94
13	60	60	60	60	60	60	60	60	65	80	85	100
14	62	62	62	62	62	62	62	62	69	82	88	101
15	64	64	64	64	64	64	64	64	73	84	91	102
16	66	66	66	66	66	66	66	66	77	86	94	103
17	68	68	68	68	68	68	68	68	81	88	97	104
18	70	70	70	70	70	70	70	70	85	90	100	105
23	70	70	70	70	70	70	70	85	90	100	105	105
28	70	70	70	70	70	70	85	90	100	105	105	105
33	70	70	70	70	70	85	90	100	105	105	105	105
38	70	70	70	70	85	90	100	105	105	105	105	105
43	70	70	70	85	90	100	105	105	105	105	105	105
48	70	70	85	90	100	105	105	105	105	105	105	105
53	70	85	90	100	105	105	105	105	105	105	105	105
58	85	90	100	105	105	105	105	105	105	105	105	105
63	90	100	105	105	105	105	105	105	105	105	105	105
68	100	105	105	105	105	105	105	105	105	105	105	105
73+	105	105	105	105	105	105	105	105	105	105	105	105

^{*} The assumption varies by duration for 18+, but is shown every five years for display purposes.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

Series 11 and Prior Actuarial Memorandum

August 15, 2018

		Мо	rtality Du	urational	Adjustn	nent Fac	tors for	Group B	usiness			
						Issue	Age	-				
Duration*	<25	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
1	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	40%
2	70	70	70	70	70	70	70	70	70	70	70	60
3	80	80	80	80	80	80	80	80	80	80	80	90
4	86	86	86	86	86	86	86	86	88	90	90	100
5	92	92	92	92	92	92	92	92	96	100	100	105
6	83	83	83	83	83	83	83	83	88	94	94	102
7	83	83	83	83	83	83	83	83	90	96	96	104
8	83	83	83	83	83	83	83	83	90	98	98	105
9	81	81	81	81	81	81	81	81	88	98	99	105
10	79	79	79	79	79	79	79	79	86	98	101	105
11	77	77	77	77	77	77	77	77	83	98	102	105
12	74	74	74	74	74	74	74	74	81	97	102	105
13	72	72	72	72	72	72	72	72	78	96	102	105
14	74	74	74	74	74	74	74	74	82	98	105	105
15	76	76	76	76	76	76	76	76	86	99	105	105
16	77	77	77	77	77	77	77	77	90	101	105	105
17	79	79	79	79	79	79	79	79	94	102	105	105
18	81	81	81	81	81	81	81	81	98	104	105	105
23	77	77	77	77	77	77	77	94	99	105	105	105
28	74	74	74	74	74	74	89	95	105	105	105	105
33	70	70	70	70	70	85	90	100	105	105	105	105
38	70	70	70	70	85	90	100	105	105	105	105	105
43	70	70	70	85	90	100	105	105	105	105	105	105
48	70	70	85	90	100	105	105	105	105	105	105	105
53	70	85	90	100	105	105	105	105	105	105	105	105
58	85	90	100	105	105	105	105	105	105	105	105	105
63	90	100	105	105	105	105	105	105	105	105	105	105
68	100	105	105	105	105	105	105	105	105	105	105	105
73+	105	105	105	105	105	105	105	105	105	105	105	105

^{*} The assumption varies by duration for 18+, but is shown every five years for display purposes.

c. <u>Voluntary Lapse Rates</u> vary by policy duration, policy form cohort, and premium payment option. The lifetime-pay voluntary lapse rates are shown in the table below.

	Prior to	Series 11	Series 11
Duration	Series 11	Individual	Group
1	16.50%	8.50%	6.50%
2	8.50	4.00	6.00
3	5.00	2.75	4.00
4	3.50	2.00	3.50
5	2.00	1.50	3.00
6	1.50	1.25	2.50
7	1.50	1.25	2.00
8	1.50	1.00	1.50
9	1.50	0.75	1.30
10+	1.00	0.60	1.30

The voluntary lapse rates in the above table were adjusted based on the following criteria for the limited-pay options:

 For the ten-pay option, a reduction of 65% of the above lapse rates is assumed for durations one through four, a reduction of 70% of the above lapse rates is assumed for durations five through eight, and 0% lapse thereafter.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

Series 11 and Prior Actuarial Memorandum

August 15, 2018

- For the twenty-pay option, a reduction of 50% of the above lapse rates is assumed for durations one through eight, a reduction of 75% of the above lapse rates is assumed for durations nine through fifteen, and 0% lapse thereafter.
- d. <u>Benefit Expiry Rates</u> reflect assumed policy termination due to exhaustion of benefits on limited benefit period policies. The rates are based on the *Guidelines* with adjustments for historical benefit expiry experience and vary by gender, benefit period, and attained age as shown in the following table.

	Benefit						Attaine	d Age*				
Gender	Period in Years	<65	65	70	75	80	85	90	95	100	105	110+
Female	1	0.0%	0.1%	0.1%	0.3%	0.7%	2.5%	6.1%	10.7%	13.4%	16.7%	33.0%
	2	0.0	0.0	0.1	0.2	0.5	1.6	4.5	8.7	11.7	16.3	33.0
	3	0.0	0.0	0.1	0.1	0.4	1.2	3.4	6.9	9.7	15.0	33.0
	4	0.0	0.0	0.0	0.1	0.3	1.0	2.5	5.0	7.8	13.2	33.0
	5	0.0	0.0	0.0	0.1	0.2	0.7	1.7	3.8	6.3	11.2	33.0
	Unlimited	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Male	1	0.0	0.0	0.1	0.2	0.5	1.5	3.9	6.3	7.8	9.4	33.0
	2	0.0	0.0	0.1	0.1	0.3	1.0	2.5	4.3	5.4	7.3	33.0
	3	0.0	0.0	0.1	0.1	0.2	0.7	1.7	3.0	4.0	5.8	33.0
	4	0.0	0.0	0.0	0.1	0.1	0.4	1.1	2.0	2.8	4.6	33.0
	5	0.0	0.0	0.0	0.0	0.1	0.3	8.0	1.5	2.3	3.6	33.0
	Unlimited	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

^{*} The assumption varies by attained age, but is shown every five years for display purposes.

e. <u>Policyholder Behavior Due to the Rate Increase.</u> At the time of a rate increase, insureds have the option to elect a CBUL or reduced benefit options (RBO). An increase in morbidity for adverse selection due to the rate increase based on the percentage of policies that elect CBUL and RBO is assumed.

Insureds who elect a CBUL are modeled as a lapse (i.e., the CBUL benefit is not modeled), which results in a slightly lower lifetime loss ratio than if the CBUL benefit had been modeled. The following table provides the CBUL and RBO election rates, reduction to premiums and benefits due to the impact of RBO elections, and increase in morbidity for lifetime-pay policies based on the varying cumulative rate increase levels. Limited-pay policies are assumed to not elect CBUL or RBO.

Policyholder Behavior Assumptions[1]

Benefit Period	CBUL Election Rate	RBO Election Rate	Approximate Reduction for RBO	Morbidity Increase for Adverse Selection
Non-Lifetime	11%	20%	13%	5.5%
Lifetime	12	25	21	6.5

^[1] The values shown are based on the average cumulative amounts found in Section 2. The assumption is applied on a seriatim basis and prorated for the requested increase needed to achieve the cumulative amounts in Section 2.

f. <u>Interest Rate</u> consistent with the maximum valuation interest rate applicable to the year of issue (ranges from 3.5% to 5.5% and averages 4.3%) is used to demonstrate compliance with the minimum loss ratio requirements.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

Series 11 and Prior Actuarial Memorandum

August 15, 2018

- g. Annual Improvement in the mortality and morbidity assumptions is assumed for 15 years starting in 2018. Annual mortality improvement factors vary by attained age based on the G2 improvement scale from the 2012 Individual Annuity Mortality table. Annual morbidity improvement is assumed to be 1.0%.
- h. <u>Expenses</u> have not been explicitly projected. Originally filed expense assumptions are assumed to remain appropriate, except that reductions are made to the renewal commission rates so that the total commissions paid before and after any increase in premium are similar (i.e., commissions are not paid on the increased premium).

The above assumptions are based on the experience of the above-listed policy form(s) and similar forms issued by MedAmerica and its affinity partners and, where appropriate, other similar business, industry experience, and actuarial judgment. The above assumptions are deemed reasonable for the particular policy form(s) in this filing and are considered "most likely" (without explicit margin).

In establishing the assumptions described in this section, the policy design, underwriting, and claims adjudication practices for the above-referenced policy form(s) were taken into consideration. Appendix A to this memorandum provides a description of the development of and justification for the assumptions used in this filing.

The company is not currently marketing long-term care products. As a result, the requirement to reflect on any assumptions that deviate from those used for pricing other forms currently available for sale is not applicable.

7. Marketing Method

Agents and brokers of the company marketed these products.

8. Underwriting Description

Policies on the individual forms were fully underwritten.

On the group forms, actively at work employees were subject to short form underwriting. All others were subject to full underwriting.

Groups of at least 500 employees were eligible to elect modified guaranteed issue underwriting for those actively at work. If the employer agreed to contribute 100% of premium for a base plan for a minimum of three years, no underwriting was required for those actively at work.

For both individual and group business, the company used various underwriting tools in addition to the application, which may have included medical records, an attending physician's statement, telephone interview, and/or face-to-face assessment.

9. Premiums

Premiums are unisex and payable for life unless the insured selected a ten-year or twenty-year premium payment option. The premiums may vary by policy form, issue age, elimination period, benefit period, initial daily benefit, inflation option, premium payment option, underwriting class, joint/group discounts, home care percentage, copayment option, marital status at issue, and the selection of any riders.

10. Issue Age Range

Issue ages are from 18 to 85.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

Series 11 and Prior Actuarial Memorandum

August 15, 2018

11. Area Factors

Area factors are not used for these products.

12. Premium Modalization Rules

The following modal factors and percent distributions (based on the nationwide in-force count as of December 31, 2017) are applied to the annual premium (AP):

Premium Mode	Modal Factors	Percent Distribution
Annual	1.00*AP	45%
Semi-Annual	0.52*AP	4
Quarterly	0.26*AP	29
Monthly	0.09*AP	22

13. Reserves

Active life reserves and reserves for the election of a CBUL have not been used in the experience exhibits for this rate increase analysis. Claim reserves as of December 31, 2017 have been discounted to the incurral date of each respective claim and included in historical incurred claims. An incurred but not reported (IBNR) reserve balance as of December 31, 2017 has been allocated to the 2017 calendar year and included in historical incurred claims.

14. Trend Assumptions

As this is not medical insurance, an explicit medical cost trend is not included in the projections.

15. Demonstration of Satisfaction of Loss Ratio Requirements

This filing uses pooled nationwide experience of the above-listed form(s) and similar individual and group policy forms issued nationwide by MedAmerica and its affinity partners. The pooled experience is appropriate to increase credibility and allow for a uniform rate increase request across similar business. Applying a uniform rate increase to the pool of forms maintains the original pricing relationships of the product design and differences between individual and group business.

Further, pooling experience is appropriate because the products issued are identical, the marketing and distribution employed is similar, and the same company (MedAmerica) administers and manages the entire block (including underwriting and claims handling). MedAmerica has 50% to 100% of the risk of the affinity partner forms via reinsurance arrangements with each affinity partner.

Exhibit I provides actual and projected experience using current assumptions. Actual experience is provided from inception through 2017 and then projected on a seriatim basis for 60 years using the current assumptions described above in Section 6. The actual and projected experience is based on nationwide premiums that reflect prior rate increases filed for use between 2010 and April 2018, which average 64% across all jurisdictions. The after increase projected experience reflects the additional increase needed to achieve the cumulative increases shown in Section 2 on a seriatim basis.

Values in Exhibit I are shown (a) before and (b) after the nationwide requested rate increase. Included are calendar year earned premiums, incurred claims, end of year lives, annual loss ratios, and cumulative loss ratios. As shown in Exhibit I-b, the anticipated lifetime loss ratio with the nationwide requested rate increase exceeds the minimum loss ratio required by pre-rate stability regulation.

The following table demonstrates that the lifetime loss ratios by policy form cohort and benefit period exceed the minimum loss ratio required by pre-rate stability regulation. The final row corresponds to that shown in Exhibit I.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

Series 11 and Prior Actuarial Memorandum

August 15, 2018

Lifetime Loss Ratios at the Maximum Valuation Interest Rate by Policy Form Cohort and Benefit Period

Policy Form	Benefit	Before	After			
Cohort	Period	Increase	Increase			
Prior to Series 11	All	103%	98%			
Series 11 Individual	All	124	105			
Series 11 Group	All	103	91			
All	Non-Lifetime	96	87			
All	Lifetime	161	132			
All	All	113	100			

Exhibit II provides a demonstration that the nationwide requested rate increase meets the 58%/85% test required by post-rate stability regulation. This exhibit shows that the sum of the accumulated value of incurred claims without the inclusion of active life reserves, and the present value of projected incurred claims, without the inclusion of active life reserves, will not be less than the sum of the following:

- 1. Accumulated value of the initial earned premium times 58%.
- 2. 85% of the accumulated value of prior premium rate schedule increases,
- 3. Present value of projected initial earned premium times 58%, and
- 4. 85% of the present value of projected premium in excess of the projected initial earned premium.

The projected incurred claims in Exhibit II were increased by 15% from the current assumptions described in Section 6 to reflect assumptions that include moderately adverse conditions.

The following table demonstrates that the 58%/85% test is passed by policy form cohort and benefit period. The 'All' row corresponds to that shown in Exhibit II. Values in the table are shown in millions of dollars.

58%/85% Test by Policy Form Cohort and Benefit Period

Policy Form Cohort	Benefit Period	Item 5 ^[1]	Item 7 ^[2]	Result ^[3]		
Prior to Series 11	All	\$148.5	\$256.7	Pass		
Series 11 Individual	All	322.9	585.2	Pass		
Series 11 Group	All	138.8	216.0	Pass		
All	Non-Lifetime	431.0	655.9	Pass		
All	Lifetime	179.2	402.0	Pass		
All	All	610.2	1,057.9	Pass		

- [1] Item 5 is the Lifetime Earned Premium Times Prescribed Factor.
- [2] Item 7 is Lifetime Incurred Claims with Rate Increase.
- [3] Test of whether Item 7 is not less than Item 5.

16. Actual-to-Expected Experience

The following table provides a comparison of actual and projected experience using current assumptions to that expected using original pricing assumptions. Values in the following table are shown (a) before and (b) after the nationwide requested rate increase.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

Series 11 and Prior Actuarial Memorandum

August 15, 2018

Actual and Expected Loss Ratios by Policy Form Cohort and Benefit Period

		Lif	Lifetime Loss Ratio			Expected
Policy Form	Benefit	Before	After		Before	After
Cohort	Period	Increase	Increase	Expected	Increase	Increase
Prior to Series 11	All	98%	93%	66%	1.49	1.42
Series 11 Individual	All	115	98	58	1.97	1.69
Series 11 Group	All	91	81	70	1.31	1.16
All	Non-Lifetime	88	81	64	1.39	1.27
All	Lifetime	150	124	60	2.51	2.08
All	All	105	93	63	1.68	1.49

Actual and projected experience in the above table is identical to that described in Exhibit I, except uses the current most-likely interest rate assumption of 5.00%. This rate represents MedAmerica's expectation of its long-term investment earnings rate, which is supported by the average net investment earnings rate projected for MedAmerica's cash flow testing.

Expected experience uses the actual policies sold and projects from issue on a seriatim basis using the original pricing assumptions.

Exhibit III provides a comparison of the current and original pricing assumptions that underlie the actual and expected experience described above.

17. History of Previous Rate Revisions

Please see the enclosed cover letter, which provides the jurisdiction-specific average prior rate increase and rate history for the above-listed form(s).

Nationwide, there have been two prior rate increase requests on this block of business, which began in December 2009. Departments of insurance filed these increases for use between 2010 and 2017. As the goal of achieving similar cumulative rate increases across all jurisdictions is ongoing, additional increases have also been filed for use in 2018. On average, a cumulative increase of 64% has been filed for use on this block of business.

18. Analysis Performed to Consider a Rate Increase

The experience table in Section 16 above demonstrates that experience has been more adverse from that expected using original pricing assumptions as the A:E loss ratios exceeds 1.0. The adverse experience is due to a combination of higher persistency and lower interest.

The following table provides a comparison of actual and projected nationwide experience to that expected in pricing with respect to morbidity, mortality, lapse (combination of voluntary lapse and benefit expiry), interest, and improvement. The current and original pricing assumptions are provided in Exhibit III. Please note that to isolate the impact of each changed assumption from pricing, the experience in the table below has been restated to reflect no prior rate increases.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

Series 11 and Prior Actuarial Memorandum

August 15, 2018

Impact of Changing from Pricing to Current Assumptions

Scenario	Lifetime Loss Ratio (LLR)	Incremental Impact on the LLR ^[1]	Increase Needed ^[2]
Original pricing assumptions	63%	N/A	N/A
Historical experience through 2017 & projections with pricing assumptions	71	14%	180%
Historical experience through 2017 & projections w	ith pricing assum	ptions except for	current:
Interest	92	29	265
Interest, lapse	97	5	41
Interest, lapse, mortality	123	28	198
Interest, lapse, mortality, morbidity	124	0	2
Interest, lapse, mortality, morbidity, improvement	119	-4	-26
Historical experience through 2017 & projections with all current most-likely assumptions ^[3]	119	90	634

^[1] Calculated as the ratio of the lifetime loss ratio in a given row to that in the row immediately above it less one.
[2] Shows the rate increase needed to reproduce the lifetime loss ratio in the row immediately above it. Calculated without regard to CBUL, RBO, adverse selection, and higher waiver claims due to the needed rate increase.
[3] This row is calculated in regards to the pricing lifetime loss ratio of 63%.

For the business subject to rate stability regulation, an analysis of the projected loss ratio compared to that assumed at the time of original pricing revealed that experience has unfolded more than moderately adverse and crossed the original pricing threshold for which the company could consider a rate increase. At the time the product was priced, MedAmerica management determined the threshold for future increases would be defined as experience exhibiting deterioration of more than 10% of premium compared to that assumed in pricing. Section 16 demonstrates that the 'All' lifetime loss ratio before the requested rate increase using current assumptions is over 100% and well in excess of this original pricing threshold.

19. Average Annual Premium in Pennsylvania (Based on December 31, 2017 In-Force)

The number of insureds and the corresponding average annual premium that will be affected by this and the identical, concurrent rate increase filing are shown in the table(s) below. The values provided in the table(s) below exclude policies assumed to be paid up prior to implementation of the requested rate increase, and the annualized premium reflects all rate increases filed for use as of April 12, 2018.

Pennsylvania - MedAmerica

Policy Form Cohort	Benefit Period	Number of Insureds	Before Increase Premium	After Requested Increase Premium
	Non-Lifetime	111	\$1,774	\$2,499
Prior to Series 11	Lifetime	15	3,469	8,298
	Total	126	1,975	3,189
	Non-Lifetime	76	2,723	3,836
Series 11 Individual	Lifetime	32	3,475	8,313
	Total	108	2,946	5,163
	Non-Lifetime	67	1,663	2,343
Series 11 Group	Lifetime	0	0	0
	Total	67	1,663	2,343
	Non-Lifetime	254	2,028	2,858
Total	Lifetime	47	3,473	8,308
	Total	301	2,254	3,709

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

Series 11 and Prior Actuarial Memorandum

August 15, 2018

Pennsylvania - Blue Cross of Northeastern Pennsylvania

Policy Form Cohort	Benefit Period	Number of Insureds	Before Increase Premium	After Requested Increase Premium
	Non-Lifetime	96	\$2,034	\$2,865
Series 11 Individual	Lifetime	1	5,301	12,681
	Total	97	2,067	2,967
	Non-Lifetime	10	885	1,246
Series 11 Group	Lifetime	0	0	0
	Total	10	885	1,246
	Non-Lifetime	106	1,925	2,713
Total	Lifetime	1	5,301	12,681
	Total	107	1,957	2,806

20. Proposed Effective Date

This rate increase will apply to policies on their next premium payment date following at least a 60-day policyholder notification period following being filed for use by the department of insurance, but no sooner than 12 months after the prior rate increase was effective.

21. Distribution of Business as of December 31, 2017 (Based on Nationwide In-Force Insured Count)

Issue Ages	Percent Distribution
<40	8%
40-44	7
45-49	11
50-54	17
55-59	21
60-64	18
65-69	11
70-74	6
75+	1

Elimination Period	Percent Distribution
0-Day	4%
20-Day	21
30-Day	<1
60-Day	6
90-Day	53
100-Day	5
180-Day	10
365-Day	<1

Benefit Period	Percent Distribution
1-Year	<1%
2-Year	17
3-Year	39
4-Year	8
5-Year	18
Lifetime	18

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

Series 11 and Prior Actuarial Memorandum

August 15, 2018

Inflation Option	Percent Distribution
None	40%
Simple for Life	3
Compound for Life	38
Simple for 20 Years	19
GPO	<1

Premium Payment Option	Percent Distribution
Ten-Pay	14%
Twenty-Pay	10
Lifetime-Pay	76

Coverage Type	Percent Distribution
Facility Only	11%
Comprehensive	88
Home Health Only	1

22. Number of Insureds and Annualized Premium (Based on December 31, 2017 In-Force)

The number of insureds and annualized premium that will be affected by this and the identical, concurrent rate increase filing are shown in the tables below. The values provided in the tables below exclude policies assumed to be paid up prior to implementation of the requested rate increase, and the annualized premium reflects all rate increases filed for use as of April 12, 2018.

Pennsylvania – MedAmerica

r emisylvama – wedAmerica						
Policy Form Cohort	Benefit Period	Number of Insureds	Annualized Premium			
	Non-Lifetime	111	\$196,859			
Prior to Series 11	Lifetime	15	52,031			
	Total	126	248,890			
	Non-Lifetime	76	206,931			
Series 11 Individual	Lifetime	32	111,204			
	Total	108	318,135			
	Non-Lifetime	67	111,402			
Series 11 Group	Lifetime	0	0			
	Total	67	111,402			
	Non-Lifetime	254	515,192			
Total	Lifetime	47	163,235			
	Total	301	678,427			

Pennsylvania – Blue Cross of Northeastern Pennsylvania

Policy Form Cohort	Benefit Period	Number of Insureds	Annualized Premium
	Non-Lifetime	96	\$195,242
Series 11 Individual	Lifetime	1	5,301
	Total	97	200,543
	Non-Lifetime	10	8,847
Series 11 Group	Lifetime	0	0
	Total	10	8,847
	Non-Lifetime	106	204,089
Total	Lifetime	1	5,301
	Total	107	209,390

BLUE CROSS OF NORTHEASTERN PENNSYLVANIA Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

Series 11 and Prior Actuarial Memorandum

August 15, 2018

Nationwide

Policy Form Cohort	Benefit Period	Number of Insureds	Annualized Premium
	Non-Lifetime	855	\$1,882,265
Prior to Series 11	Lifetime	401	1,054,068
	Total	1,256	2,936,333
	Non-Lifetime	5,095	8,845,290
Series 11 Individual	Lifetime	1,713	4,713,899
	Total	6,808	13,559,189
	Non-Lifetime	5,149	7,885,909
Series 11 Group	Lifetime	73	179,276
	Total	5,222	8,065,185
	Non-Lifetime	11,099	18,613,464
Total	Lifetime	2,187	5,947,243
	Total	13,286	24,560,707

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

Series 11 and Prior Actuarial Memorandum

August 15, 2018

23. Actuarial Certification

I am a Principal and Consulting Actuary for Milliman, Inc. and retained by MedAmerica to render an opinion with regard to long-term care insurance rates. I am a member of the American Academy of Actuaries. I meet the Academy's qualification standards to render this actuarial opinion and am familiar with the requirements for filing long-term care insurance premiums and rate increases.

This memorandum has been prepared in conformity with all applicable Actuarial Standards of Practice, including Actuarial Standards of Practice No. 8, "Regulatory Filings for Health Benefits, Accident and Health Insurance, and Entities Providing Health Benefits" and 18, "Long-Term Care Insurance".

I hereby certify that, to the best of my knowledge and judgment, this rate submission is in compliance with the applicable laws and regulations of this jurisdiction and the rules of this department of insurance.

In my opinion, the rates are not excessive or unfairly discriminatory, and bear reasonable relationship to the benefits based on the loss ratio standards of this jurisdiction.

This filing will enhance premium adequacy, but may not be sufficient to prevent future rate action. Additional rate increases are needed to certify that rates will remain stable under moderately adverse conditions.

In forming my opinion, I have used actuarial assumptions and actuarial methods (which gave consideration to policy design, underwriting, and claim adjudication) and such tests of the actuarial calculations as I considered necessary. Based on these assumptions, or statutory requirements where necessary, this premium rate filing is in compliance with the loss ratio standards of this jurisdiction.

I have relied on data and information provided by MedAmerica to develop this memorandum, including but not limited to management's view of when a rate change may be considered, policy design, underwriting and claim adjudication process, seriatim in-force data, claim data, and the company's long-term earnings rate. I have not audited or independently verified the data and information provided, but have reviewed it for reasonableness.

The basis for contract reserves has been previously filed and there is no anticipation of any changes.

Missy Gordon, FSA, MAAA Principal and Consulting Actuary

Date: August 15, 2018

Exhibit I-a MedAmerica and Affinity Partners Actual and Projected Experience by Calendar Year Nationwide Experience Before Requested Rate Increase Series 11 and Prior Policy Forms

Section Calendar Premium Claims C = B / A D D C = B / A D D C = B / A D D C = B / A D D D D D D D D D	tive LR terest
Calendar Year Eamed Premium Incurred Claims End of Year Lives (Colum with I val. In with I val	
Calendar Year Earned Premium Incurred Claims Incurred Loss Ratio End of Year Lives With I Val. Int 1992 1993 557,528 112,935 20% 634 1994 1,500,452 28,746 2% 1,976 1995 2,485,029 109,652 4% 1,943 1997 4,391,783 264,541 6% 3,003 1998 6,825,955 1,489,714 22% 4,763 1999 6,825,955 1,489,714 22% 4,763 1990 6,825,955 1,489,714 22% 4,763 2001 11,902,742 2,210,887 19% 8,449 2002 10,096,324 4,269,807 2,7% 11,471 Experience 2004 22,113,898 6,347,428 23% 19,115 2005 28,578,579 6,751,292 24% 20,244 2006 28,839,355 7,395,470 26% 20,095 2033,387 10,644,803 38% 20,145	
Year Premium Claims Loss Ratio Lives 1993 1993 557,528 112,935 20% 634 1994 1,500,462 28,746 2% 1,376 1996 3,462,207 134,262 4% 2,687 1996 3,462,207 134,262 4% 2,687 1998 5,340,763 631,867 12% 3,664 1,998 1999 6,825,955 1,469,714 22% 4,763 4,391,783 264,541 6% 3,003 4,391,783 264,541 6% 3,003 4,391,783 264,541 6% 3,003 4,391,783 264,541 6% 3,003 4,391,783 2,248,	,
1993	
1994	09
1995	199
1996 3,462,207 134,262 4% 2,687 1997	79 69
1997	59
1999	59
2000	79
Historical 2002	119
Historical 2002 16,096,324 4,269,807 27% 11,471 2005 21,497,993 3,540,618 16% 17,712 2005 22,578,579 6,751,292 24% 20,244 20,246 20,3	119 139
Historical Experience 2004	169
Experience 2004 27,113,898 6,347,428 23% 19,115 2006 28,578,579 6,751,292 24% 20,244 2006 28,839,355 7,395,470 26% 20,095 2007 28,383,387 10,644,803 38% 20,145 2009 26,881,880 11,107,735 41% 19,480 2010 25,543,217 15,851,176 62% 18,490 2011 24,605,324 14,100,771 57% 17,662 2012 25,238,498 16,193,346 64% 17,589 2013 24,380,172 14,635,134 60% 17,254 2014 22,501,372 23,851,886 106% 16,796 2015 21,535,035 24,822,983 115% 16,188 2016 21,200,216 22,803,799 108% 15,979 2017 20,290,067 24,920,645 123% 15,486 2019 20,409,564 24,519,507 120% 14,074 2022 19,511,160 27,458,679 141% 13,103 2022 18,478,095 29,023,103 157% 12,617 20226 13,997,487 33,746,050 226% 11,167 2026 13,997,487 35,318,229 252% 10,687 2026 13,997,487 35,318,229 252% 10,687 2026 13,997,487 35,318,229 252% 10,687 2026 13,397,487 35,318,229 252% 10,687 2026 13,397,487 35,318,229 252% 10,687 2026 13,397,487 35,318,229 252% 10,687 2026 12,159,600 38,493,952 316% 9,737 2028 12,159,960 38,493,952 316% 9,737 2028 12,159,960 38,493,952 316% 9,737 2029 2034 7,623,677 40,050,776 353% 9,269 2034 7,653,677 40,050,776 353% 9,269 2035 7,007,189 48,806,821 686% 6,593 6,390,910 48,984,238 766% 6,173 2036 6,390,910 48,984,238 766% 6,173 2037 5,805,860 49,641,116 855% 5,762 2038 5,252,740 49,951,719 951% 5,362 2041 3,789,925 48,805,734 1,168% 4,240 2041 3,789,925 48,805,734 1,288% 4,240 2041 3,789,925 48,805,734 1,288% 4,240 2041 3,789,925 48,805,734 1,288% 4,240 2041 3,789,925 48,805,734 1,288% 4,240 2041 3,789,925 48,805,734 1,288% 4,240 2041 3,789,925 48,805,734 1,288% 4,240 2041 3,789,925 48,805,734 1,288% 4,240 2041 3,789,925 48,805,734 1,288% 4,240 204	169
2006	189
2007	199
2008	209
2009	22 ⁹ 23 ⁹
2010	249
2012 25,238,498 16,193,346 64% 17,589 2013 24,380,172 14,635,134 60% 17,254 2014 22,501,372 23,851,886 106% 16,796 2015 21,535,035 24,822,983 1115% 16,188 2016 21,200,216 22,803,799 108% 15,979 2017 20,290,067 24,920,645 123% 15,486 2019 20,409,564 24,519,507 120% 14,074 2020 20,2280,014 25,947,839 128% 13,589 2021 19,511,160 27,458,679 141% 13,103 157% 12,617 2023 17,235,027 30,574,267 177% 12,132 2024 16,001,079 32,186,531 201% 11,649 2025 14,960,197 33,746,050 226% 11,167 2026 13,997,487 35,318,229 2552% 10,687 2027 13,097,004 36,915,618 282% 10,210 2028 12,169,960 38,493,952 316% 9,737 Projected 2029 11,337,776 40,050,776 353% 9,269 Future 2030 10,539,591 41,549,905 394% 8,806 Experience 2031 9,772,280 42,944,911 439% 8,350 (60 Years) 2032 9,035,048 44,180,071 489% 7,900 8,329,513 45,499,037 546% 7,458 2037 5,805,860 49,641,116 855% 5,762 2038 5,252,740 49,951,719 951% 5,362 2039 4,732,129 49,936,198 1,055% 4,974 2040 4,244,382 49,556,133 1,188% 4,240 4240	279
2013	299
2014	319
2015	339
2016 21,200,216 22,803,799 108% 15,979 20,290,067 24,920,645 123% 15,486 2018 20,160,101 23,437,745 116% 14,591 2019 20,409,564 24,519,507 120% 14,074 2020 20,280,014 25,947,839 128% 13,589 2021 19,511,160 27,458,679 141% 13,103 2022 18,478,095 29,023,103 157% 12,617 2023 17,235,027 30,574,267 177% 12,132 2024 16,001,079 32,186,531 201% 11,649 2025 14,960,197 33,746,050 226% 11,167 2026 13,997,487 35,318,229 252% 10,687 2027 13,097,004 36,915,618 282% 10,210 2028 12,169,960 38,493,952 316% 9,737 2028 12,169,960 38,493,952 316% 9,737 2029 11,337,776 40,050,776 353% 9,269 41,549,905 394% 8,806 2029 10,539,591 41,549,905 394% 8,806 2031 9,772,280 42,944,911 439% 8,350 (60 Years) 2032 9,035,048 44,180,071 489% 7,900 2033 8,329,513 45,499,037 546% 7,458 2034 7,653,677 46,871,039 612% 7,022 2035 7,007,189 48,086,821 686% 6,593 2036 6,390,910 48,984,238 766% 6,173 2037 5,805,860 49,641,116 855% 5,762 2038 5,252,740 49,951,719 951% 5,362 2039 4,732,129 49,936,198 1,055% 4,974 2040 4,244,382 49,955,6133 1,168% 4,600 2041 3,789,925 48,805,734 1,288% 4,240	369 399
2017 20,290,067 24,920,645 123% 15,486 2018 20,160,101 23,437,745 116% 14,591 2019 20,409,564 24,519,507 120% 14,074 2020 20,280,014 25,947,839 128% 13,589 2021 19,511,160 27,458,679 141% 13,103 2022 18,478,095 29,023,103 157% 12,617 2023 17,235,027 30,574,267 177% 12,132 2024 16,001,079 32,186,531 201% 11,649 2025 14,960,197 33,746,050 226% 11,167 2026 13,997,487 35,318,229 252% 10,687 2027 13,097,004 36,915,618 282% 10,210 2028 12,169,960 38,493,952 316% 9,737 Projected 2029 11,337,776 40,050,776 353% 9,269 Future 2030 10,539,591 41,549,905 394% 8,806 Experience 2031 9,772,280 42,944,911 439% 8,350 (60 Years) 2032 9,035,048 44,180,071 489% 7,900 2033 8,329,513 45,499,037 546% 7,458 2034 7,653,677 46,871,039 612% 7,022 2035 7,007,189 48,986,821 686% 6,593 2036 6,390,910 48,984,238 766% 6,173 2037 5,805,860 49,641,116 855% 5,762 2038 5,252,740 49,951,719 951% 5,362 2039 4,732,129 49,936,198 1,055% 4,974 2040 4,244,382 49,556,133 1,168% 4,600 2041 3,789,925 48,805,734 1,288% 4,240	419
2019	449
2020	469
2021	489
2022	509 529
2023	549
2025	569
2026	589
Projected 2029 11,3097,004 36,915,618 282% 9,737 2028 12,169,960 38,493,952 316% 9,737 269 2030 10,539,591 41,549,905 394% 8,806 2031 9,772,280 42,944,911 439% 8,350 2032 9,035,048 44,180,071 489% 7,900 2033 8,329,513 45,499,037 546% 7,458 2034 7,653,677 46,871,039 612% 7,002 2035 7,007,189 48,086,821 686% 6,593 2036 6,390,910 48,984,238 766% 6,173 2037 5,805,860 49,641,116 855% 5,762 2038 5,252,740 49,951,719 951% 5,362 2039 4,732,129 49,936,198 1,055% 4,974 2040 4,244,382 49,556,133 1,168% 4,600 2041 3,789,925 48,805,734 1,288% 4,240	609
Projected 2029 11,337,776 40,050,776 353% 9,269 Future 2030 10,539,591 41,549,905 394% 8,806 Experience (60 Years) 2032 9,035,048 44,180,071 489% 7,900 2033 8,329,513 45,499,037 546% 7,458 2034 7,653,677 46,871,039 612% 7,022 2035 7,007,189 48,086,821 686% 6,593 2036 6,390,910 48,984,238 766% 6,173 2037 5,805,860 49,641,116 855% 5,762 2038 5,252,740 49,951,719 951% 5,362 2039 4,732,129 49,936,198 1,055% 4,974 2040 4,244,382 49,556,133 1,168% 4,600 2041 3,789,925 48,805,734 1,288% 4,240	639 659
Projected Future 2029 2030 11,337,776 10,539,591 40,050,776 41,549,905 353% 394% 9,269 8,806 Experience (60 Years) 2031 2032 9,772,280 9,035,048 42,944,911 44,180,071 489% 44,180,071 7,900 489% 7,900 7,900 2033 2034 7,653,677 7,653,677 46,871,039 48,086,821 612% 686% 6,593 6,593 2036 2036 6,390,910 6,390,910 48,984,238 49,954,116 766% 6,173 2037 2038 5,252,740 5,252,740 49,951,719 49,936,198 1,055% 4,974 2040 4,244,382 49,556,133 1,168% 4,600 2041 4,240 3,789,925	679
Future 2030 10,539,591 41,549,905 394% 8,806 Experience (60 Years) 9,772,280 42,944,911 439% 7,900 2033 8,329,513 45,499,037 546% 7,458 2034 7,653,677 46,871,039 612% 7,022 2035 7,007,189 48,086,821 686% 6,593 2036 6,390,910 48,984,238 766% 6,173 2037 5,805,860 49,641,116 855% 5,762 2038 5,252,740 49,951,719 951% 5,362 2039 4,732,129 49,936,198 1,055% 4,974 2040 4,244,382 49,556,133 1,168% 4,600 2041 3,789,925 48,805,734 1,288% 4,240	709
(60 Years) 2032 2033 2034 2034 2035 2036 2036 2037 2037 2037 2038 2038 2038 2039 2039 2039 2040 2040 2041 9,035,048 3,329,513 45,499,037 46,871,039 46,871,039 46,871,039 48,984,238 48,984,238 49,641,116 49,951,719 49,951,719 49,956,133 49,556,133 49,556,133 49,556,133 49,556,133 49,556,133 49,556,133 49,556,133 49,556,133 49,556,133 49,556,133 49,640 49,641,116 49,951,719 49,936,198 49,936,198 49,556,133	729
2033 8,329,513 45,499,037 546% 7,458 2034 7,653,677 46,871,039 612% 7,022 2035 7,007,189 48,086,821 686% 6,593 2036 6,390,910 48,984,238 766% 6,173 2037 5,805,860 49,641,116 855% 5,762 2038 5,252,740 49,951,719 951% 5,362 2039 4,732,129 49,936,198 1,055% 4,974 2040 4,244,382 49,556,133 1,168% 4,600 2041 3,789,925 48,805,734 1,288% 4,240	749
2034 7,653,677 46,871,039 612% 7,022 2035 7,007,189 48,086,821 686% 6,593 2036 6,390,910 48,984,238 766% 6,173 2037 5,805,860 49,641,116 855% 5,762 2038 5,252,740 49,951,719 951% 5,362 2039 4,732,129 49,936,198 1,055% 4,974 2040 4,244,382 49,556,133 1,168% 4,600 2041 3,789,925 48,805,734 1,288% 4,240	779
2035 7,007,189 48,086,821 686% 6,593 2036 6,390,910 48,984,238 766% 6,173 2037 5,805,860 49,641,116 855% 5,762 2038 5,252,740 49,951,719 951% 5,362 2039 4,732,129 49,936,198 1,055% 4,974 2040 4,244,382 49,556,133 1,168% 4,600 2041 3,789,925 48,805,734 1,288% 4,240	799 819
2036 6,390,910 48,984,238 766% 6,173 2037 5,805,860 49,641,116 855% 5,762 2038 5,252,740 49,951,719 951% 5,362 2039 4,732,129 49,936,198 1,055% 4,974 2040 4,244,382 49,556,133 1,168% 4,600 2041 3,789,925 48,805,734 1,288% 4,240	849
2038 5,252,740 49,951,719 951% 5,362 2039 4,732,129 49,936,198 1,055% 4,974 2040 4,244,382 49,556,133 1,168% 4,600 2041 3,789,925 48,805,734 1,288% 4,240	869
2039 4,732,129 49,936,198 1,055% 4,974 2040 4,244,382 49,556,133 1,168% 4,600 2041 3,789,925 48,805,734 1,288% 4,240	889
2040 4,244,382 49,556,133 1,168% 4,600 2041 3,789,925 48,805,734 1,288% 4,240	909
2041 3,789,925 48,805,734 1,288% 4,240	929 949
	969
	989
2043 2,981,852 46,247,223 1,551% 3,571	999
2044 2,627,355 44,626,890 1,699% 3,263	1019
2045 2,304,637 42,794,267 1,857% 2,973	1029
2046 2,012,700 40,800,636 2,027% 2,702 2047 1,750,230 38,606,295 2,206% 2,450	1049 1059
2047 1,750,250 35,606,295 2,206% 2,450 2,45	1099
2053-2057 2,572,498 101,166,015 3,933% 5,318	1129
2058-2062 1,086,882 58,328,449 5,367% 3,008	1139
2063-2067 437,018 31,208,982 7,141% 1,591	1139
2068-2072	1139 1139

With Interest Accum./Disc. To 12/31/2017 at Max. Val. Interest

History	676,463,033	295,592,596	44%
Future	207,442,993	707,218,337	341%
Lifetime	883,906,026	1,002,810,933	113%

Actuarial Memorandum Exhibits

Exhibit I-b MedAmerica and Affinity Partners Actual and Projected Experience by Calendar Year Nationwide Experience After Requested Rate Increase Series 11 and Prior Policy Forms

			Actual or Project			Cumulative LR
		Α	using Current B	C = B / A	D	with Interest E
		,,	5	0-577	5	_
						Actual
						(Column C)
	Calendar	Earned	Incurred	Incurred	End of Year	with Max.
	Year 1992	Premium 17,324	Claims 0	Loss Ratio 0%	Lives 111	Val. Interest 0%
	1993	557,528	112,935	20%	634	19%
	1994	1,500,482	28,746	2%	1,376	7%
	1995	2,485,029	109,652	4%	1,943	6%
	1996	3,462,207	134,262	4%	2,687	5%
	1997	4,391,783	264,541	6%	3,003	5%
	1998 1999	5,340,763 6,825,955	631,867 1,469,714	12% 22%	3,664 4,763	7% 11%
	2000	8,935,626	1,172,992	13%	6,197	11%
	2001	11,902,742	2,210,887	19%	8,449	13%
	2002	16,096,324	4,269,807	27%	11,471	16%
Historical	2003	21,497,993	3,540,618	16%	17,712	16%
Experience	2004	27,113,898	6,347,428	23%	19,115	18%
	2005	28,578,579	6,751,292	24%	20,244	19%
	2006	28,839,355	7,395,470	26% 38%	20,095 20.145	20% 22%
	2007 2008	28,383,387 27,838,059	10,644,803 8,302,139	30%	19,941	23%
	2009	26,881,880	11,107,735	41%	19,480	24%
	2010	25,543,217	15,851,176	62%	18,490	27%
	2011	24,605,324	14,100,771	57%	17,662	29%
	2012	25,238,498	16,193,346	64%	17,589	31%
	2013	24,380,172	14,635,134	60%	17,254	33%
	2014 2015	22,501,372 21,535,035	23,851,886 24,822,983	106% 115%	16,796 16,188	36% 39%
	2016	21,200,216	22,803,799	108%	15,979	41%
	2017	20,290,067	24,920,645	123%	15,486	44%
	2018	20,160,101	23,437,745	116%	14,591	46%
	2019	23,940,291	23,836,189	100%	13,538	47%
	2020	27,226,638	24,345,168	89%	12,921	49%
	2021 2022	27,446,759	25,633,115 26,999,149	93% 101%	12,403 11,937	50% 52%
	2022	26,662,533 24,891,098	28,397,202	114%	11,485	53%
	2024	23,073,543	29,863,010	129%	11,034	55%
	2025	21,562,554	31,288,551	145%	10,585	56%
	2026	20,164,124	32,734,152	162%	10,137	58%
	2027	18,849,598	34,208,980	181%	9,691	60%
	2028	17,491,936	35,672,675	204%	9,249	62%
Projected	2029	16,276,327 15,110,600	37,124,754	228% 255%	8,811	63% 65%
Future Experience	2030 2031	13,990,305	38,533,648 39,855,468	285% 285%	8,378 7,950	67%
(60 Years)	2032	12,914,476	41,035,606	318%	7,528	69%
(00 1 1 1 1 1)	2033	11,885,784	42,302,158	356%	7,113	71%
	2034	10,901,426	43,623,147	400%	6,703	73%
	2035	9,961,176	44,805,033	450%	6,299	75%
	2036	9,066,553	45,696,313	504%	5,902	77%
	2037 2038	8,218,997 7,419,435	46,364,725 46,710,600	564% 630%	5,514 5,136	78% 80%
	2039	6,668,635	46,751,367	701%	4,768	82%
	2040	5,966,935	46,446,529	778%	4,413	84%
	2041	5,314,804	45,791,886	862%	4,072	85%
	2042	4,712,524	44,776,689	950%	3,746	87%
	2043	4,159,472	43,476,736	1,045%	3,435	88%
	2044	3,654,613	41,994,709	1,149%	3,142	89%
	2045 2046	3,196,271 2,782,780	40,307,806 38,461,398	1,261% 1,382%	2,865	91% 92%
	2046	2,782,780	36,414,550	1,382%	2,606 2,365	92%
	2048-2052	7,819,761	149,015,565	1,906%	8,808	96%
	2053-2057	3,440,166	95,678,209	2,781%	5,165	98%
	2058-2062	1,419,019	55,182,238	3,889%	2,932	99%
	2063-2067	555,906	29,587,701	5,322%	1,555	100%
	2068-2072	206,207	14,241,293	6,906% 8 564%	720	100%
	2073-2077	73,271	6,275,070	8,564%	271	100%

With Interest Accum./Disc. To 12/31/2017 at Max. Val. Interest

History	676,463,033	295,592,596	44%
Future	281,100,696	662,874,765	236%
Lifetime	957,563,729	958,467,361	100%

Actuarial Memorandum Exhibits

Exhibit II Demonstration that the Requested Cumulative Rate Increase Passes the 58%/85% Loss Ratio Minimum MedAmerica and Affinity Partners' Nationwide Experience with Prior Approved Increases Series 11 and Prior Policy Forms

Accumulated value of initial earned premium	646,425,805 x	58%	=	374,926,967		
2a Accumulated value of earned premium 2b Accumulated value of prior premium rate schedule increases (2a - 1)	676,463,033 30,037,228 x	85%	=	25,531,644		
3 Present value of future projected initial earned premium	108,296,977 x	58%	=	62,812,246		
4a Present value of future projected premium	281,100,696					
4b Present value of future projected premium in excess of the projected initial earned premiums (4a - 3) 172,803,719 x 85% =						
5 Lifetime Earned Premium Times Prescribed Factor: Sum of 1, 2b, 3, and 4b				610,154,018		
6a Accumulated value of incurred claims without the inclusion of active life reserves 6b Present value of future projected incurred claims without the inclusion of active life reserves				295,592,596 762,305,980		
7 Lifetime Incurred Claims with Rate Increase: Sum 6a and 6b				1,057,898,576		
8 Test: 7 is not less than 5				Pass		
All values are accumulated or discounted at the maximum valuation interest rate for contract reserves applicable for the year of issue, which ran	nges from 3.5% to 5.5%.					

All values are accumulated or discounted at the maximum valuation interest rate for contract reserves applicable for the year of issue, which ranges from 3.5% to 5.5% Future projected initial earned premium schedule (i.e., without the requested rate increase) reflects the assumed impact of CBUL and RBO.

The future projected incurred claims (item 6b) were increased by 15% to reflect assumptions with moderately adverse experience.

Actuarial Memorandum Exhibits

Exhibit III MedAmerica and Affinity Partners Comparison of Current and Original Pricing Assumptions

Current Assumptions	Series 11 and Prior
Original Assumptions	Prior to Series 11
	Series 11

Morbidity

Expected claim costs are developed using the 2014 Milliman Long-Term Care Guidelines (Guidelines) with adjustments for underwriting selection, all-lives exposure basis, and three years of retrospective improvement to bring the Guidelines forward to 2017. The claim costs were further adjusted based on historical claim experience by policy form cohort, attained age, duration, individual vs. group, payment type, and coverage type, to the extent credible. These adjustment factors can be found in Exhibit A-4a of Appendix A of the actuarial memorandum.

For Series 5, the original pricing expected nursing home incidence rates and continuance tables were developed from a number of sources, but primarily using data published by the Connecticut Department of Health Services. The 1985 National Nursing Home Survey was also used. Selected frequencies were adjusted up for up to the first 12 years following issue to reflect the favorable morbidity expected as a result of the underwriting process. Frequency and length of treatment of the home care and adult day care benefit were based on the 1982 National Long-Term Care Survey. They are adjusted to reflect the effects of elimination periods, policy maximums, and eligibility standards.

For Series 8 and 9, the Institutional Benefit rates were developed using source data from the 1977 and 1985 National Nursing Home Surveys. The Home and Community Benefits were developed using source data from the 1989 National Long-Term Care Survey. Adjustments were made to the source data to reflect the selection effect of underwriting and the non-duplication of benefits with other payment sources.

The original pricing expected nursing home and home care incidence rates and continuance tables were taken from the 1997Guidelines and adjusted for MedAmerica's experience available at the time this rate schedule was developed relative to the Guidelines. All values were adjusted to reflect the effects of product types, elimination periods, policy maximums, and the eligibility standards.

Current Assumptions	Series 11 and Prior		
Original	Prior to Series 11		
Assumptions	Series 11 Individual		
	Series 11 Group		

Mortality

1994 Group Annuitant Mortality (GAM) Static gender-distinct table with retrospective improvement applied to bring this table forward to 2017. These mortality rates are further adjusted based on historical mortality experience by issue age band and duration. Tables providing these adjustment factors are provided in Section 6 of the actuarial memorandum.

Series 5 policy forms used the 1965-70 US Society of Actuaries Basic Mortality Table without selection.

Series 8 and Series 9 policy forms used the 1980 Commissioners Standard Ordinary Basic Mortality Tables assuming a gender mix of 60% female and 40% male and without selection.

1980 Commissioners Standard Ordinary Basic Mortality Table.

Premier Group policy forms use the 1980 Commissioners Standard Ordinary Basic Mortality Table. TNSE policy forms use the 1983 GAM Static table.

Exhibit III MedAmerica and Affinity Partners Comparison of Current and Original Pricing Assumptions

Current Assumptions	Series 11 and Prior
------------------------	---------------------

Lapse Rates

Voluntary lapse rates (excludes benefit expiry) vary by policy duration and policy form cohort.

Lif		Lapse Ra	
	Prior to	Series 11	Series 11
Duration	Series 11	Individual	Group
1	16.50%	8.50%	6.50%
2	8.50%	4.00%	6.00%
3	5.00%	2.75%	4.00%
4	3.50%	2.00%	3.50%
5	2.00%	1.50%	3.00%
6	1.50%	1.25%	2.50%
7	1.50%	1.25%	2.00%
8	1.50%	1.00%	1.50%
9	1.50%	0.75%	1.30%
10+	1.00%	0.60%	1.30%

For the 10-pay option, a reduction of 65% of these lapse rates is assumed for durations 1 to 4, a reduction of 70% of these lapse rates is assumed for durations 5 to 8, and 0% lapse thereafter. For the 20-pay option, a reduction of 50% of these lapse rates is assumed for durations 1 to 8, a reduction of 75% of these lapse rates is assumed for durations 9 to 15, and 0% lapse thereafter.

Exhibit III MedAmerica and Affinity Partners Comparison of Current and Original Pricing Assumptions

Lapse Rates

Lapse rates vary by policy form series, duration, premium payment option, and issue age.

	Series 5 Lapse Rates											
	Issue Age											
Duration	<61 61 62 63 64 65 66 67 68 69 70+											
1	20.00%	19.00%	18.00%	17.00%	16.00%	15.00%	14.00%	13.00%	12.00%	11.00%	10.00%	
2	15.00%	14.00%	13.00%	12.00%	11.00%	10.00%	9.00%	8.00%	7.00%	6.00%	5.00%	
3	10.00%	9.40%	8.80%	8.20%	7.60%	7.00%	6.40%	5.80%	5.20%	4.60%	4.00%	
4	8.00%	7.60%	7.20%	6.80%	6.40%	6.00%	5.60%	5.20%	4.80%	4.40%	4.00%	
5	6.00%	5.70%	5.40%	5.10%	4.80%	4.50%	4.20%	3.90%	3.60%	3.30%	3.00%	
6	5.00%	4.80%	4.60%	4.40%	4.20%	4.00%	3.80%	3.60%	3.40%	3.20%	3.00%	
7	5.00%	4.80%	4.60%	4.40%	4.20%	4.00%	3.80%	3.60%	3.40%	3.20%	3.00%	
8	5.00%	4.80%	4.60%	4.40%	4.20%	4.00%	3.80%	3.60%	3.40%	3.20%	3.00%	
9+	5.00%	4.70%	4.40%	4.10%	3.80%	3.50%	3.20%	2.90%	2.60%	2.30%	2.00%	

Series 8 Lapse Rates								
	Issue Age							
Duration	Ouration <85 85+							
1	15.00%	12.00%						
2	10.00%	8.00%						
3	8.00%	6.40%						
4	6.00%	4.80%						
5+	5.00%	4.00%						

	Series 9 Lapse Rates											
		Issue Age										
Duration	<76	<76 76 77 78 79 80 81 82 83 84 85+										
1	15.00%	14.70%	14.40%	14.10%	13.80%	13.50%	13.20%	12.90%	12.60%	12.30%	12.00%	
2	10.00%	9.80%	9.60%	9.40%	9.20%	9.00%	8.80%	8.60%	8.40%	8.20%	8.00%	
3	8.00%	7.84%	7.68%	7.52%	7.36%	7.20%	7.04%	6.88%	6.72%	6.56%	6.40%	
4	6.00%	5.88%	5.76%	5.64%	5.52%	5.40%	5.28%	5.16%	5.04%	4.92%	4.80%	
5+	5.00%	4.90%	4.80%	4.70%	4.60%	4.50%	4.40%	4.30%	4.20%	4.10%	4.00%	

Policy Form Series 8 and 9 issued business under a group trust in a small number of jurisdictions. The original pricing assumptions for claim costs, mortality, and interest did not vary between individual and group trust business but the original pricing voluntary termination rates did. The Series 8 and 9 group trust original pricing voluntary termination rates are shown in the following table

Series 8 and 9 Group Trust											
		Issue Age									
Duration	<25 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+										
1	16.00%	15.00%	13.50%	12.00%	11.00%	10.00%	8.00%	6.00%	4.00%	3.00%	
2	11.00%	10.00%	8.50%	7.00%	7.00%	7.00%	5.50%	4.50%	3.50%	3.00%	
3	7.00%	6.00%	6.00%	6.00%	6.00%	6.00%	5.00%	4.50%	3.00%	2.00%	
4	5.00%	5.00%	5.00%	5.00%	5.00%	5.00%	5.00%	4.50%	3.00%	2.00%	
5	5.00%	5.00%	5.00%	5.00%	5.00%	5.00%	5.00%	4.50%	3.00%	2.00%	
6	5.00%	5.00%	5.00%	5.00%	5.00%	5.00%	5.00%	4.50%	3.00%	2.00%	
7+	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	

The original pricing voluntary lapse rates were expected to be 0.0% for durations 10 and later for policyholders who selected the 10-pay option.

Original Assumptions Prior to Series 11

Exhibit III MedAmerica and Affinity Partners Comparison of Current and Original Pricing Assumptions

Lapse Rates

Lapse rates vary by duration, premium payment option, and issue age. Lapse rates for the lifetime payment option are provided in the tables below for Series 11 Individual, Premier Group, and TNSE policy forms.

Series 11 Individual								
		La	pse Rates	by Issue A	Age			
Duration	<60	60-64	65-69	70-74	75-79	80+		
1	10.00%	11.00%	12.00%	12.00%	12.00%	12.00%		
2	7.00%	7.00%	7.00%	6.00%	4.00%	2.00%		
3	5.00%	4.00%	3.00%	3.00%	3.00%	2.00%		
4	3.00%	3.00%	2.00%	2.00%	2.00%	2.00%		
5	3.00%	2.00%	2.00%	2.00%	2.00%	2.00%		
6+	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%		

	Premier Group								
		La	pse Rates	by Issue A	Age				
Duration	<60	60-64	65-69	70-74	75-79	80+			
1	10.00%	11.00%	12.00%	12.00%	12.00%	12.00%			
2	7.00%	7.00%	7.00%	6.00%	4.00%	2.00%			
3	5.00%	4.00%	3.00%	3.00%	3.00%	2.00%			
4	3.00%	3.00%	2.00%	2.00%	2.00%	2.00%			
5	3.00%	2.00%	2.00%	2.00%	2.00%	2.00%			
6+	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%			

	TNSE								
		Lapse R	Rates by Is	sue Age					
Duration	<60	60-64	65-69	70-79	80+				
1	5.00%	5.00%	5.00%	4.00%	3.00%				
2	5.00%	5.00%	5.00%	4.00%	3.00%				
3	5.00%	4.00%	3.00%	3.00%	3.00%				
4	4.00%	4.00%	3.00%	3.00%	3.00%				
5	4.00%	3.00%	3.00%	3.00%	3.00%				
6+	3.00%	3.00%	3.00%	3.00%	3.00%				

For the 10-pay option, a reduction of 50% of these lapse rates is assumed for durations 1 to 6, and 0% lapse thereafter. For the 20-pay option, a reduction of 50% of these lapse rates is assumed for durations 1 to 13, and 0% lapse thereafter.

Original Series 11

Exhibit III MedAmerica and Affinity Partners Comparison of Current and Original Pricing Assumptions

Current Assumptions	Series 11 and Prior
Original Assumptions	Series 11 and Prior

Benefit Expiry Rates

Benefit expiry rates reflect assumed policy termination due to exhaustion of benefits on limited benefit period policies. The rates are based on the Guidelines with adjustments for historical benefit expiry experience and vary by gender, benefit period, and attained age. A table containing the benefit expiry rates is provided in Section 6 of the actuarial memorandum.

Benefit expiry was not separated from the lapse assumption.

Current Assumptions	Series 11 and Prior
	Prior to Series 11
Original Assumptions	Series 11 Individual
7.00umptione	Series 11 Group

Interest Rate

The current most-likely earnings rate assumption is 5.00%. This rate represents MedAmerica's expectation of its long-term investment earnings rate, which is supported by the average net investment earnings rate projected for MedAmerica's cash flow testing

The maximum valuation interest rate applicable to the year of issue ranges from 3.5% to 5.5% and averages 4.3%

Series 5 policy forms used an original pricing earnings rate assumption of 7.10% and Series 8 and 9 policy forms used an original pricing earnings rate assumption of 7.50%.

An original pricing earnings rate assumption of 7.50% was assumed.

Premier Group policy forms used an original pricing earnings rate assumption of 7.50% and TNSE policy forms used an original pricing earnings rate assumption of 6.00%.

Current Assumptions	Series 11 and Prior
Original Assumptions	Series 11 and Prior

Improvement

Annual improvement in the mortality and morbidity assumptions is assumed for 15 years starting in 2018. Annual mortality improvement factors vary b attained age based on the G2 improvement scale from the 2012 Individual Annuity Mortality table. Annual morbidity improvement is assumed to be 1.0%.

No mortality or morbidity improvement was assumed.

Milliman developed the current actuarial assumptions used in this filing.

The persistency and morbidity assumptions were developed using historical experience. Where actual experience had low credibility or did not exist, industry experience and actuarial judgement was also used. The experience used to develop these assumptions includes historical experience of MedAmerica Insurance Company (MAPA); MAPA's two sister companies, MedAmerica Insurance Company of Florida (MAFL) and MedAmerica Insurance Company of New York (MANY) (MAPA, MAFL, and MANY collectively referred to as MedAmerica); and MedAmerica's affinity partners that issued the same products and, where appropriate, other similar business. For persistency, policy termination experience through December 31, 2015 was used. For morbidity, claim experience through June 30, 2016 was used with six months of runout.

Improvement (mortality and morbidity) was developed based on individual annuitant or industry experience, along with actuarial judgment. The rate increase dependent assumptions were developed using historical experience, and actuarial judgement where experience had low credibility or did not exist.

Predictive analytics was used in the development of the morbidity assumption. The persistency assumption utilized traditional techniques and credibility measures.

The rest of this appendix provides details on the development and justification of the current assumptions.

Persistency

The assumptions for mortality and lifetime-pay voluntary lapse were developed based on detailed historical experience through December 31, 2015 for MedAmerica's organic (including affinity partners) and acquired business. For the acquired business, experience prior to acquisition was excluded as it predates MedAmerica's administration of the block. The assumptions for limited-pay voluntary lapse were developed based on experience through March 31, 2015.

The benefit expiry assumption was developed using the 2014 Milliman Long-Term Care Guidelines (Guidelines) with adjustments based on MedAmerica's actual benefit expiry experience through December 31, 2015 on its organic business.

Mortality Durational Factors for Individual Policies

Exhibit A-1a supports the individual business mortality assumption and provides the following information for all companies and products (both individual and group) combined, but separately for issue age bands (i) 75 and older, (ii) 70 to 74, (iii) 65 to 69, and (iv) 60 to 64:

- Exposure that reflects a full year of exposure for each death and the length of time a covered life is exposed
 to the risk of death during the year for each life that does not die.
- Mortality rates for actual, expected, and an additional standard table for comparison. All of these rates were brought forward to 2015 for consistency with the basis of the expected table by applying mortality improvement factors that reflect annual improvement of 0.5% for females and 1.0% for males.

Actual mortality rates equal the number of deaths divided by exposure. The number of deaths includes a scalar to capture improvement between the year of death and 2015. For example, if 10 males died in 2010, then the number of deaths (10) would be multiplied by 5 years of improvement (0.951).

2015GAM mortality rates equal 94GAM with 21 years of improvement, which results in scalars of 90% for females and 81% for males. These are the expected mortality rates to which the factors in Section 6 of the actuarial memorandum are applied.

2015IAM is equal to 2012 Individual Annuity Mortality (2012IAM) Period standard table mortality rates with 3 years of improvement (scalars of 98.5% for females and 97% for males).

- Ratios of actual and standard table mortality rates to the 2015GAM expected (A:E) mortality rates.
- Credibility percentage based on the number of deaths (with improvement scalars described above) and the credibility measure described at the end of this appendix.
- A:E ratio that is credibility weighted with the two standard table options for a complement.
- Smoothed durational factors that correspond to that shown in Section 6 of the actuarial memorandum.

We developed the smoothed factors by issue age band and duration. We started with the older issue ages to develop an ultimate factor and then worked backward to younger issue age bands, making experience adjustments for the first 20 durations. In developing these experience adjustments, we considered the A:E ratios, level of credibility, whether in the select or ultimate period, and A:E credibility-weighted ratios.

An ultimate level of 105% of 2015GAM was assumed based on the combined experience of issue ages 70 and older for attained ages older than 95 to the extent credible. For the first 20 durations, the factors were pegged for the midpoint of a quinquennial durational band and then interpolated in between to develop smoothed factors. The smoothed factors were determined such that the bands of quinquennial durations reproduced the actual experience, to the extent credible.

Theoretical adjustments are made, following the diagonal, according to the adjustments made for older issue age bands to maintain mortality relationships across attained ages. For example, we assume an 85% factor for attained age 80, which appears in duration 18 for issue age 62 and duration 23 for issue age 57 as shown in Section 6 of the actuarial memorandum; following along this diagonal the assumption is consistent.

Exhibit A-1b provides similar information as Exhibit A-1a for individual business only with issue ages under 60. For development of the mortality assumption for issue ages under 60, the experience was split between individual and group because there is a material amount of group experience under 60. Mortality can differ between individual and group business because of adverse selection associated with group underwriting.

For projection purposes, two years of additional improvement was applied to the 2015GAM mortality rates to bring them forward to 2017 using the G2 improvement scale from the 2012IAM table. The G2 scale is discussed further in the Improvement section below.

Mortality Durational Factors for Group Certificates

Exhibit A-1c supports the group business mortality assumption and provides exposure, actual and expected mortality rates, mortality A:E ratios, credibility percent, and smoothed scalars. The expected mortality rates include the individual durational mortality factors described above. The smoothed scalars were developed based on group products for issue ages under 60 only because it captures most of the group experience. We did not analyze group experience for other issue ages. These scalars are applied to the individual mortality durational factors, but capped at 105%, to produce the group mortality durational factors shown in Section 6 of the actuarial memorandum.

Lifetime-Pay Voluntary Lapse Rates

Exhibit A-2a provides total exposure, composite termination rates, expected mortality rates, derived voluntary lapse rates, credibility percent, and smoothed voluntary lapse rates by duration for lifetime-pay Prior to Series 11 policies. Exhibit A-2b and Exhibit A-2c provide similar information for Series 11 Individual and Series 11 Group policies, respectively.

In general, the smoothed voluntary lapse rates were set in such a way that the combined duration smoothed rates were close to the derived voluntary lapse rates (see the rows at the bottom of the exhibits). The smoothed voluntary lapse rates in the early durations were chosen to reproduce actual history, to the extent possible, so that the transition from historical to projected policy persistency was smooth. In developing the ultimate voluntary lapse rate, the level of credibility of the actual voluntary lapse experience and the experience of other forms were considered, as applicable. The degree of closeness of the smoothed voluntary lapse rate compared to actual experience depends on the level of credibility.

The actual composite (mortality and voluntary lapse) termination rates were calculated by duration as follows:

Annualized Composite Termination Rate = Number of Deaths and Voluntary Lapses during the Year

Number of Lives Exposed during the Year

A death or voluntary lapse (excluding benefit expiry) was assigned to the duration in which it occurred, or the preceding duration, if the termination was on the anniversary date. Each death or voluntary lapse contributes 1.0 to the numerator and a full year to the denominator. For lives whose benefits expire or do not terminate, the number of lives exposed to termination is based on the length of time a covered life is exposed to the risk of termination due to death or voluntary lapse during the year. This calculation logic is consistent with that used in the LTC Insurance Persistency Experience reports sponsored by LIMRA International and the SOA LTC Experience Committee.

The expected mortality rate assumes the gender-distinct 2015GAM table with the durational factors shown in Section 6 of the actuarial memorandum applied by duration.

The derived voluntary lapse rate is then calculated according to the following formula:

Derived Voluntary Lapse Rate = 1 - 1 - Composite Termination Rate 1 - Expected Mortality Rate ...

Limited-Pay Voluntary Lapse Rates

The algorithm for the limited-pay options is similar to that used in original pricing. The smoothed lapse rates are a scalar of the lifetime-pay lapse rates. Less than 4% of the in-force policies with a limited-pay option will be subject to the lapse assumption because they will not yet be paid-up during the first six years of the projection. As a result, the impact of the limited-pay assumptions on the projections is assumed to be immaterial.

For the ten-pay and twenty-pay options, the scalars were developed from a comparison of the lifetime-pay derived lapse rates to the limited-pay option's derived lapse rates based on MedAmerica and its affinity partners' experience on all products combined. The relationships derived from this analysis were used to develop the smoothed lapse assumptions as shown in Section 6 of the actuarial memorandum.

Benefit Expiry

Benefit expiry rates reflect assumed policy lapses due to exhaustion of benefits based on the 2014 *Guidelines* with adjustments for historical benefit expiry experience and vary by attained age, gender, and benefit period. Policies with lifetime benefits do not have an expiry assumption (i.e., rate of 0%).

We compared MedAmerica's actual benefit expiry experience through December 31, 2015 to that expected by the 2014 *Guidelines*. We developed adjustment factors by attained age based on the experience of a subset of MedAmerica's organic business, which included the Series 11 and Prior business. Factors were developed by quinquennial attained age band and then interpolated to produce scalars for each attained age. These scalars were then applied to the benefit expiry rates developed by the 2014 *Guidelines* in order to produce the final benefit expiry assumptions shown in Section 6 of the actuarial memorandum.

Exhibit A-3 provides exposure, actual and expected benefit expiry rates, A:E ratios, credibility percent, credibility-weighted A:E ratios, and smoothed adjustment factors. The exposure used reflects a full year of exposure for each benefit expiry and the length of time a covered life is exposed to the risk of benefit expiry during the year for each life that does not expire benefits.

Morbidity

The claim costs were developed using the 2014 *Guidelines* with experience-adjustment factors based on all products of MedAmerica, its affinity partners, and any acquired business from January 1, 2004 through June 30, 2016, with runout through December 31, 2016. The experience-adjustment factors were developed using predictive analytics as described in the Predictive Analytics section below.

- Exhibit A-4a provides the adjustment factors that are to be applied to the 2014 *Guidelines* claim costs for the Series 11 and Prior policy forms.
- Exhibit A-4b provides a summary of A:E experience for the Series 11 and Prior policy forms.
 - o Exposure [A] reflects the length of time a covered life is in force (i.e., an exact exposure basis).
 - o Actual incurred claim counts [B] and dollars [C] are based on historical claim experience from inception through June 30, 2016, with runout through December 31, 2016. Actual incurred claim dollars were valued as paid claims plus claim reserves. Paid claims and claim reserves were discounted to the year of incurral.
 - 2014 Guidelines expected incurred claims [D] are valued as the 2014 Guidelines claim costs multiplied by actual all-lives exposure. The claim costs vary by gender, attained age, policy duration, benefit period, elimination period, payment type, level of home care coverage, inflation type, and coverage type (comprehensive/facility only/home health care only). Policy design, claims adjudication, and degree of underwriting were considered in developing the claim costs.
 - Adjusted expected incurred claims [E] are calculated by applying each applicable adjustment from Exhibit A-4a to the 2014 *Guidelines* expected incurred claims [D].

- A:E ratios are calculated as actual incurred claims to the 2014 *Guidelines* expected incurred claims [F] and adjusted expected incurred claims [G]. The adjusted A:E [G] provides an indication of fit. This fit will not be perfect (i.e., ratio deviates from 1.0) because the main goal is to develop an assumption that generalizes well to new data by balancing assumption complexity and fit on the historical experience.
- Exhibit A-4c provides information similar to Exhibit A-4b, except provides the experience for all products of MedAmerica, its affinity partners, and any acquired business.

Prior to developing the experience-adjustment factors, the 2014 *Guidelines* were adjusted for an assumed level of morbidity improvement. The 2014 *Guidelines* claim costs reflect morbidity improvement such that they are as of calendar year 2014. We assume this improvement has also occurred in the actual historical experience. Therefore, a backward or forward projection of morbidity improvement was applied to the expected claim costs on a seriatim basis based on the calendar year in which a given policy's duration fell. An annual improvement level of 1.0% was used in the backward or forward projections.

For projection purposes, three years of 1.0% improvement was applied to the 2014 *Guidelines* to bring them forward to 2017.

Improvement

For projected mortality improvement, the G2 improvement scale from the 2012IAM mortality table was used. The G2 improvement scale varies by attained age and is applied beginning in the first projection year and continues for 15 projection years.

For projected morbidity improvement, a level of 1.0% is assumed for 15 years beginning January 1, 2018. This assumption is set based on the underlying morbidity improvement from the 2014 *Guidelines*. This level is also reasonable based on the SOA July 2016 study, *Long Term Care Morbidity Improvement Study: Estimates for the Non-Insured U.S. Elderly Population Based on the National Long Term Care Survey 1984-2004.* This study reported population annual morbidity improvement of 2.3% for unisex, 2.5% for males, and 2.1% for females. The SOA July 2016 study uses population data, so it is uncertain how well these findings will translate to an insured population. The SOA June 2011 study suggests that an annuitant cohort has more mortality improvement over the general population, so it is possible that this could be true for morbidity as well. Based on these studies, a reasonable range for morbidity improvement is between 0.0% to 2.5% for males and 0.0% to 2.1% for females for 10 to 20 years.

Rate Increase Dependent Assumptions

At the time of a rate increase, insureds have options to elect a contingent benefit upon lapse (CBUL) or reduced benefit options (RBO). Adverse selection is assumed relative to CBUL and RBO elections. These insured behavior assumptions are provided in Section 6 of the actuarial memorandum. These assumptions are based on MedAmerica's actual CBUL and RBO election rate experience to the extent it exists and is credible and actuarial judgment, particularly at the higher rate increase magnitudes where little experience exists.

Contingent Benefit Upon Lapse Election

The assumed CBUL election rate varies based on the cumulative rate increase. The assumption is applied on a seriatim basis and prorated for the requested increase needed to achieve the cumulative rate increase amounts. No CBUL elections are assumed for limited-pay policies.

Reduced Benefit Options

We assume that those electing RBO will reduce their benefits so that premiums after the increase are closer to those before the increase. We assume that the percent reduction in premium corresponds to an equivalent percent reduction in claims. We assume a RBO election rate that varies based on the cumulative rate increase. The assumption is applied on a seriatim basis and prorated for the requested increase needed to achieve the cumulative rate increase amounts. No RBO elections are assumed for limited-pay policies.

The reduction to premium and claims varies based on the level of the rate increase and can then be determined as follows:

Reduction to premium and claims due to the election of RBO

= 1 – (Average premium level after the rate increase with RBO election / Premium level after the full rate increase without any RBO election), where

Average premium level after the rate increase with RBO election

= weighted average premium level of those assumed to elect RBO with those assumed to accept the full rate increase

Adverse Selection

The adverse selection assumption is a function of the CBUL and RBO election rates, such that the relative increase to morbidity due to adverse selection varies by the rate increase's magnitude. The increase to morbidity due to adverse selection was developed from the following formula and actuarial judgment. We assume that at the time of the rate increase, insureds that elect a CBUL will be selective in that their relative morbidity is 25% lower than that of the remaining pool. Similarly, we assume that at the time of the rate increase, insureds that elect an RBO will be selective in that their relative morbidity is 12.5% lower than that of the remaining pool.

PoolMorb = AdvSelMorb x (1 - CBUL - RBO) + [(1 - 25%) x AdvSelMorb] x CBUL + [(1 - 12.5%) x AdvSelMorb] x RBO, where

PoolMorb = morbidity of the pool before the rate increase = 1.0

AdvSelMorb = adverse morbidity of the remaining pool after the rate increase due to selective lapses

CBUL = percentage of policies that elect CBUL RBO = percentage of policies that elect RBO

Solving the above for the adverse selection component results in the following formula for lifetime-pay policies:

Adverse Selection = $1 / (1 - 25\% \times CBUL - 12.5\% \times RBO)$

Predictive Analytics

In developing the morbidity experience-adjustment factors, predictive analytics was employed in the form of a penalized generalized linear model (GLM).

A penalized GLM is similar to a traditional GLM. The only difference is that it adds an additional constraint that penalizes the size of the model's coefficients in order to control overfitting the model to the historical data. This penalty placed on the coefficients can be seen as a credibility lever, which controls how much weight is given to the company's actual experience. A high penalty would give no weight to the data, leaving the benchmark assumption (i.e., the 2014 *Guidelines* for morbidity) unadjusted. No penalty would give full weight to the company's actual data potentially making large adjustments to the benchmark, which could be overfitting the actual experience. When using a penalized GLM it is important to choose a penalty that gives the right amount of weight to the actual data to avoid underfitting or overfitting the experience.

A standard approach for choosing such a penalty is to use a k-fold cross-validation to test a series of penalty values. A k-fold cross-validation splits the data into k subsets and iteratively trains and tests the model independently on each subset of the data. This process gives an estimation of how well a model will generalize to new data that was not used to develop the assumption. Through the k-fold cross-validation we evaluated the impact the penalty had on the model's generalizability by testing a range of 100 penalties. We selected the penalty that minimized the k-fold cross-validation prediction error. Using this approach, we were able to determine the amount of weight to give actual experience versus the benchmark assumption through a statistically robust and automated process.

Credibility

The methodology employed to develop the persistency assumptions considers actual historical experience and its associated credibility. Credibility percentage for the persistency assumptions was determined as (Number of Events / Credibility Threshold)^{1/2}, with events defined as deaths, voluntary lapses, or benefit expiries. A credibility standard of a 90% confidence interval for the number of events with an error of plus or minus 7.5% was chosen. Based on these parameters, 481 events is the criterion for full credibility.

Exhibit A-1a
Actual-to-Expected (A:E) Mortality Experience through December 31, 2015
All Products

			Mortality Rate		Ratios to	2015GAM		A:E Credibility-	Weighted with:	Smoothed
		Actual	2015GAM	2015IAM	Actual	2015IAM	Credibility	2015GAM	2015IAM	Durational
Duration	Exposure	(A)	(E)	(X)	(A:E)	(X:E)	Percent	(E:E=1.00)	(X:E)	Factors
Issue Age 75+										
1-5	24,998	1.8%	4.4%	3.1%	0.40	0.70	95%	0.43	0.41	0.41
6-10	20,553	5.0%	7.0%	5.5%	0.71	0.78	100%	0.71	0.71	0.71
11-15	11,268	10.1%	10.5%	8.8%	0.96	0.84	100%	0.96	0.96	0.96
16-20	3,330	16.3%	16.1%	14.2%	1.02	0.88	100%	1.02	1.02	1.04
21-25	415	25.3%	22.2%	20.6%	1.14	0.93	47%	1.07	1.03	1.05
26+	25	7.8%	32.1%	30.8%	0.24	0.96	6%	0.95	0.91	1.05
21+	440	24.3%	22.8%	21.2%	1.07	0.93	47%	1.03	0.99	1.05
All	60,589	5.4%	7.2%	5.7%	0.75	0.79	100%	0.75	0.75	0.75
	Issue Ages 70 - 74									
1-5	39,706	0.9%	2.2%	1.4%	0.41	0.64	87%	0.49	0.45	0.40
6-10	38,186	2.4%	3.7%	2.5%	0.66	0.67	100%	0.66	0.66	0.45
11-15	27,286	4.9%	6.0%	4.4%	0.83	0.74	100%	0.83	0.83	0.84
16-20	10,157	9.1%	9.4%	7.7%	0.98	0.82	100%	0.98	0.98	0.98
21-25	2,029	14.6%	14.3%	12.3%	1.02	0.86	78%	1.02	0.99	1.04
26+	138	25.8%	20.4%	18.6%	1.27	0.91	27%	1.07	1.01	1.05
21+	2,167	15.3%	14.7%	12.7%	1.04	0.87	83%	1.03	1.01	1.04
All	117,501	3.3%	4.4%	3.2%	0.75	0.73	100%	0.75	0.75	0.75
					Issue Ages 65	- 69				
1-5	67,094	0.6%	1.4%	0.9%	0.42	0.65	90%	0.48	0.44	0.40
6-10	65,409	1.4%	2.2%	1.4%	0.64	0.64	100%	0.64	0.64	0.65
11-15	50,103	2.9%	3.7%	2.4%	0.78	0.66	100%	0.78	0.78	0.79
16-20	23,101	5.3%	5.9%	4.3%	0.90	0.74	100%	0.90	0.90	0.90
21-25	6,829	9.5%	9.3%	7.6%	1.03	0.82	100%	1.03	1.03	0.99
26+	533	13.8%	13.6%	11.6%	1.01	0.86	39%	1.01	0.92	1.04
21+	7,362	9.8%	9.6%	7.9%	1.03	0.82	100%	1.03	1.03	0.99
All	213,069	2.2%	3.0%	2.0%	0.75	0.69	100%	0.75	0.75	0.74
					Issue Ages 60			1		
1-5	93,335	0.3%	0.9%	0.6%	0.41	0.72	82%	0.51	0.46	0.39
6-10	85,284	0.8%	1.4%	0.9%	0.57	0.65	100%	0.57	0.57	0.59
11-15	58,636	1.5%	2.3%	1.5%	0.68	0.65	100%	0.68	0.68	0.67
16-20 21-25	27,386	3.2%	3.8%	2.5%	0.85	0.67	100% 100%	0.85 0.90	0.85 0.90	0.83
21-25 26+	9,435 782	5.5% 9.5%	6.1% 9.1%	4.5% 7.5%	0.90 1.05	0.75 0.82	39%	1.02	0.90	0.90 0.97
21+	10,217	5.8%	6.3%	4.8%	0.92	0.76	100%	0.92	0.91	0.91
∠1+ All	274,857	5.8% 1.2%	6.3% 1.8%	4.8% 1.2%	0.92	0.76	100%	0.92	0.92	0.91
AII	214,001	1.270	1.070	1.270	0.00	00.0	100%	0.00	00.0	0.07

Exhibit A-1b
Actual-to-Expected (A:E) Mortality Experience through December 31, 2015
Individual Products

			Mortality Rate		Ratios to	2015GAM		A:E Credibility-	Weighted with:	Smoothed
		Actual	2015GAM	2015IAM	Actual	2015IAM	Credibility	2015GAM	2015IAM	Durational
Duration	Exposure	(A)	(E)	(X)	(A:E)	(X:E)	Percent	(E:E=1.00)	(X:E)	Factors
					Issue Age <	60				
1-5	213,822	0.1%	0.3%	0.2%	0.39	0.86	66%	0.59	0.55	0.38
6-10	134,800	0.3%	0.5%	0.4%	0.54	0.77	88%	0.59	0.56	0.54
11-15	57,646	0.6%	0.9%	0.7%	0.61	0.69	83%	0.67	0.62	0.60
16-20	24,577	1.1%	1.5%	1.0%	0.70	0.67	74%	0.78	0.69	0.70
21-25	9,193	1.7%	2.4%	1.6%	0.70	0.67	57%	0.83	0.68	0.79
26+	759	2.9%	4.4%	3.1%	0.65	0.72	21%	0.93	0.70	0.87
21+	9,952	1.8%	2.6%	1.7%	0.69	0.68	61%	0.81	0.68	0.80
All	440,797	0.3%	0.6%	0.4%	0.56	0.75	100%	0.56	0.56	0.57

Exhibit A-1c
Actual-to-Expected (A:E) Mortality Experience through December 31, 2015
Group Products

		Actual	Expected			
		Mortality	Mortality	Mortality	Credibility	Smoothed
Duration	Exposure	Rate	Rate ^[1]	A:E	Percent	Scalars

	Issue Age <60								
1-5	120,598	0.2%	0.1%	2.00	65%	2.00			
6-10	109,681	0.3%	0.2%	1.48	85%	1.50			
11-15	71,689	0.5%	0.4%	1.20	83%	1.20			
16-20	25,556	0.7%	0.6%	1.15	59%	1.15			
21-25	11,926	0.8%	0.9%	0.93	45%	1.10			
26-30	305	1.3%	1.2%	1.06	9%	1.05			
31+	0	N/A	N/A	N/A	0%	1.00			

^[1] Includes the durational adjustment factors developed for individual business.

Exhibit A-2a

Derived Lifetime-Pay Voluntary Lapse Experience through December 31, 2015

Prior to Series 11 Policy Forms

		Composite	Expected	Derived		Smoothed
		Termination	Mortality	Lapse	Credibility	Lapse
Duration	Exposure	Rates	Rates	Rates	Percent	Rates
1	5,409	16.9%	0.6%	16.4%	100%	16.50%
2	4,493	9.3%	0.9%	8.4%	89%	8.50%
3	4,076	6.5%	1.3%	5.2%	68%	5.00%
4	3,810	5.3%	1.5%	3.6%	55%	3.50%
5	3,607	4.0%	1.9%	2.0%	41%	2.00%
6	3,457	3.1%	2.0%	0.9%	34%	1.50%
7	3,345	3.7%	2.3%	1.2%	29%	1.50%
8	3,209	4.6%	2.5%	1.8%	33%	1.50%
9	3,047	4.0%	2.8%	1.0%	30%	1.50%
10	2,913	4.5%	3.1%	1.2%	31%	1.00%
11	2,765	5.4%	3.4%	1.8%	27%	1.00%
12	2,604	5.2%	3.7%	1.3%	25%	1.00%
13	2,447	5.5%	3.9%	1.4%	22%	1.00%
14	2,289	5.6%	4.2%	1.2%	20%	1.00%
15	2,087	4.9%	4.6%	0.2%	16%	1.00%
16	1,858	5.7%	5.0%	0.6%	18%	1.00%
17	1,504	6.8%	5.5%	1.3%	18%	1.00%
18	1,104	6.6%	6.0%	0.5%	9%	1.00%
19	710	7.2%	6.6%	0.5%	8%	1.00%
20	422	8.8%	7.1%	1.7%	6%	1.00%
21	224	8.9%	7.5%	1.4%	6%	1.00%
22	99	12.1%	8.9%	3.5%	6%	1.00%
23	28	7.2%	10.6%	-3.8%	5%	1.00%
24	1	0.0%	12.6%	-14.4%	0%	1.00%
1-3	13,978	11.4%	0.9%	10.5%	100%	10.6%
4-6	10,875	4.1%	1.8%	2.2%	77%	2.4%
7-9	9,601	4.1%	2.5%	1.4%	53%	1.5%
5+	37,720	4.8%	3.4%	1.3%	100%	1.3%
6+	34,113	4.9%	3.6%	1.2%	92%	1.2%
7+	30,656	5.1%	3.8%	1.2%	85%	1.2%
8+	27,311	5.3%	4.0%	1.2%	80%	1.1%
9+	24,103	5.4%	4.2%	1.1%	73%	1.1%
10+	21,056	5.6%	4.3%	1.1%	66%	1.0%
All	55,509	6.5%	2.7%	3.8%	100%	3.8%

Exhibit A-2b

Derived Lifetime-Pay Voluntary Lapse Experience through December 31, 2015

Series 11 Individual Policy Forms

		Composite	Expected	Derived		Smoothed
		Termination	Mortality	Lapse	Credibility	Lapse
Duration	Exposure	Rates	Rates	Rates	Percent	Rates
1	12,157	8.6%	0.2%	8.3%	100%	8.50%
2	11,116	4.4%	0.4%	4.0%	96%	4.00%
3	10,632	3.4%	0.5%	2.8%	79%	2.75%
4	10,244	2.6%	0.6%	2.0%	65%	2.00%
5	9,933	2.1%	0.8%	1.3%	54%	1.50%
6	9,696	2.3%	0.9%	1.4%	54%	1.25%
7	9,432	2.4%	1.1%	1.3%	52%	1.25%
8	9,116	2.1%	1.3%	0.8%	41%	1.00%
9	8,825	2.4%	1.5%	0.9%	38%	0.75%
10	8,499	2.5%	1.7%	0.8%	36%	0.60%
11	8,129	2.5%	1.9%	0.6%	34%	0.60%
12	7,460	2.7%	2.1%	0.5%	31%	0.60%
13	5,806	3.0%	2.4%	0.5%	25%	0.60%
14	4,305	3.2%	2.8%	0.4%	23%	0.60%
15	2,813	3.4%	3.2%	0.2%	12%	0.60%
16	1,878	3.6%	3.4%	0.2%	8%	0.60%
17	1,351	5.0%	3.5%	1.6%	8%	0.60%
18	108	2.8%	3.7%	-1.0%	0%	0.60%
1-3	33,905	5.6%	0.4%	5.2%	100%	5.2%
4-6	29,874	2.4%	0.8%	1.6%	100%	1.6%
7-9	27,373	2.3%	1.3%	1.0%	76%	1.0%
5+	87,352	2.6%	1.6%	0.9%	100%	0.9%
6+	77,419	2.6%	1.8%	0.8%	100%	0.8%
7+	67,722	2.7%	1.9%	0.8%	100%	0.8%
8+	58,290	2.7%	2.0%	0.7%	89%	0.7%
9+	49,175	2.8%	2.1%	0.6%	80%	0.6%
10+	40,349	2.9%	2.3%	0.6%	70%	0.6%
All	131,501	3.3%	1.2%	2.1%	100%	2.1%

Exhibit A-2c
Derived Lifetime-Pay Voluntary Lapse Experience through December 31, 2015
Series 11 Group Policy Forms

		Composite	Expected	Derived		Smoothed
		Termination	Mortality	Lapse	Credibility	Lapse
Duration	Exposure	Rates	Rates	Rates	Percent	Rates
1	7,058	6.4%	0.1%	6.3%	95%	6.50%
2	6,497	6.4%	0.2%	6.2%	91%	6.00%
3	5,951	4.4%	0.2%	4.2%	71%	4.00%
4	5,489	4.0%	0.3%	3.7%	63%	3.50%
5	5,008	3.3%	0.3%	3.0%	56%	3.00%
6	4,811	2.7%	0.4%	2.3%	46%	2.50%
7	4,644	2.2%	0.4%	1.8%	40%	2.00%
8	4,498	2.3%	0.5%	1.8%	40%	1.50%
9	4,297	1.7%	0.6%	1.1%	32%	1.30%
10	4,093	2.0%	0.6%	1.4%	36%	1.30%
11	3,468	2.4%	0.7%	1.7%	32%	1.30%
12	2,846	1.8%	0.8%	1.0%	26%	1.30%
13	1,498	1.3%	0.8%	0.5%	12%	1.30%
14	346	3.2%	0.7%	2.5%	10%	1.30%
15	74	1.4%	0.9%	0.5%	5%	1.30%
16	31	3.2%	1.0%	2.2%	5%	1.30%
17	3	0.0%	1.5%	-1.5%	0%	1.30%
1-3	19,506	5.8%	0.2%	5.6%	100%	5.6%
4-6	15,308	3.4%	0.3%	3.0%	96%	3.0%
7-9	13,439	2.1%	0.5%	1.6%	65%	1.6%
5+	35,618	2.3%	0.5%	1.8%	100%	1.8%
6+	30,609	2.2%	0.6%	1.6%	98%	1.6%
7+	25,799	2.1%	0.6%	1.5%	87%	1.5%
8+	21,154	2.0%	0.6%	1.4%	77%	1.3%
9+	16,656	1.9%	0.7%	1.3%	66%	1.3%
10+	12,359	2.0%	0.7%	1.3%	57%	1.3%
All	60,612	3.6%	0.4%	3.2%	100%	3.2%

Exhibit A-3
Actual-to-Expected (A:E) Benefit Expiration Experience through December 31, 2015
Subset of MedAmerica Organic Business

		Actual	Expected			Credibility-	Smoothed
Attained		Expiry	Expiry	Expiry	Credibility	Weighted	Adjustment
Age Band	Exposure	Rate	Rate	A:E	Percent	A:E	Factors
<80	528,089	0.03%	0.04%	0.70	56%	0.83	0.85
80-84	50,683	0.52%	0.41%	1.27	74%	1.20	1.25
85-89	22,568	1.52%	1.04%	1.46	85%	1.39	1.45
90+	6,638	4.43%	2.47%	1.79	78%	1.62	1.65
All	607,979	0.17%	0.14%	1.28	100%	1.28	1.28

Exhibit A-4a MedAmerica and Affinity Partners Morbidity Adjustment Factors Series 11 and Prior Policy Forms

	Product-Sp	Product-Specific Adjustment Factors						
	Prior to	Series 11	Series 11					
Duration	Series 11	Individual	Group					
1	1.01	1.00	0.89					
2	1.03	0.98	0.83					
3	1.04	0.96	0.78					
4	1.09	0.99	0.74					
5	1.17	0.97	0.71					
6	1.19	0.97	0.76					
7	1.18	1.00	0.82					
8	1.16	1.02	0.91					
9	1.09	0.97	1.01					
10	1.01	0.98	1.13					
11	0.96	1.01	1.23					
12	0.97	1.04	1.24					
13	1.00	1.06	1.17					
14	1.05	1.09	1.09					
15	1.11	1.14	1.00					
16	1.12	1.11	0.96					
17	1.11	1.07	0.95					
18	1.08	1.05	0.96					
19	1.04	1.03	0.98					
20+	1.02	1.02	0.99					

	Product-Sp	ecific Adjustm	ent Factors		Payment Type	Adjustment Factors			Non-MANY Ad	ustment Factor
Attained	Prior to	Series 11	Series 11	Attained	Series 11 and Pric		Series 11	Attained	Series 11 and	Series 11
Age	Series 11	Individual	Group	Age	Non-Tax-Qualified (NTQ)	Tax-Qualified (TQ)	Group	Age	Prior Individual	Group
<55	1.05	1.00	1.02	<55	0.99	0.94	1.07	<55	1.07	1.01
55	1.05	1.00	1.02	55	0.99	0.94	1.07	55	1.07	1.01
56	1.05	1.00	1.02	56	0.99	0.94	1.07	56	1.07	1.01
57	1.04	1.00	1.01	57	0.94	0.92	1.12	57	1.06	1.00
58	1.02	0.97	0.99	58	0.88	0.92	1.11	58	0.99	0.98
59	1.09	0.94	0.99	59	0.90	0.88	1.11	59	0.95	0.99
60	1.09	0.93	0.97	60	0.91	0.91	1.04	60	0.89	0.99
61	1.15	0.93	0.98	61	0.91	0.90	1.02	61	0.89	1.01
62	1.23	0.89	0.99	62	0.96	0.87	0.92	62	0.88	1.03
63	1.36	0.86	1.00	63	1.05	0.81	0.90	63	0.94	1.03
64	1.28	0.87	0.99	64	0.96	0.81	0.90	64	1.00	1.01
65	1.23	0.90	0.97	65	0.89	0.85	0.91	65	1.00	1.00
66	1.20	0.90	0.95	66	0.89	0.82	0.93	66	1.09	0.98
67	1.18	0.95	0.93	67	0.90	0.87	1.01	67	1.17	0.97
68	1.08	1.07	0.95	68	0.83	0.95	1.07	68	1.25	1.00
69	1.08	1.11	0.93	69	0.88	1.01	1.04	69	1.26	1.00
70	1.06	1.09	0.93	70	0.94	0.99	1.01	70	1.28	1.00
71	1.00	1.10	0.94	71	0.98	1.03	0.99	71	1.13	1.01
72	0.94	1.13	0.95	72	1.00	1.05	0.96	72	1.09	1.02
73	0.94	1.09	0.95	73	1.06	1.05	0.96	73	1.03	1.01
74	0.94	1.10	0.98	74	1.11	1.04	0.97	74	1.03	1.02
75	0.91	1.13	0.99	75	1.14	1.04	0.93	75	0.99	1.03
76	0.90	1.13	1.00	76	1.10	1.08	0.93	76	1.00	1.03
77	0.92	1.05	0.99	77	1.08	1.07	0.88	77	0.97	1.02
78	0.90	1.05	0.98 0.98	78 79	1.07 1.06	1.09 1.12	0.82 0.77	78	0.97 0.97	1.00 1.00
79 80	0.89 0.93	1.04 1.03	1.00	80	1.03	1.12	0.77	79 80	1.02	1.00
81	0.93	1.03	1.00	81	1.06	1.19	0.79	81	1.02	1.01
82	0.96	1.03	1.01	82	1.08	1.13	0.78	82	1.12	1.03
83	0.90	1.10	1.04	83	1.14	1.14	0.82	83	1.13	1.05
84	0.99	1.09	1.06	84	1.08	1.10	0.94	84	1.11	1.03
85	0.99	1.09	1.04	85	1.10	1.07	0.95	85	1.08	1.03
86	0.96	1.09	1.03	86	1.09	1.09	0.98	86	1.05	1.02
87	0.98	1.06	1.01	87	1.10	1.17	0.98	87	1.03	1.01
88	0.97	1.05	1.00	88	1.06	1.18	0.97	88	1.02	1.00
89	0.98	1.07	0.99	89	1.09	1.22	0.97	89	1.05	0.99
90	0.98	1.06	0.99	90	1.06	1.24	0.96	90	1.05	0.99
91	0.99	1.06	0.99	91	1.04	1.24	0.97	91	1.05	0.99
92	1.00	1.05	0.99	92	1.02	1.15	0.98	92	1.05	0.99
93	1.01	1.02	0.99	93	1.02	1.11	0.99	93	1.04	0.99
94	1.01	0.99	0.99	94	1.01	1.06	0.99	94	1.00	0.99
95	1.02	0.98	1.00	95	1.03	1.04	0.99	95	1.00	1.00
96	1.01	0.97	1.00	96	1.02	1.01	0.98	96	0.98	1.00
97	1.00	0.97	1.00	97	1.03	1.01	0.98	97	0.97	1.00
98	1.00	0.98	1.00	98	1.00	1.01	0.97	98	0.98	1.00
99	1.00	0.99	1.00	99	1.00	1.01	0.97	99	0.99	1.00
100	1.00	0.99	1.00	100	1.00	1.02	0.98	100	0.99	1.00
101+	1.00	1.00	1.00	101+	1.00	1.02	0.98	101+	1.00	1.00

Coverage	Adjustment
Type	Factor
Comprehensive	0.90
Nursing Home Only	1.03
Home Care Only	1.10

Exhibit A-4b

MedAmerica and Affinity Partners

Actual-to-Expected (A:E) Morbidity Experience through June 30, 2016 with Claim Runout

Series 11 and Prior Policy Forms

Policy or		Actual Incur	red Claims	Expected Inc	urred Claims	A:E Incurr	ed Claims
Policyowner	Exposure	Count	Dollars	2014 Guidelines	New	2014 Guidelines	New
Characteristic	[A]	[B]	[C]	[D]	[E]	[F] = [C] / [D]	[G] = [C] / [E]
Group / Individual							
Individual	193,242	2,249	178,975,634	156,954,375	176,559,724	1.14	1.01
Group	70,814	144	12,926,716	15,433,614	12,861,010	0.84	1.01
Payment-Type / Tax Status (TQ	e Tax-Qualified, NTC	Q = Non-Tax-Qualif	ied)				
Cash / TQ	-	-	-	-	-	-	-
Reimbursement / NTQ	39,927	917	65,409,856	59,812,646	63,796,383	1.09	1.03
Reimbursement / TQ	224,130	1,476	126,492,493	112,575,343	125,624,350	1.12	1.01
Coverage Type							
Comprehensive	227,746	1,884	150,906,765	139,676,235	147,922,870	1.08	1.02
Nursing Home Only	32,685	460	38,605,492	30,464,462	38,400,192	1.27	1.01
Home Care Only	3,625	49	2,390,092	2,247,291	3,097,671	1.06	0.77
Attained Age							
< 60	83,038	42	4,870,844	5,365,561	4,676,717	0.91	1.04
60 - 69	79,848	159	19,010,143	18,287,944	16,392,665	1.04	1.16
70 - 79	70,206	692	61,059,411	58,372,138	61,346,118	1.05	1.00
80 - 89	28,701	1,254	93,780,632	78,168,887	93,335,869	1.20	1.00
90 +	2,264	246	13,181,321	12,193,459	13,669,365	1.08	0.96
Policy Duration				-			
< 7	100,261	233	18,673,085	21,414,416	20,738,173	0.87	0.90
7 - 10	81,762	596	50,705,841	45,309,295	48,390,377	1.12	1.05
11 - 15	68,137	1,050	84,288,017	73,690,605	83,520,887	1.14	1.01
16 - 20	13,264	475	36,640,193	30,113,053	34,827,994	1.22	1.05
21 +	632	39	1,595,214	1,860,621	1,943,302	0.86	0.82
Product							
Series 11 Group	70,814	144	12,926,716	15,433,614	12,861,010	0.84	1.01
Series 11 Individual	153,316	1,332	113,565,777	97,141,729	112,763,341	1.17	1.01
Prior to Series 11	39,927	917	65,409,856	59,812,646	63,796,383	1.09	1.03
Total	264,057	2,393	191,902,350	172,387,989	189,420,734	1.11	1.01

Exhibit A-4c
MedAmerica, Affinity Partners, and Acquired Business
Actual-to-Expected (A:E) Morbidity Experience through June 30, 2016 with Claim Runout
All Products

Policy or		Actual Incur	red Claims	Expected Inco	urred Claims	A:E Incurre	ed Claims
Policyowner	Exposure	Count	Dollars	2014 Guidelines	New	2014 Guidelines	New
Characteristic	[A]	[B]	[C]	[D]	[E]	[F] = [C] / [D]	[G] = [C] / [E]
Group / Individual							
Individual	912,916	9,926	800,367,697	733,049,215	794,361,129	1.09	1.01
Group	346,699	1,374	130,339,904	156,675,596	133,888,114	0.83	0.97
Payment-Type / Tax Status (TQ		Q = Non-Tax-Qualif					
Cash / TQ	343,731	558	62,039,510	57,638,053	59,620,193	1.08	1.04
Reimbursement / NTQ	300,053	6,653	510,365,552	479,343,318	507,745,230	1.06	1.01
Reimbursement / TQ	615,831	4,089	358,302,538	352,743,439	360,883,820	1.02	0.99
Coverage Type							
Comprehensive	1,136,716	8,789	756,597,258	749,849,298	758,592,612	1.01	1.00
Nursing Home Only	106,185	2,145	154,205,174	127,829,789	153,061,713	1.21	1.01
Home Care Only	16,715	366	19,905,169	12,045,724	16,594,918	1.65	1.20
Attained Age							
< 60	453,624	244	33,805,437	30,149,268	30,328,735	1.12	1.11
60 - 69	360,462	666	78,589,161	88,054,403	75,788,341	0.89	1.04
70 - 79	291,092	2,748	262,147,876	268,144,812	267,494,038	0.98	0.98
80 - 89	138,826	5,979	465,876,836	417,634,186	464,847,833	1.12	1.00
90 +	15,611	1,663	90,288,290	85,742,142	89,790,297	1.05	1.01
Policy Duration							
< 7	497,039	823	75,787,355	82,648,988	79,201,077	0.92	0.96
7 - 10	307,411	1,867	174,015,180	164,578,241	170,058,801	1.06	1.02
11 - 15	278,526	3,765	317,411,016	297,015,693	316,181,994	1.07	1.00
16 - 20	129,643	3,188	245,115,546	230,142,856	242,291,028	1.07	1.01
21 +	46,996	1,657	118,378,503	115,339,033	120,516,343	1.03	0.98
Total	1,259,615	11,300	930,707,601	889,724,811	928,249,243	1.05	1.00

BLUE CROSS OF NORTHEASTERN PENNSYLVANIA

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

Supplement to the Series 11 and Prior Actuarial Memorandum

August 15, 2018

<u>Product</u> <u>Number</u>

Series 11 Group

Comprehensive FormGRP11-341-PA-200Comprehensive CertificateGRP11-342-PA-1100

1. Purpose of Filing

This supplement has been prepared for the purpose of demonstrating that the requested rate increase complies with Chapter 18 Section 3803(c) and (e), and Reg. 89.83 of the Insurance Regulations for the state of Pennsylvania. It may not be appropriate for other purposes.

This supplement to the actuarial memorandum captures the pooled nationwide experience of the above-listed policy form(s) and similar individual and group policy forms of the same product series issued nationwide by MedAmerica Insurance Company (MedAmerica) and its affinity partners. Pennsylvania-specific experience is not considered fully credible, but is being provided as required.

2. Demonstration of Compliance with Chapter 18 Section 3803

(c) and (e): We believe that we comply with these subsections of the regulation by submitting these rates before they are being used.

3. Demonstration of Compliance with Reg. 89.83

- 89.83 (a): This subsection requires no action.
- 89.83 (b): This subsection is not applicable since this filing is not for rates for a new policy form.
- 89.83 (c): Revision of Current Rates
- (1): For policies issued prior to September 16, 2002, the effective date of rate stability in Pennsylvania, the minimum loss ratio requirement is 60%, as specified in Reg. 89a.117.(b). For policies issued on or after September 16, 2002, the loss ratio requirements are specified in Reg. 89a.118.(c)(2), (i.e., the 58%/85% test). Demonstration of satisfaction of these requirements is discussed in Section 15 of the enclosed actuarial memorandum

As of December 31, 2017, 149 of the 408 policies that are in force and subject to the requested rate increase in Pennsylvania were issued on or after September 16, 2002 (approximately 37%). However, because the company manages this block of business as a whole, this rate increase filing complies with both sets of requirements for all of the policies, regardless of issue date.

- (2): Section 3 of the actuarial memorandum provides a description of benefits. Copies of the affected policy forms may be provided upon request.
- (2)(i): The primary reason why these forms are in need of a premium rate increase is due to emerging experience running more adverse than expected in pricing.

The company is requesting a premium rate increase that varies by benefit period to achieve the cumulative rate increases as shown in Section 2 of the enclosed actuarial memorandum. The company is seeking this current rate increase request to help alleviate the adverse performance on this block of business. The cumulative rate increase levels were determined to vary by benefit period to better align the rate increase with the adverse experience. The table in Section 2 of the enclosed actuarial memorandum provides the average prior, requested, and cumulative increase by benefit period based on the nationwide distribution. The enclosed cover letter provides similar information on a Pennsylvania-specific distribution.

The current rate schedules along with the proposed rate schedules are enclosed with this filing. Please note that the actual rates implemented may vary slightly from those shown due to rounding algorithms.

Exhibit I of the actuarial memorandum provides nationwide earned premium and incurred claim actual

BLUE CROSS OF NORTHEASTERN PENNSYLVANIA

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

Supplement to the Series 11 and Prior Actuarial Memorandum

August 15, 2018

and projected experience using current assumptions, as described in Section 6 of the actuarial memorandum. Attachment 1 to this supplement provides nationwide written premium and paid claim actual and projected experience using current assumptions. Values in Exhibit I and Attachment 1 are shown both before and after the requested rate increase. The interest rate used in Exhibit I and Attachment 1 to accumulate and discount values is the maximum valuation interest rate for contract reserves applicable for the year of issue (which ranges from 3.5% to 5.5%, and averages 4.3%).

Attachments 2 and 3 to this supplement provide similar information as Exhibit I and Attachment 1 respectively, except provides Pennsylvania-specific experience.

(2)(ii)(A): There have been two rate increases approved and implemented on these policy forms in Pennsylvania. The cumulative prior approved increase is 67% and has been implemented on the individual and group policy forms. The most recent rate increase was filed for use by the Department on September 22, 2017.

(2)(ii)(B): Table 1a shows the original pricing commission scales by issue age and duration for lifetime-pay individual policies.

Table 1a Commission Percentages by Issue Age and Duration^[1]

Commission Percentages by Issue Age and Duration 11							
	Issue	Commissions by Duration					
Individual Policy Form	Ages	1	2-10	11+			
LTC-LBP-2PA LTC-LBP8-MA-PA LTC-CD5-2PA LTC-CD8-MA-PA	<71 71-79 80+	45-78 40-68 35-58	10-21 8-18 5-15	0-5 0-5 0-5			
LTC-CD9-MA-PA	All Ages	30-50	5-10	5-10			
LTQ11-336-PA-998 NTQ11-337-PA-998 HTQ11-338-PA-998 LTQ11-336-MA-PA-998 NTQ11-337-MA-PA-998 HTQ11-338-MA-PA-998 LTQ11-336-MA-PA-601 HTQ11-338-MA-PA-601 NTQ11-337-MA-PA-601	<75 75+	30-50 20-40	5-10 5-10	0-10 0-10			
FLQ11-336-PA-998 FLQ11-336-MA-PA-601	<75 75+	25-45 15-35	0-5 0-5	0-5 0-5			

^[1] The maximum writing agent commissions are 50% in the first policy year and 10% for policy years two through ten.

Table 1b provides similar information for lifetime-pay group certificates by duration and whether the group was sold by a commissioned agent. The commission scale, without other sales and marketing expenses, was not readily available.

Table 1b
Commission Percentages by Duration and Agent Type
Group Policy Forms: GRP11-341-MA-PA-601 and GRP11-341-PA-200

Duration	Commissioned	Non-Commissioned		
Duration	Commissioned	Non-Commissioned		
1	30%	40%		
2+	7%	0%		

Commissions for limited-pay policies are reduced to levels that are approximately equivalent to the above commissions for lifetime-pay policies and certificates, on a present value basis, based on original pricing assumptions.

The actual commission scales will differ slightly from those that appear in Table 1 as the company adjusts renewal commission rates so that the total commissions paid before and after any increase in premium are similar (i.e., commissions are not paid on the increased premium).

BLUE CROSS OF NORTHEASTERN PENNSYLVANIA

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

Supplement to the Series 11 and Prior Actuarial Memorandum

August 15, 2018

(2)(ii)(C)(I): Premiums earned and written since inception for nationwide experience can be found in Exhibit I of the actuarial memorandum and Attachment 1 to this supplement, respectively. Premiums earned and written since inception for Pennsylvania-specific experience can be found in Attachments 2 and 3, respectively. Attachment 4 to this supplement provides reserve balances and the calculation basis for both nationwide and Pennsylvania-specific experience.

(2)(ii)(C)(II): Attachment 4 to this supplement provides a breakdown of historical incurred claims and active life reserve balance, including a description of the calculation basis, for both nationwide and Pennsylvania-specific experience.

Attachment 5 to this supplement provides actual and projected experience on a durational basis using current assumptions. Included are policy year earned premiums, incurred claims, durational loss ratios, end of year lives, and cumulative loss ratios with interest. Values in Attachment 5 are shown both before and after the requested rate increase. The number of durations shown was chosen to capture the majority of the durations underlying Exhibit I. Similar to Exhibit I and Attachments 1 through 3, the values used to calculate the cumulative loss ratios are accumulated and discounted at the maximum valuation interest rate.

Attachment 6 to this supplement provides similar information to Attachment 5 for Pennsylvania-specific experience.

(2)(ii)(D): We believe that we have provided information sufficient to support the rate increase requested in this filing.

(2)(iii): We understand that data used in this rate increase filing is in agreement with those used in the annual statement filed with the department.

89.83 (d): We believe the proposed rate tables provided with this filing comply with this subsection.

4. Microsoft Excel spreadsheet containing all numerical data

An Excel workbook containing the values shown in Exhibits I and II of the actuarial memorandum and Attachments 1 through 6 of this supplement is enclosed with this filing, as required.

Attachment 1-a MedAmerica and Affinity Partners Written Premium and Paid Claim Experience and Projections by Calendar Year Nationwide Experience Before Requested Rate Increase Series 11 and Prior Policy Forms

		Actual or Pr	ojected Experience	e using Current	
			Without Interest		Cumulative Loss
	Calendar	Written	Paid	Loss	Ratio w/ Max.
	Year	Premium	Claims	Ratio	Val. Interest
	1992	127,778	0	0%	09
	1993	820,223	435	0%	09
	1994	1,859,170	45,498	2% 2%	29
	1995	2,806,773	63,694	2% 2%	29 29
	1996	3,903,160	75,596	2 % 1%	29
	1997	4,551,144 5,678,298	67,538 125,276	1% 2%	29
	1998	, , , , , , , , , , , , , , , , , , ,		2 % 6%	39
	1999 2000	7,358,468 9,549,709	465,964 970,921	10%	5%
	2000	12,759,812	1,121,497	9%	6%
	2002	17,246,296	1,445,750	8%	69
Historical	2003	23,386,345	2,546,158	11%	79
Experience	2004	27,585,079	3,105,399	11%	89
Experience	2005	28,686,362	4,315,104	15%	99
	2006	28,696,090	5,258,176	18%	119
	2007	28,305,082	6,694,088	24%	129
	2008	27,586,766	8,446,221	31%	149
	2009	26,643,606	8,314,848	31%	159
	2010	25,164,298	9,151,070	36%	179
	2011	24,665,824	11,323,437	46%	199
	2012	25,263,705	13,322,263	53%	219
	2013	23,672,984	15,681,015	66%	239
	2014	22,143,196	17,656,283	80%	259
	2015	21,396,467	20,902,456	98%	289
	2016	20,967,910	21,690,779	103%	309
	2017	20,134,198	23,189,988	115%	339
	2018	20,197,632	25,010,516	124%	359
	2019	20,404,820	23,992,732	118%	389
	2020	20,103,807	26,193,624	130%	409
	2021	19,245,584	25,273,392	131%	429
	2022	18,183,066	27,035,029	149%	449
	2023	16,826,582	28,651,925	170%	469
	2024	15,723,641	30,208,948	192%	489
	2025	14,697,399	31,800,481	216%	509
	2026	13,766,339	33,443,815	243%	539
	2027	12,830,331	35,137,970	274%	55
	2028	11,954,715	36,830,801	308%	57
Projected	2029	11,133,053	38,519,259	346%	59'
Future	2030	10,345,240	40,193,337	389%	62'
Experience	2031	9,587,177	41,834,566	436%	64
(60 Years)	2032	8,859,642	43,413,680	490%	66'
	2033	8,163,214	44,951,688	551%	69'
	2034	7,495,998	46,472,785	620%	71'
	2035	6,858,137	47,952,641	699%	73'
	2036	6,250,749	49,328,826	789%	75
	2037	5,674,587	50,556,514	891%	78
	2038	5,130,410	51,588,684	1,006%	80
	2039	4,618,674	52,384,538	1,134%	82' 84'
	2040	4,139,694	52,904,873	1,278%	
	2041	3,694,053	53,116,312	1,438%	86 88
	2042	3,281,823	52,991,841	1,615%	
	2043 2044	2,902,813	52,524,296 51,735,500	1,809%	90 92
		2,556,226	51,735,500 50,645,850	2,024%	93
	2045	2,241,006	50,645,859	2,260%	93 95
	2046 2047	1,956,099	49,284,270	2,520%	96
	2047 2048-2052	1,700,208 5,550,786	47,667,687	2,804%	
		5,559,786	207,468,960 148,359,344	3,732% 5,950%	102 105
	2053-2057 2058-2062	2,493,525	, ,	5,950% 8 904%	105 107
		1,053,534	93,809,214 54,174,980	8,904% 12,777%	107 108
	2063-2067	423,987	34,174,980	12,777%	
	2068-2072	161,570	28,538,559	17,663%	108

	111	i iliterest Accum.	DISC. 10 12/31/201	at wax. val. litte	
History		689,721,452	227,096,145	33%	
Future		204,492,115	744,122,821	364%	
Lifetime		894,213,567	971,218,966	109%	

Attachment 1-b MedAmerica and Affinity Partners Written Premium and Paid Claim Experience and Projections by Calendar Year Nationwide Experience After Requested Rate Increase Series 11 and Prior Policy Forms

		Actual or Pr	ojected Experient Without Interest	ce using Current	
	Calandar	Written	Paid	Loss	Cumulative Loss
	Calendar				Ratio w/ Max. Val. Interest
	Year	Premium	Claims	Ratio	
	1992	127,778	0	0%	09
	1993	820,223	435	0%	29
	1994	1,859,170	45,498	2% 2%	29
	1995	2,806,773	63,694	2%	
	1996	3,903,160	75,596	1%	2º 2º
	1997	4,551,144	67,538	2%	
	1998	5,678,298	125,276	2% 6%	2
	1999	7,358,468	465,964		3
	2000	9,549,709	970,921	10% 9%	5 6
	2001	12,759,812	1,121,497		
Llistaviaal	2002	17,246,296	1,445,750	8%	6
Historical	2003	23,386,345	2,546,158	11%	7
Experience	2004	27,585,079	3,105,399	11%	8
	2005	28,686,362	4,315,104	15%	9
	2006	28,696,090	5,258,176	18%	11
	2007	28,305,082	6,694,088	24%	12
	2008	27,586,766	8,446,221	31%	14
	2009	26,643,606	8,314,848	31%	15
	2010	25,164,298	9,151,070	36%	17
	2011	24,665,824	11,323,437	46%	19
	2012	25,263,705	13,322,263	53%	21
	2013	23,672,984	15,681,015	66%	23
	2014	22,143,196	17,656,283	80%	25
	2015	21,396,467	20,902,456	98%	28
	2016	20,967,910	21,690,779	103%	30
	2017	20,134,198	23,189,988	115%	33
	2018	20,198,468	25,010,516	124%	35
	2019	25,670,134	23,844,499	93%	37
	2020	27,244,327	25,681,826	94%	39
	2021	27,399,614	24,458,255	89%	41
	2022	26,265,349	25,887,698	99%	42
	2023	24,285,564	27,203,771	112%	44
	2024	22,669,589	28,489,718	126%	45
	2025	21,178,879	29,838,017	141%	47
	2026	19,824,971	31,264,271	158%	49
	2027	18,454,605	32,763,536	178%	51
	2028	17,174,419	34,279,784	200%	52
Projected	2029	15,973,784	35,807,175	224%	54
Future	2030	14,822,994	37,334,920	252%	56
Experience	2031	13,716,036	38,845,240	283%	58
(60 Years)	2032	12,654,363	40,309,877	319%	60
	2033	11,639,001	41,747,747	359%	62
	2034	10,667,386	43,180,246	405%	64
	2035	9,740,017	44,583,721	458%	66
	2036	8,858,743	45,899,129	518%	68
	2037	8,024,506	47,083,268	587%	69
	2038	7,238,399	48,090,682	664%	71
	2039	6,500,924	48,881,755	752%	73
	2040	5,812,375	49,417,859	850%	75
	2041	5,173,418	49,666,141	960%	77
	2042	4,583,818	49,599,330	1,082%	78
	2043	4,043,127	49,209,773	1,217%	80
	2044	3,550,005	48,517,316	1,367%	81
	2045	3,102,776	47,540,129	1,532%	83
	2046	2,699,659	46,303,966	1,715%	84
	2047	2,338,605	44,822,855	1,917%	85
	2048-2052	7,571,687	195,468,492	2,582%	90
	2053-2057	3,325,083	140,095,314	4,213%	93
	2058-2062	1,370,739	88,669,592	6,469%	95
	2063-2067	537,388	51,269,465	9,541%	95
	2068-2072	199,700	27,067,311	13,554%	96
	2073-2077	71,166	13,053,096	18,342%	96

. •	,,,,,	i iliterest Accum./i	DISC. 10 12/31/20	i / at wax. vai. iiitei	63
History		689,721,452	227,096,145	33%	
Future		278,940,307	701,456,765	251%	
Lifetime		968,661,759	928,552,910	96%	

Attachment 2-a

MedAmerica and BCNEPA

Earned Premium and Incurred Claim Experience and Projections by Calendar Year Pennsylvania-Specific Experience Before Requested Rate Increase Series 11 and Prior Policy Forms

		Ac	tual or Projected I	Experience using	Current Assumpti	
	_					Cumulative Loss
	Calendar	Earned	Incurred	Incurred	End of Year	Ratio w/ Max.
	Year	Premium	Claims	Loss Ratio	Lives	Val. Interest
	1992	17,324		0%	111	0%
	1993	547,119		21%	580	19%
	1994	1,333,538		2%	1,190	8%
	1995	1,802,548		3%	1,165	5%
	1996	1,608,703	5,871	0%	1,055	49
	1997	1,439,865	114,890	8%	953	5%
	1998	1,347,126	235,553	17%	912	7%
	1999	1,286,732	377,829	29%	872	9%
	2000	1,267,260	481,212	38%	859	12%
	2001	1,235,696	713,556	58%	895	16%
	2002	1,431,379	745,816	52%	1,036	19%
Historical	2003	1,554,846	464,534	30%	1,078	20%
Experience	2004	1,652,124	958,964	58%	1,139	23%
	2005	1,597,784		41%	1,089	249
	2006	1,498,700		50%	1,021	26%
	2007	1,403,330		67%	983	289
	2008	1,324,472		61%	906	29%
	2009	1,241,850	· · · · · · · · · · · · · · · · · · ·	62%	858	30%
	2010			72%	720	31%
		1,132,473	. , .		664	349
	2011	1,041,535		139%		
	2012	1,071,362		123%	605	369
	2013	1,063,820		92%	553	389
	2014	996,939		147%	516	409
	2015	911,937		283%	472	449
	2016	835,842		63%	440	449
	2017	775,386		160%	408	469
	2018	760,674	,	124%	368	479
	2019	754,171	912,244	121%	347	479
	2020	704,396	902,411	128%	327	489
	2021	654,895	899,849	137%	308	499
	2022	604,697	906,857	150%	289	509
	2023	551,089	914,609	166%	272	509
	2024	474,637	930,780	196%	256	519
	2025	393,735	952,011	242%	240	529
	2026	360,503	981,243	272%	225	539
	2027	327,655	1,013,561	309%	211	549
	2028	298,791		351%	198	549
Projected	2029	272,820		399%	186	559
Future	2030	248,557		453%	174	569
Experience	2031	225,879		512%	162	579
(60 Years)	2032	204,655		576%	151	589
(00 10010)	2033	184,750		654%	141	59°
	2033	166,046		741%	131	59°
	2035	148,495		848%	121	60°
				961%	111	61
	2036	132,090				
	2037	116,799		1,083%	103	62'
	2038	102,620		1,215%	94	62
	2039	89,556		1,353%	86	63
	2040	77,609	1,161,816	1,497%	78	64
	2041	66,781	1,099,251	1,646%	71	64
	2042	57,055		1,815%	64	65
	2043	48,384		2,015%	58	65
	2044	40,721	920,292	2,260%	52	66
	2045	34,004		2,529%	46	66
	2046	28,170		2,845%	41	66
	2047	23,146	740,704	3,200%	36	67
	2048-2052	63,486	2,740,701	4,317%	121	68
	2053-2057	18,324		6,918%	52	68
	2058-2062	4,035		10,203%	18	68
	2063-2067	633		15,408%	5	68'
	2068-2072	60		24,644%	1	68
	2073-2077	3		48,074%	0	68

•	Title intologe Atoouring	D100. 10 12/01/201	at max. van mitor
History	62,246,630	28,376,392	46%
Future	5,964,173	18,048,511	303%
Lifetime	68.210.803	46,424,902	68%

Attachment 2-b

MedAmerica and BCNEPA

Earned Premium and Incurred Claim Experience and Projections by Calendar Year Pennsylvania-Specific Experience After Requested Rate Increase Series 11 and Prior Policy Forms

Projected Future Experience (60 Years)	Calendar Year 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	Earned Premium 17,324 547,119 1,333,538 1,802,548 1,608,703 1,439,865 1,347,126 1,286,732 1,267,260 1,235,696 1,431,379 1,554,846 1,652,124 1,597,784 1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362 1,063,820 996,939	112,935 28,746 55,039 5,871 114,890 235,553 377,829 481,212 713,556 745,816 464,534 958,964 656,165 747,377 934,486 806,835 771,521 811,757	Incurred Loss Ratio 0% 21% 2% 3% 0% 8% 17% 29% 388% 558% 52% 30% 588% 41% 50% 61% 62%	End of Year Lives 1111 580 1,190 1,165 1,055 953 912 872 859 895 1,036 1,078 1,139 1,089 1,021 983 906 858	Cumulative Loss Ratio w/ Max. Val. Interest 0% 19% 8% 5% 4% 5% 7% 9% 12% 16% 19% 20% 23% 244% 26% 28% 29% 30%
Projected Future Experience (60 Years)	Year 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	Premium 17,324 547,119 1,333,538 1,802,548 1,608,703 1,439,865 1,347,126 1,286,732 1,267,260 1,235,696 1,431,379 1,554,846 1,652,124 1,597,784 1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362 1,063,820	Claims 0 112,935 28,746 55,039 5,871 114,890 235,553 377,829 481,212 713,556 745,816 464,534 958,964 656,165 747,377 934,486 806,835 771,521 811,757	Loss Ratio 0% 21% 2% 3% 0% 8% 17% 29% 38% 58% 52% 30% 58% 41% 50% 67% 61%	Lives 111 580 1,190 1,165 1,055 953 912 872 859 895 1,036 1,078 1,139 1,089 1,021 983 906	Val. Interest 0% 19% 8% 5% 4% 5% 7% 9% 12% 16% 20% 23% 24% 26% 28%
Projected Future Experience (60 Years)	1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	17,324 547,119 1,333,538 1,802,548 1,608,703 1,439,865 1,347,126 1,286,732 1,267,260 1,235,696 1,431,379 1,554,846 1,652,124 1,597,784 1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362 1,063,820	0 112,935 28,746 55,039 5,871 114,890 235,553 377,829 481,212 713,556 745,816 464,534 958,964 656,165 747,377 934,486 806,835 771,521 811,757	0% 21% 2% 3% 0% 8% 17% 29% 38% 58% 52% 30% 55% 67% 61%	111 580 1,190 1,165 1,055 953 912 872 859 895 1,036 1,078 1,139 1,089 1,021 983	0% 19% 8% 5% 4% 5% 7% 9% 12% 16% 20% 23% 24% 26% 28%
Projected Future Experience (60 Years)	1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	547,119 1,333,538 1,802,548 1,608,703 1,439,865 1,347,126 1,286,732 1,267,260 1,235,696 1,431,379 1,554,846 1,652,124 1,597,784 1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362 1,063,820	112,935 28,746 55,039 5,871 114,890 235,553 377,829 481,212 713,556 745,816 464,534 958,964 656,165 747,377 934,486 806,835 771,521 811,757	21% 2% 3% 0% 8% 17% 29% 38% 58% 52% 30% 58% 41% 50% 67%	580 1,190 1,165 1,055 953 912 872 859 895 1,036 1,078 1,139 1,089 1,021 983	19% 8% 5% 44% 5% 7% 9% 12% 16% 19% 20% 23% 24% 26% 28%
Projected Future Experience (60 Years)	1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	1,333,538 1,802,548 1,608,703 1,439,865 1,347,126 1,286,732 1,267,260 1,235,696 1,431,379 1,554,846 1,652,124 1,597,784 1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362 1,063,820	28,746 55,039 5,871 114,890 235,553 377,829 481,212 713,556 745,816 464,534 958,964 656,165 747,377 934,486 806,835 771,521 811,757	2% 3% 0% 8% 17% 29% 38% 58% 52% 30% 58% 41% 67% 61%	1,190 1,165 1,055 953 912 872 859 895 1,036 1,078 1,139 1,089 1,021 983	8% 5% 4% 5% 7% 9% 12% 16% 19% 20% 23% 24% 26% 28%
Projected Future Experience (60 Years)	1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	1,802,548 1,608,703 1,439,865 1,347,126 1,286,732 1,267,260 1,235,696 1,431,379 1,554,846 1,652,124 1,597,784 1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362 1,063,820	55,039 5,871 114,890 235,553 377,829 481,212 713,556 745,816 464,534 958,964 656,165 747,377 934,486 806,835 771,521 811,757	3% 0% 8% 17% 29% 38% 52% 30% 58% 41% 67% 61%	1,165 1,055 953 912 872 859 895 1,036 1,078 1,139 1,082 1,021 983 906	5% 4% 5% 7% 9% 12% 16% 29% 23% 24% 26% 28% 29%
Projected Future Experience (60 Years)	1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2011 2012 2013 2014 2015 2016	1,608,703 1,439,865 1,347,126 1,286,732 1,267,260 1,235,696 1,431,379 1,554,846 1,652,124 1,597,784 1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362 1,063,820	5,871 114,890 235,553 377,829 481,212 713,556 745,816 464,534 958,964 656,165 747,377 934,486 806,835 771,521 811,757	0% 8% 17% 29% 38% 58% 52% 30% 41% 50% 67%	1,055 953 912 872 859 895 1,036 1,078 1,139 1,089 1,021 983 906	4% 5% 7% 9% 12% 16% 29% 24% 26% 28% 29%
Projected Future Experience (60 Years)	1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	1,439,865 1,347,126 1,286,732 1,267,260 1,235,696 1,431,379 1,554,846 1,652,124 1,597,784 1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362 1,063,820	114,890 235,553 377,829 481,212 713,556 745,816 464,534 958,964 656,165 747,377 934,486 806,835 771,521 811,757	8% 17% 29% 38% 58% 52% 30% 41% 50% 67% 61%	953 912 872 859 895 1,036 1,078 1,139 1,089 1,021 983 906	5% 7% 9% 12% 16% 19% 20% 23% 24% 26% 28%
Projected Future Experience (60 Years)	1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	1,347,126 1,286,732 1,267,260 1,235,696 1,431,379 1,554,846 1,652,124 1,597,784 1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362	235,553 377,829 481,212 713,556 745,816 464,534 958,964 656,165 747,377 934,486 806,835 771,521 811,757	17% 29% 38% 58% 52% 30% 41% 50% 67% 61%	912 872 859 895 1,036 1,078 1,139 1,089 1,021 983 906	7% 9% 12% 16% 19% 20% 23% 24% 26% 28%
Projected Future Experience (60 Years)	1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	1,286,732 1,267,260 1,235,696 1,431,379 1,554,846 1,652,124 1,597,784 1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362	377,829 481,212 713,556 745,816 464,534 958,964 656,165 747,377 934,486 806,835 771,521 811,757	29% 38% 58% 52% 30% 58% 41% 50% 67% 61%	872 859 895 1,036 1,078 1,089 1,021 983 906	9% 12% 16% 19% 20% 23% 24% 26% 28% 29%
Projected Future Experience (60 Years)	2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	1,267,260 1,235,696 1,431,379 1,554,846 1,652,124 1,597,784 1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362	481,212 713,556 745,816 464,534 958,964 656,165 747,377 934,486 806,835 771,521 811,757	38% 58% 52% 30% 58% 41% 50% 67% 61%	859 895 1,036 1,078 1,139 1,089 1,021 983 906	12% 16% 19% 20% 23% 24% 26% 28% 29%
Projected Future Experience (60 Years)	2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	1,235,696 1,431,379 1,554,846 1,652,124 1,597,784 1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362 1,063,820	713,556 745,816 464,534 958,964 656,165 747,377 934,486 806,835 771,521 811,757	58% 52% 30% 58% 41% 50% 67% 61%	895 1,036 1,078 1,139 1,089 1,021 983 906	16% 19% 20% 23% 24% 26% 28% 29%
Projected Future Experience (60 Years)	2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	1,431,379 1,554,846 1,652,124 1,597,784 1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362 1,063,820	745,816 464,534 958,964 656,165 747,377 934,486 806,835 771,521 811,757	52% 30% 58% 41% 50% 67% 61%	1,036 1,078 1,139 1,089 1,021 983 906	19% 20% 23% 24% 26% 28% 29%
Projected Future Experience (60 Years)	2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	1,554,846 1,652,124 1,597,784 1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362 1,063,820	464,534 958,964 656,165 747,377 934,486 806,835 771,521 811,757	30% 58% 41% 50% 67% 61%	1,078 1,139 1,089 1,021 983 906	20% 23% 24% 26% 28% 29%
Projected Future Experience (60 Years)	2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	1,652,124 1,597,784 1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362 1,063,820	958,964 656,165 747,377 934,486 806,835 771,521 811,757	58% 41% 50% 67% 61%	1,139 1,089 1,021 983 906	23% 24% 26% 28% 29%
Projected Future Experience (60 Years)	2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	1,652,124 1,597,784 1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362 1,063,820	958,964 656,165 747,377 934,486 806,835 771,521 811,757	41% 50% 67% 61%	1,139 1,089 1,021 983 906	24% 26% 28% 29%
Projected Future Experience (60 Years)	2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	1,597,784 1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362 1,063,820	656,165 747,377 934,486 806,835 771,521 811,757	41% 50% 67% 61%	1,089 1,021 983 906	24% 26% 28% 29%
Projected Future Experience (60 Years)	2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	1,498,700 1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362 1,063,820	747,377 934,486 806,835 771,521 811,757	50% 67% 61%	1,021 983 906	26% 28% 29%
Projected Future Experience (60 Years)	2007 2008 2009 2010 2011 2012 2013 2014 2015 2016	1,403,330 1,324,472 1,241,850 1,132,473 1,041,535 1,071,362 1,063,820	934,486 806,835 771,521 811,757	67% 61%	983 906	28% 29%
Projected Future Experience (60 Years)	2008 2009 2010 2011 2012 2013 2014 2015 2016	1,324,472 1,241,850 1,132,473 1,041,535 1,071,362 1,063,820	806,835 771,521 811,757	61%	906	29%
Projected Future Experience (60 Years)	2009 2010 2011 2012 2013 2014 2015 2016	1,241,850 1,132,473 1,041,535 1,071,362 1,063,820	771,521 811,757			
Projected Future Experience (60 Years)	2010 2011 2012 2013 2014 2015 2016	1,132,473 1,041,535 1,071,362 1,063,820	811,757	02 /0	030	
Projected Future Experience (60 Years)	2011 2012 2013 2014 2015 2016	1,041,535 1,071,362 1,063,820	- , -	72%	720	
Projected Future Experience (60 Years)	2012 2013 2014 2015 2016	1,071,362 1,063,820	1,452,008		720	31%
Projected Future Experience (60 Years)	2013 2014 2015 2016	1,063,820		139%	664	34%
Projected Future Experience (60 Years)	2014 2015 2016			123%	605	36%
Projected Future Experience (60 Years)	2015 2016	996.939	· ·	92%	553	38%
Projected Future Experience (60 Years)	2016	· ·		147%	516	40%
Projected Future Experience (60 Years)		911,937	2,584,558	283%	472	44%
Projected Future Experience (60 Years)		835,842		63%	440	44%
Projected Future Experience (60 Years)	2017	775,386	1,243,392	160%	408	46%
Projected Future Experience (60 Years)	2018	760,674	946,118	124%	368	47%
Projected Future Experience (60 Years)	2019	907,254	898,719	99%	331	47%
Projected Future Experience (60 Years)	2020	1,029,343	870,116	85%	312	48%
Projected Future Experience (60 Years)	2021	958,603	866,234	90%	293	48%
Projected Future Experience (60 Years)	2022	887,762	871,494	98%	276	49%
Projected Future Experience (60 Years)	2023	812,496	877,624	108%	260	49%
Projected Future Experience (60 Years)	2024	704,891	· ·	126%	244	50%
Projected Future Experience (60 Years)	2025	590,874	· ·	154%	230	51%
Projected Future Experience (60 Years)	2026	543,882	,	172%	216	51%
Projected Future Experience (60 Years)	2027	497,291	· ·	194%	203	52%
Projected Future Experience (60 Years)	2028	456,178	· ·	219%	190	53%
Future Experience (60 Years)	2029	418,998	· ·	247%	178	53%
Experience (60 Years)	2030	384,065		278%	167	54%
(60 Years)	2031	351,199		312%	156	55%
	2031			349%	145	56%
		320,210		393%		
:	2033 2034	290,899		442%	135 126	56% 57%
		263,102				
	2035	236,757		502%	116	589
	2036	211,874		565%	108	58%
	2037	188,425		633%	99	599
	2038	166,441		706%	91	60%
:	2039	145,965		782%	83	609
	2040	127,043	1,095,841	863%	76	619
	2041	109,723	1,037,805	946%	69	619
:	2042	94,023	978,903	1,041%	62	629
	2043	79,906		1,156%	56	629
	2044	67,335	· ·	1,297%	50	629
		56,248	,	1,454%	45	639
		46,570		1,640%	40	639
	2045	38,206		1,852%	35	63'
	2045 2046	103,980		2,526%	119	64'
	2045 2046 2047	29,371		4,157%	52	64
	2045 2046 2047 2048-2052			6,309%	18	65
	2045 2046 2047 2048-2052 2053-2057	ເວດຄ		9,805%	5	65
	2045 2046 2047 2048-2052 2053-2057 2058-2062	6,326		· ·		
207	2045 2046 2047 2048-2052 2053-2057	6,326 970 86	14,458 1,402	16,764% 37,112%	1 0	65°

•	ritii iiitti toot Accuiii.	DISC. 10 12/01/201	r at max. val. intere
History	62,246,630	28,376,392	46%
Future	8,388,229	17,253,536	206%
Lifetime	70,634,859	45.629.928	65%

Attachment 3-a MedAmerica and BCNEPA

Written Premium and Paid Claim Experience and Projections by Calendar Year Pennsylvania-Specific Experience Before Requested Rate Increase Series 11 and Prior Policy Forms

		Actual or P	Assumptions		
		10.00	Without Interest		Cumulative Loss
	Calendar	Written	Paid	Loss	Ratio w/ Max.
	Year	Premium	Claims	Ratio	Val. Interest
	1992	127,778		0%	0%
	1993	771,602		0%	0%
	1994	1,645,943		3%	2%
	1995	1,722,034	63,694	4%	3%
	1996	1,554,699	57,268	4%	3%
	1997	1,395,175	34,233	2%	3%
	1998	1,334,369	1,801	0%	2%
	1999	1,284,526	169,733	13%	4%
	2000	1,267,362	413,900	33%	6%
	2001	1,240,506	488,498	39%	9%
	2002	1,491,280	609,346	41%	12%
Historical	2003	1,584,734		47%	15%
Experience	2004	1,622,837		40%	17%
	2005	1,563,977		42%	18%
	2006	1,461,395		58%	20%
	2007	1,384,149		66%	22%
	2007	1,305,785		73%	24%
		1,225,767		63%	26%
	2009				
	2010	1,088,485		72%	27%
	2011	1,043,979		88%	28%
	2012	1,065,687		104%	30%
	2013	1,052,019	' '	138%	33%
	2014	970,770		140%	35%
	2015	882,638		152%	36%
	2016	818,490	1,227,672	150%	38%
	2017	760,776	1,107,692	146%	39%
	2018	768,048	1,114,166	145%	41%
	2019	735,083	1,041,033	142%	42%
	2020	686,564	1,091,422	159%	43%
	2021	636,519	1,004,184	158%	44%
	2022	581,413	1,018,060	175%	45%
	2023	535,512	1,021,265	191%	46%
	2024	452,822	1,021,291	226%	46%
	2025	381,065		269%	47%
	2026	349,812		296%	48%
	2027	316,773		332%	49%
	2028	289,689		371%	50%
Projected	2029	264,365		416%	51%
Future	2030	240,710		468%	52%
Experience	2031	218,567		529%	52%
(60 Years)	2032	197,817	' '	599%	53%
(00 10013)	2033	178,350		681%	54%
	2034	160,029		778%	55%
	2035	142,880		891%	56%
		, , , , , , , , , , , , , , , , , , ,	, ,		
	2036	126,848		1,024%	57%
	2037	111,927		1,179%	57%
	2038	98,124		1,357%	58%
	2039	85,431		1,561%	59%
	2040	73,857	' '	1,793%	59%
	2041	63,404		2,053%	60%
	2042	54,033	1,267,629	2,346%	61%
			1,225,347	2,681%	61%
	2043	45,706			
	2044	38,365	1,177,953	3,070%	62%
			1,177,953		62% 62%
	2044	38,365	1,177,953 1,126,016	3,070%	62%
	2044 2045	38,365 31,943	1,177,953 1,126,016 1,070,507	3,070% 3,525%	62% 63%
	2044 2045 2046	38,365 31,943 26,382	1,177,953 1,126,016 1,070,507 1,011,871	3,070% 3,525% 4,058%	62% 63% 63%
	2044 2045 2046 2047	38,365 31,943 26,382 21,602	1,177,953 1,126,016 1,070,507 1,011,871 4,078,047	3,070% 3,525% 4,058% 4,684%	62% 63% 63% 64%
	2044 2045 2046 2047 2048-2052	38,365 31,943 26,382 21,602 58,660 16,494	1,177,953 1,126,016 1,070,507 1,011,871 4,078,047 2,386,124	3,070% 3,525% 4,058% 4,684% 6,952%	62% 63% 63% 64% 65%
	2044 2045 2046 2047 2048-2052 2053-2057 2058-2062	38,365 31,943 26,382 21,602 58,660 16,494 3,492	1,177,953 1,126,016 1,070,507 1,011,871 4,078,047 2,386,124 1,068,505	3,070% 3,525% 4,058% 4,684% 6,952% 14,467% 30,598%	62% 63% 63% 64% 65% 65%
	2044 2045 2046 2047 2048-2052 2053-2057	38,365 31,943 26,382 21,602 58,660 16,494	1,177,953 1,126,016 1,070,507 1,011,871 4,078,047 2,386,124 1,068,505 368,806	3,070% 3,525% 4,058% 4,684% 6,952% 14,467%	62% 63% 63% 64% 65%

Y	ıu	i iiiterest Accuiii./	DISC. 10 12/31/20	i / al iviax. Vai. iiile	163
History		63,514,860	25,010,392	39%	
Future		5,803,498	20,373,916	351%	
Lifetime		69,318,358	45,384,308	65%	

Attachment 3-b MedAmerica and BCNEPA

Written Premium and Paid Claim Experience and Projections by Calendar Year Pennsylvania-Specific Experience After Requested Rate Increase Series 11 and Prior Policy Forms

		Actual or P	Assumptions		
	0 1 1	147.70	Without Interest		Cumulative Loss
	Calendar	Written	Paid	Loss	Ratio w/ Max.
	Year	Premium	Claims	Ratio	Val. Interest
	1992	127,778		0%	0%
	1993	771,602		0%	0%
	1994	1,645,943	45,498	3%	2%
	1995	1,722,034	63,694	4%	3%
	1996	1,554,699	57,268	4%	3%
	1997	1,395,175	34,233	2%	3%
	1998	1,334,369	1,801	0%	2%
	1999	1,284,526		13%	4%
	2000	1,267,362		33%	6%
	2001	1,240,506		39%	9%
	2002	1,491,280		41%	12%
Historical	2003	1,584,734		47%	15%
Experience	2003	1,622,837		40%	17%
Lxperience				42%	18%
	2005	1,563,977			
	2006	1,461,395		58%	20%
	2007	1,384,149		66%	22%
	2008	1,305,785		73%	24%
	2009	1,225,767	769,442	63%	26%
	2010	1,088,485	781,353	72%	27%
	2011	1,043,979	922,011	88%	28%
	2012	1,065,687	1,110,217	104%	30%
	2013	1,052,019	1,452,492	138%	33%
	2014	970,770	1,354,569	140%	35%
	2015	882,638		152%	36%
	2016	818,490	, ,	150%	38%
	2017	760,776		146%	39%
	2018	768,134		145%	41%
	2019	1,001,678		104%	42%
	2019			108%	42%
		1,004,397		106%	43%
	2021	932,807			
	2022	854,988		117%	44%
	2023	790,514		126%	45%
	2024	674,059		147%	45%
	2025	572,868		173%	46%
	2026	528,608		189%	47%
	2027	481,693	1,012,024	210%	48%
	2028	443,030	1,029,603	232%	48%
Projected	2029	406,702	1,051,293	258%	49%
Future	2030	372,558	1,076,123	289%	50%
Experience	2031	340,379	1,102,476	324%	51%
(60 Years)	2032	309,984	1,128,508	364%	51%
,	2033	281,233		411%	52%
	2034	253,901	' '	465%	53%
	2035	228,067		529%	53%
	2036	203,655	' '	604%	54%
	2037	180,685		691%	55%
				790%	55%
	2038	159,206			
	2039	139,240		904%	56%
	2040	120,847		1,034%	57%
	2041	104,075		1,180%	57%
	2042	88,905		1,346%	58%
	2043	75,316	1,157,368	1,537%	58%
	2044	63,253	1,113,441	1,760%	59%
	2045	52,641		2,024%	59%
	2046	43,412		2,336%	60%
	2047	35,461		2,707%	60%
	2048-2052	95,303		4,075%	61%
	2053-2057	26,094		8,754%	62%
	2058-2062	5,376		19,119%	62%
	2063-2067	778		45,785%	62% 62%
	2068-2072	61		154,878%	
	2073-2077	3	18,654	704,457%	62%

V.	,,,,	i iiiterest Accuiii./	DISC. 10 12/31/20	i i al iviax. Vai. ii ile	51 C3
History		63,514,860	25,010,392	39%	
Future		8,265,714	19,611,028	237%	
Lifetime		71,780,574	44,621,421	62%	

Attachment 4 MedAmerica and Affinity Partners Breakdown of Historical Incurred Claims and Reserve Balances at December 31, 2017 Series 11 and Prior Policy Forms

Nationwide Experience

		Discount	ed to the Year o	f Incurral		Year-End
Incurred	Incurred	Paid	Disabled	IBNR	Total Claim	Active Life
Year	Claims ^[1]	Claims	Life Reserve	Reserve	Reserve ^[2]	Reserve ^[3]
1992	C	0	0		0	
1993	112,935	112,935	0		0	
1994	28,746	28,746	0		0	
1995	109,652	109,652	0		0	
1996	134,262	134,262	0		0	
1997	264,541	264,541	0		0	
1998	631,867	631,867	0		0	
1999	1,469,714	1,469,714	0		0	
2000	1,172,992	1,172,992	0		0	
2001	2,210,887	2,210,887	0		0	
2002	4,269,807	4,064,255	205,552		205,552	
2003	3,540,618	3,458,785	81,833		81,833	
2004	6,347,428	6,347,428	0		0	
2005	6,751,292	6,696,149	55,142		55,142	
2006	7,395,470	7,250,654	144,815		144,815	
2007	10,644,803	10,436,770	208,033		208,033	
2008	8,302,139	8,054,916	247,223		247,223	
2009	11,107,735	10,753,245	354,490		354,490	
2010	15,851,176	14,586,415	1,264,761		1,264,761	
2011	14,100,771	12,993,675	1,107,096		1,107,096	
2012	16,193,346		1,578,154		1,578,154	
2013	14,635,134	12,960,808	1,674,325		1,674,325	
2014	23,851,886	18,031,891	5,819,995		5,819,995	
2015	24,822,983	12,768,901	12,054,082		12,054,082	
2016	22,803,799	8,083,382	14,720,417		14,720,417	
2017	24,920,645	2,347,721	18,261,410	4,311,514	22,572,924	364,824,332

Pennsylvania-Specific Experience

			Year-End			
Incurred	Incurred	Paid	ed to the Year o Disabled	IBNR	Total Claim	Active Life
Year	Claims ^[1]	Claims	Life Reserve	Reserve	Reserve ^[2]	Reserve ^[3]
1992	0	0	0		0	
1993	112,935	112,935	0		0	
1994	28,746	28,746	0		0	
1995	55,039	55,039	0		0	
1996	5,871	5,871	0		0	
1997	114,890	114,890	0		0	
1998	235,553	235,553	0		0	
1999	377,829	377,829	0		0	
2000	481,212	481,212	0		0	
2001	713,556	713,556	0		0	
2002	745,816	745,816	0		0	
2003	464,534	464,534	0		0	
2004	958,964	958,964	0		0	
2005	656,165	656,165	0		0	
2006	747,377	747,377	0		0	
2007	934,486	934,486	0		0	
2008	806,835	806,835	0		0	
2009	771,521	771,521	0		0	
2010	811,757	811,757	0		0	
2011	1,452,008	1,387,348	64,660		64,660	
2012	1,319,481	1,319,481	0		0	
2013	974,543	974,543	0		0	
2014	1,467,384	1,289,703	177,681		177,681	
2015	2,584,558	1,076,139	1,508,419		1,508,419	
2016	525,602	333,238	192,364		192,364	
2017	1,243,392	179,432	900,732	163,229	1,063,960	7,914,795

^[1] Incurred claims are the sum of paid claims, disabled life reserve, and incurred but not reported (IBNR) reserve.

^[2] Claim reserve is the sum of disabled life reserve and IBNR reserve.

^[3] Active life reserve is defined as interpolated terminal reserves plus unearned premium reserves.

Attachment 5-a MedAmerica and Affinity Partners Nationwide Experience and Projections by Policy Year - Before Requested Rate Increase Series 11 and Prior Policy Forms

	Actu	al and Projected	Experience using Current Assumptions		
					Cumulative Loss
Policy	Earned	Incurred	Incurred	End of Year	Ratio w/ Max.
Year	Premium	Claims	Loss Ratio	Lives	Val. Interest
1	40,275,560	1,790,212	4%	26,501	4%
2	37,032,678	1,729,579	5%	24,979	5%
3	35,321,458	3,355,869	10%	23,897	6%
4	34,016,996	7,663,584	23%	22,928	10%
5	33,082,266	6,111,353	18%	22,287	11%
6	32,236,859	9,180,833	28%	21,670	13%
7	31,566,303	9,263,909	29%	21,045	15%
8	31,036,982	14,824,301	48%	20,354	18%
9	30,607,480	15,252,383	50%	19,680	21%
10	30,850,832	14,088,046	46%	19,090	23%
11	23,940,528	15,743,219	66%	18,461	25%
12	23,458,850	19,515,154	83%	17,881	28%
13	22,909,980	20,069,844	88%	17,285	30%
14	22,357,195	20,948,952	94%	16,619	33%
15	21,880,393	25,206,442	115%	15,928	36%
16	21,635,429	26,143,634	121%	15,240	38%
17	21,254,521	25,845,168	122%	14,662	41%
18	20,619,386	29,805,039	145%	14,092	44%
19	19,748,712	29,473,692	149%	13,547	46%
20	18,873,510	31,469,623	167%	12,989	49%
21	16,976,069	33,022,731	195%	12,419	51%
22	15,935,403	34,346,390	216%	11,884	54%
23	14,904,863	36,462,246	245%	11,340	57%
24	13,912,995	39,088,811	281%	10,812	59%
25	12,949,490	41,031,726	317%	10,284	62%
26	12,004,731	43,060,339	359%	9,759	65%
27	11,076,341	45,085,790	407%	9,237	68%
28	10,177,589	46,959,068	461%	8,721	71%
29	9,314,782	48,608,638	522%	8,212	74%
30	8,491,031	50,027,930	589%	7,712	77%
31	7,708,194	51,300,127	666%	7,223	80%
32	6,966,224	52,430,692	753%	6,743	82%
33	6,264,675	53,290,986	851%	6,275	85%
34	5,605,543	53,914,070	962%	5,820	88%
35	4,990,495	54,114,933	1,084%	5,381	90%
36	4,419,959	53,881,883	1,219%	4,958	93%
37	3,893,685	53,221,693	1,367%	4,552	95% 95%
38	3,411,321	52,170,072	1,529%	4,166	98%
39	2,972,835	50,746,406	1,707%	3,801	100%
40	2,577,401	49,033,101	1,707 %	3,457	102%
41	2,223,063	47,018,934	2,115%	3,457 3,135	104%
42	1,907,594	44,802,883	2,115%	2,834	105%
43	1,628,555	42,442,056	2,349% 2,606%	2,634 2,556	107%
43	1,383,668	39,918,797	2,885%	2,356	107%
45	1,170,353			2,299	108%
	985,666	37,252,023	3,183% 3,504%	2,063 1,848	111%
46	985,666 826,717	34,542,256		1,848 1,652	111%
47		31,870,919	3,855%		
48	690,769 575,177	29,295,161	4,241% 4,671%	1,474	112% 113%
49	575,177	26,866,556	4,671%	1,313	113%
50 51.55	477,448	24,526,559	5,137%	1,168	114%
51-55	1,390,243	89,798,673	6,459%	4,129	116%
56-60	506,612	47,819,793	9,439%	2,186	117%
61-65	169,793	22,337,374	13,156%	1,053	117%
66-70	50,688	9,094,629	17,942%	416	117%
Total	741,245,890	1,796,865,085	242%	560,016	117%

Attachment 5-b MedAmerica and Affinity Partners Nationwide Experience and Projections by Policy Year - After Requested Rate Increase Series 11 and Prior Policy Forms

	Actu	al and Projected	Experience using	Current Assump	
					Cumulative Loss
Policy	Earned	Incurred	Incurred	End of Year	Ratio w/ Max.
Year	Premium	Claims	Loss Ratio	Lives	Val. Interest
1	40,275,560	1,790,212	4%	26,501	4%
2	37,032,678	1,729,579	5%	24,979	5%
3	35,325,127	3,355,832	9%	23,895	6%
4	34,043,332	7,663,302	23%	22,921	10%
5	33,168,899	6,110,456	18%	22,270	11%
6	32,359,669	9,179,241	28%	21,648	13%
7	31,714,439	9,261,471	29%	21,017	15%
8	31,230,351	14,820,139	47%	20,317	18%
9	30,892,348	15,245,091	49%	19,631	21%
10	31,214,055	14,077,314	45%	19,038	23%
11	24,372,761	15,728,501	65%	18,407	25%
12	23,994,041	19,495,312	81%	17,821	28%
13	23,581,204	20,042,339	85%	17,218	30%
14	23,244,407	20,903,051	90%	16,531	33%
15	23,233,806	25,106,897	108%	15,791	35%
16	24,058,554	25,892,054	108%	14,981	38%
17	25,307,317	25,324,752	100%	14,229	40%
18	26,275,375	28,933,831	110%	13,536	42%
19	26,395,659	28,212,589	107%	12,942	44%
20	25,946,825	29,841,524	115%	12,369	46%
21	23,724,464	31,054,673	131%	11,801	48%
22	22,686,237	32,085,897	141%	11,278	50%
23	21,452,085	33,936,297	158%	10,758	52%
24	20,111,279	36,338,236	181%	10,261	54%
25	18,743,428	38,102,273	203%	9,764	57%
26	17,421,578	39,957,754	229%	9,267	59%
27	16,113,418	41,824,754	260%	8,778	61%
28	14,814,421	43,569,499	294%	8,294	64%
29	13,557,474	45,122,755	333%	7,817	66%
30	12,356,165	46,472,337	376%	7,348	68%
31	11,213,581	47,692,789	425%	6,888	71%
32	10,130,214	48,788,032	482%	6,437	73%
33	9,105,893	49,636,816	545%	5,996	75%
34	8,143,738	50,267,911	617%	5,567	78%
35	7,246,215	50,506,233	697%	5,152	80%
36	6,413,990	50,345,252	785%	4,752	82%
37	5,646,673	49,785,553	882%	4,368	84%
38	4,943,648	48,859,057	988%	4,001	86%
39	4,304,811	47,583,820	1,105%	3,654	88%
40	3,728,891	46,033,892	1,235%	3,327	89%
41	3,212,985	44,200,051	1,376%	3,020	91%
42	2,753,869	42,166,870	1,531%	2,734	92%
43	2,733,809	39,989,892	1,703%	2,468	93%
44	1,991,805	37,649,638	1,890%	2,400	95% 95%
45	1,681,781	35,167,458	2,091%	1,996	96%
46	1,413,549	32,639,171	2,309%	1,790	97%
47	1,182,938	30,143,905	2,548%	1,601	98%
48	985,991	27,729,768	2,812%	1,430	98%
49	818,835	25,450,309	3,108%	1,430	99%
50	677,797	23,248,079	3,430%	1,135	99%
	-			4,023	101%
51-55 56 60	1,958,005	85,149,266 45,205,810	4,349% 6.444%		101%
56-60 61 65	702,875	45,295,819	6,444%	2,139	
61-65 66 70	232,436	21,137,730	9,094%	1,034	103%
66-70	68,519	8,598,533	12,549%	410	103%
Total	855,553,917	1,699,243,810	199%	548,825	103%

Attachment 6-a MedAmerica and BCNEPA Pennsylvania-Specific Experience and Projections by Policy Year - Before Requested Rate Increase Series 11 and Prior Policy Forms

	Actu	ıal and Projected	Experience using	Current Assump	
					Cumulative Loss
Policy	Earned	Incurred	Incurred	End of Year	Ratio w/ Max.
Year	Premium	Claims	Loss Ratio	Lives	Val. Interest
1	3,430,753	141,681	4%	1,862	4%
2	2,690,162	35,491	1%	1,638	3%
3	2,388,306	71,375	3%	1,512	3%
4	2,220,615	148,292	7%	1,423	4%
5	2,098,971	295,852	14%	1,347	5%
6	2,002,605	849,104	42%	1,293	10%
7	1,895,650	920,877	49%	1,228	13%
8	1,785,541	1,024,625	57%	1,159	17%
9	1,694,587	814,502	48%	1,084	19%
10	1,603,044	900,193	56%	1,015	21%
11	1,491,289	821,530	55%	946	23%
12	1,409,043	2,291,972	163%	879	29%
13	1,319,121	1,119,196	85%	832	31%
14	1,257,597	846,335	67%	779	32%
15	1,189,458	1,791,491	151%	725	35%
16	1,119,389	1,288,212	115%	659	37%
17	1,053,440	947,196	90%	588	39%
18	986,070	1,798,403	182%	522	41%
19	930,786	1,450,592	156%	481	43%
20	880,008	1,686,415	192%	444	45%
21	704,040	1,457,929	207%	403	47%
22	626,550	1,174,940	188%	363	49%
23	551,883	982,597	178%	328	50%
24	496,470	1,543,166	311%	304 280	52%
25 26	452,920	1,285,888	284%		53%
	414,767	1,257,166	303%	258 238	54%
27 28	373,997	1,270,255	340% 383%	238 219	56% 57%
29	334,726 298,523	1,283,427 1,294,137	434%	201	58%
30	265,477	1,298,849	489%	184	59%
31	235,400	1,302,025	553%	169	60%
32	208,078	1,315,925	632%	154	61%
33	183,325	1,328,723	725%	140	63%
34	160,968	1,338,096	831%	127	64%
35	140,832	1,337,987	950%	116	65%
36	122,713	1,332,745	1,086%	104	66%
37	106,422	1,308,820	1,230%	94	67%
38	91,802	1,267,639	1,381%	85	67%
39	78,733	1,215,393	1,544%	76	68%
40	67,098	1,160,844	1,730%	68	69%
41	56,796	1,098,083	1,933%	60	70%
42	47,707	1,039,156	2,178%	53	70%
43	39,730	972,647	2,448%	47	71%
44	32,785	902,515	2,753%	41	71%
45	26,796	829,189	3,094%	35	72%
46	21,676	747,872	3,450%	30	72%
47	17,341	659,519	3,803%	26	72%
48	13,713	577,813	4,214%	22	73%
49	10,715	497,037	4,639%	19	73%
50	8,269	422,650	5,111%	15	73%
51-55	18,937	1,187,780	6,272%	44	73%
56-60	3,532	348,231	9,859%	14	74%
61-65	429	71,887	16,767%	3	74%
66-70	26	9,290	35,113%	0	74%
Total	39,659,611	54,363,553	137%	24,736	74%
	,0,011	= :,= 30,000		= .,. 30	, 0

Attachment 6-b MedAmerica and BCNEPA Pennsylvania-Specific Experience and Projections by Policy Year - After Requested Rate Increase Series 11 and Prior Policy Forms

	Actu	al and Projected	Experience using	Current Assump	tions
					Cumulative Loss
Policy	Earned	Incurred	Incurred	End of Year	Ratio w/ Max.
Year	Premium	Claims	Loss Ratio	Lives	Val. Interest
1	3,430,753	141,681	4%	1,862	4%
2	2,690,162	35,491	1%	1,638	3%
3	2,388,306	71,375	3%	1,512	3%
4	2,220,615	148,292	7%	1,423	4%
5	2,098,971	295,852	14%	1,347	5%
6	2,002,605	849,104	42%	1,293	10%
7	1,895,650	920,877	49%	1,228	13%
8	1,785,541	1,024,625	57%	1,159	17%
9	1,694,587	814,502	48%	1,084	19%
10	1,603,044	900,193	56%	1,015	21%
11	1,491,289	821,530	55%	946	23%
12	1,409,346	2,291,973	163%	879	29%
13	1,320,534	1,119,202	85%	832	31%
14			67%	779	32%
	1,260,169	846,328			
15	1,205,700	1,791,432	149%	724	35%
16	1,170,871	1,287,074	110%	657	37%
17	1,158,052	943,009	81%	582	38%
18	1,162,410	1,788,862	154%	512	41%
19	1,163,541	1,433,950	123%	471	43%
20	1,126,593	1,665,574	148%	434	45%
21	904,721	1,432,110	158%	393	46%
22	821,739	1,145,181	139%	353	48%
23	739,033	949,158	128%	318	48%
24	676,361	1,505,801	223%	294	50%
25	632,476	1,242,882	197%	270	51%
26	599,497	1,206,719	201%	248	52%
27	558,391	1,214,188	217%	228	53%
28	507,082	1,223,914	241%	210	54%
29	455,919	1,232,212	270%	192	55%
30	408,652	1,234,874	302%	177	56%
31	365,299	1,236,021	338%	162	57%
32	325,568	1,247,249	383%	148	58%
33	289,213	1,257,649	435%	135	59%
34	256,007	1,265,028	494%	122	60%
35	225,740	1,263,806	560%	111	61%
36	198,173	1,258,021	635%	101	62%
37	173,080	1,235,160	714%	91	63%
38	150,280	1,196,398	796%	82	64%
39	129,654	1,147,521	885%	73	64%
40	111,077	1,096,622	987%	65	65%
41	94,458	1,038,323	1,099%	58	65%
42	79,653	983,706	1,235%	51	66%
43	66,549	921,922	1,385%	45	66%
44	55,058	856,534	1,556%	40	67%
45				34	67% 67%
	45,086	787,919	1,748%		
46	36,515	711,659	1,949%	30	68%
47	29,228	628,438	2,150%	25	68%
48	23,116	551,216	2,385%	22	68%
49	18,055	474,685	2,629%	18	68%
50	13,923	404,083	2,902%	15	68%
51-55	31,759	1,139,746	3,589%	43	69%
56-60	5,835	336,534	5,767%	14	69%
61-65	689	70,102	10,178%	3	69%
66-70	39	9,182	23,466%	0	69%
	40.000.000	50 005 405	10001	04.540	0001
Total	43,306,666	52,695,485	122%	24,546	69%



Letter of Authorization

To: Department of Insurance

MedAmerica Insurance Company ("MedAmerica") has entered into a service agreement with Milliman, Inc. ("Milliman") effective November 1, 2007, that includes long-term care rate filing services on our behalf. The agreement provides, in part, that Milliman is responsible for preparing and filing for approval with state insurance departments MedAmerica's long-term care rate increase filings. Milliman is also authorized to receive, on MedAmerica's behalf, written and oral communication from each state department of insurance for the purpose of completing the rate increase filing process.

Please accept this letter of authorization for the purpose stated above. Should you have any questions regarding the above, please forward your comments to:

MedAmerica Insurance Company 165 Court Street Rochester, NY 14647

HM Life Insurance Company

HM Life Insurance Company of New York

HM Casualty Insurance Company Title

Highmark Casualty Insurance Company

RBS Re

HM Benefits
Administrators

412.544.1000 800.328.5433

www.hmig.com

Mailing Address PO Box 535061 Pittsburgh, PA 15253-5061

Overnight Deliveries Fifth Avenue Place 120 Fifth Avenue Pittsburgh, PA 15222-3099 the SUP gentions 4/7/2016

Coverage is underwritten by HM Life Insurance Company, HM Casualty Insurance Company or Highmark Casualty Insurance Company, Pittsburgh, PA, in all states except New York. In New York, coverage is underwritten by HM Life Insurance Company of New York, New York, New York, NY. HM Life Insurance Company, HM Benefits Administrators and RBS Re provide certain administrative and customer support services. The coverage or service requested may not be available in all states.

Home Office: Wilkes-Barre, PA

Time-Sensitive! Review Options and Make Your Decision RE: Your Long Term Care Insurance Notice of Premium Increase — Please Read & Retain for Your Records

<<FIRST_NAME>> <<LAST_NAME>> <<STREET_ADDRESS1>> <<STREET_ADDRESS2>> <<CITY>> <<STATE>> <<ZIP>>

<< DATE>>
Billing Account ID: <<POLICY NUMBER>>

Dear << SALUTATION LAST NAME>>:

We are writing to notify you that we have filed a premium increase of <<INC_AMT>> with the Department of Insurance. This premium change is based on the overall experience of all contracts in your class and has nothing to do with your current age, health status, claims history or any other personal factors. This increase applies to all insureds having the same policy form as you, regardless of the effective date of coverage. Please be advised that premiums are subject to future rate increases.

The premium rate increase for your long term care insurance coverage will change on <<NEXT_BILL_DATE>>. Your <<MODAL>> premium payment will change from <<CURRENT_RATE>> to <<FUTURE RATE>>.

We understand this premium increase may affect your ability to afford your current level of benefits. Please review the options regarding your coverage that are outlined below, and make the decision that best meets your needs.

- Option #1: Continue your coverage at your current level of benefits. You may keep your current level of benefits by paying the increased premium when it is due on <<NEXT_BILL_DATE>>. If you choose this option, no additional action, other than your premium payment, is required. Please understand that paying the increased premium for coverage through 120 days from the date of the rate increase constitutes your acceptance of the rate increase and voids the offer of the Contingent Non-Forfeiture Benefit outlined in Option #3 below.
- Option #2: Offset the increased premium by reducing your level of benefits. You <u>may</u> be able to adjust your benefits to reduce your premium. Please understand that this option is not always available as you may have selected the state-mandated minimum benefits allowable for long term care insurance. Please call Customer Service toll-free at 1-800-240-1675 to discuss your options.
- Option #3: Elect the reduced Contingent Non-Forfeiture Benefit.

If you elect the Contingent Non-Forfeiture Benefit Option, no further premium is due. This option becomes effective as of your current paid through date. As of the date of this letter, your Contingent Non-Forfeiture Benefit would be <<RESULT_OF_CNF_FORMULA>>.

There are two ways to elect the Contingent Non-Forfeiture Benefit:

- Choose this option today by signing and dating the enclosed Contingent Non-Forfeiture Benefit Election Form and returning it in the enclosed postage-paid envelope; OR
- If you do not pay the increased premium <u>within 120 days of the due date</u>, which is <<NEXT_BILL_DATE>>, you will be entitled to the Contingent Non-Forfeiture Benefit. We will automatically change your coverage to the Contingent Non-Forfeiture Benefit in lieu of your policy lapsing for non-payment of premium.

<u>IMPORTANT:</u> Paying the increased premium for coverage through 120 days from <<NEXT_BILL_DATE>>, constitutes your acceptance of the rate increase and voids the Contingent Non-Forfeiture Benefit offer.

What is the Contingent Non-Forfeiture Benefit?

The Contingent Non-Forfeiture Benefit Option allows you to retain reduced long term care insurance benefits in the event you can no longer afford your premium due to a substantial premium increase. Under this option, the same **Daily Benefit Amount** in effect at the time of the lapse will be payable, but the **Lifetime Benefit Amount** will be equal to the greater of the items a) or b) below:

- a) The total amount of premiums paid and applied to Your Policy; OR
- b) Thirty (30) times the **Daily Benefit Amount**

The total of all benefits paid under your policy will not exceed the **Lifetime Benefit Amount** that would have been payable if your policy did not lapse.

Important facts to know about this reduced benefit are:

- No future premium is due.
- The Lifetime Benefit Amount is significantly less than the benefit provided if you choose to continue paying your premium.
- All riders and inflation options will be terminated.
- All other terms, conditions, limitations and exclusions in your current coverage apply to the Contingent Non-Forfeiture Benefit.

<u>IMPORTANT NOTE:</u> If your policy includes a Spousal Benefit Transfer Rider, both you and your spouse must continue to maintain identical coverage. You must both select the same option regarding this rate increase.

If you have questions on the above options please call Customer Service toll free at **1-800-240-1675**.

If you are currently on claim and your premium is being waived, the increase will be applied when your premium is no longer being waived. Please be assured that your benefits are not affected and that your claims will continue to be paid.

As always, thank you for your business with the company.

Sincerely,

Cheryl Bush, RN

Thereof Bushen

Senior Vice President, Long Term Care Operations

Home Office: Wilkes-Barre. PA

Contingent Non-Forfeiture Benefit Election Form

< <first_name>> <<last_name>></last_name></first_name>
< <street_address1>></street_address1>
< <street_address2>></street_address2>
< <city>> <<state>> <<zip>></zip></state></city>

<<Date>>
Billing Account ID: <<POLICY_NUMBER>>

I have decided to stop future premium payments and accept the reduced Contingent Non-Forfeiture Benefit.

I understand the following:

- No future premium is due; and
- I will have a reduced lifetime benefit equal to the sum of all premiums paid and applied to date, OR thirty (30) times the Daily Benefit Amount, whichever is greater; and
- The Contingent Non-Forfeiture Benefit is significantly less than the benefit provided if I chose to keep paying my premium; and
- The Contingent Non-Forfeiture Benefit is only available if I satisfy the requirements for Benefit Eligibility as defined in my policy or certificate; and
- The Contingent Non-Forfeiture Benefit will be payable up to my Daily Benefit Amount in effect on the date of this change; and
- All riders and inflation options will be terminated; and
- All other terms, conditions, limitations and exclusions in my current coverage apply to the Contingent Non-Forfeiture Benefit.

Signature:

I request my current long term care insurance coverage be reduced to the Contingent Non-Forfeiture Benefit offered by the company. This option becomes effective as of my current paid through date. A summary of Contingent Non-Forfeiture Benefits will be sent to me when this request is processed.

Signature	Date

Mailing Instructions: Sign and date this form and return in the enclosed postage-paid envelope.